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1 Summary 
Active DNA demethylation plays an important role in various biological contexts, such as 
embryonic development and embryonic stem cell (ESC) differentiation. The Ten-Eleven 
Translocation (TET) family enzymes play a key role in this process, as they iteratively oxidize 5-
methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC) and 5-
carboxylcytosine (5caC). 5fC and 5caC can subsequently be removed by Thymine DNA 
glycosylase (TDG) and unmethylated cytosine is restored by base excision repair (BER), 
completing the process of active DNA demethylation. Before the discovery of the role of TET 
enzymes in active DNA demethylation, the Growth arrest and DNA-damage-inducible protein 45 
alpha (GADD45A) had already been implicated in active DNA demethylation, but its exact role 
remained unknown. Recent findings highlighted that GADD45A physically and functionally 
cooperates with the TET family member TET1 to mediate active DNA demethylation. However, 
the mechanism by which GADD45A enhances TET1 activity is yet poorly understood. In addition, 
how TET enzymes are targeted to genomic loci, especially to enhancers, remains largely 
unresolved. In fact, whereas TET binding sites are mostly found at promoters, the oxidation 
products of TET – 5hmC, 5fC and 5caC – are mostly enriched at enhancers. In this thesis, I 
explored two TET-related topics 1) TET1 regulation by GADD45A and 2) TET regulation by 
RAD21-dependent chromatin looping. 
First, I found that the GADD45A interactor Mitogen-activated protein kinase kinase kinase 4 
(MAP3K4) is most likely not involved in enhancing TET1 activity in a GADD45A-dependent 
manner. Then, I demonstrated that GADD45A can affect TET1 post-translational modifications: 
GADD45A decreases the ubiquitination and SUMOylation of full-length TET1, while it enhances 
the SUMOylation of the catalytic domain of TET1 (TET1CD). Finally, I established that GADD45A 
stabilizes TET1 protein levels, putatively by preventing Calpain-mediated decay. Nevertheless, 
the detailed mechanism behind this stabilization remains to be resolved in the future. 
A proposed model by which TET enzymes are targeted to enhancers to oxidize 5mC is promoter-
enhancer looping. Promoter-enhancer loops are established by the Cohesin complex and can be 
abolished by depleting one of its subunits, such as RAD21. To test this model, I investigated the 
distribution of 5fC in RAD21-depleted – and hence promoter-enhancer loop depleted – mouse 
ESCs (mESCs) and observed that the deposition of 5fC at enhancers is RAD21-loop 
independent. Although these results do not provide an ultimate explanation for the discrepancy 
between TET binding sites at promoters and the enrichment of 5hmC, 5fC and 5caC at 
enhancers, this analysis supports the conclusion that targeting of enhancer demethylation does 
not rely on RAD21-dependent chromatin loops. 
 
 
ZUSAMMENFASSUNG 
2 
2 Zusammenfassung 
Aktive DNA-Demethylierung spielt eine wichtige Rolle in verschiedenen biologischen 
Zusammenhängen, wie beispielsweise der Embryonalentwicklung oder der embryonalen 
Stammzelldifferenzierung. Die Enzyme der Ten-Eleven Translocation (TET) Familie nehmen 
hierbei eine Schlüsselposition ein, indem sie 5-Methylcytosin (5mC) iterativ zu 5-
Hydroxymethylcytosin (5hmC), 5-Formylcytosin (5fC), sowie 5-Carboxylcytosin (5caC) oxidieren. 
5fC und 5caC können daraufhin von der Thymine DNA glycosylase (TDG) entfernt werden, und 
unmethyliertes Cytosin durch Enzyme der Basenexzisionsreparatur (BER) wiederhergestellt 
werden, welches den Prozess der aktiven DNA-Demethylierung vervollständigt. Bereits vor der 
Entdeckung der Rolle der TET Enzyme in der aktiven DNA-Demethylierung wurde das Protein 
Growth arrest and DNA-damage-inducible protein 45 alpha (GADD45A) mit der aktiven DNA-
Demethylierung in Verbindung gebracht, jedoch blieb dessen Wirkmechanismus unklar. Neueste 
Erkenntnisse zeigen, dass GADD45A physisch und funktionell mit TET1 in der aktiven DNA-
Demethylierung kooperiert, allerdings ist über die mechanistischen Details dieser Kooperation 
weiterhin wenig bekannt. Zudem bleibt ungelöst, wie TET Enzyme gezielt zu genomischen Loci 
rekrutiert werden. Tatsächlich befinden sich TET-Bindungsstellen überwiegend an Promotoren, 
während die TET-Oxidationsprodukte – 5hmC, 5fC, sowie 5caC – größtenteils an Enhancern 
angereichert sind. In der vorliegenden Arbeit untersuchte ich zwei TET-relevante Themen: 1) 
TET1 Regulation durch GADD45A und 2) TET Regulation durch RAD21-abhängiges Chromatin 
Looping. 
Erstens stellte sich heraus, dass die mit GADD45A interagierende Mitogen-activated protein 
kinase kinase kinase 4 (MAP3K4) höchstwahrscheinlich nicht an dem TET1-aktivierenden 
Prozess durch GADD45A involviert ist. Außerdem demonstrierte ich, dass GADD45A 
posttranslationale Modifikationen von TET1 beeinflusst: GADD45A verringert die Ubiquitinierung 
sowie die SUMOylierung des Gesamtlängen-TET1-Proteins, während es die SUMOylierung der 
katalytischen TET1-Domäne verstärkt. Ferner stabilisiert GADD45A die TET1-Proteinspiegel, 
vermutlich durch die Verhinderung eines Calpain-vermittelten Proteinabbaus. Dennoch bleibt der 
vollständige Mechanismus dieser Stabilisation noch zu klären. 
Ein vorgeschlagenes Modell, welches darlegt wie TET-Enzyme gezielt zu Enhancern zum 
Zwecke der 5mC Oxidierung rekrutiert werden, ist Promoter-Enhancer-Looping. Promoter-
Enhancer Loops werden mittels des Cohesin Komplexes generiert und können durch Depletion 
von Untereinheiten, beispielsweise RAD21, aufgelöst werden. Um dieses Modell zu testen, 
erforschte ich die Verteilung von 5fC in RAD21 depletierten, und demzufolge Promoter-Enhancer-
Loop depletierten Mausstammzellen und zeige, dass das Vorkommen von 5fC an Enhancern 
RAD21-Loop unabhängig ist. Wenngleich diese Ergebnisse keine endgültige Erläuterung der 
Diskrepanz zwischen TET-Bindungsstellen an Promotoren und der Anreicherung von 5hmC, 5fC, 
sowie 5caC an Enhancern liefern, so legen meine Ergebnisse nahe, dass DNA-Demethylierung, 
zumindest im Kontext RAD21-abhängiger Loops, unabhängig der dreidimensionalen 
Chromatinstruktur erfolgen kann. 
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3 Introduction 
3.1 DNA methylation and demethylation 
In 1898, W.G. Ruppel discovered a novel nucleic acid while attempting to isolate the bacterial 
toxin responsible for causing tuberculosis, which he named tuberculinic acid [1]. It took another 
50 years until this modification of the DNA base cytosine (C), now known as 5-methylcytosine 
(5mC), was also discovered in mammalian DNA [2]. In eukaryotes, 5mC occurs in the context of 
cytosine-guanine dinucleotides (CpGs) and is present symmetrically on both strands of the DNA 
[3]. Today, we also know the enzymes responsible for setting these marks: DNA methyl-
transferases (DNMTs), which can generate 5mC by the transfer of a methyl group from the 
cofactor S-adenosyl-L-methionine (SAM) to the 5’ position of cytosine [4]. In mammals, DNMT3A 
and DNMT3B act as the de novo methyltransferases [5], whereas DNMT1 is the maintenance 
enzyme, which ensures that DNA methylation is maintained during DNA replication [6].  
3.1.1 Molecular mechanisms of DNA methylation 
The de novo methyltransferases DNMT3A and DNMT3B contain a highly conserved 
methyltransferase (MTase) domain, as well as two chromatin reading domains: ATRX-DNMT3-
DNMT3L (ADD) and PWWP [3]. The ADD domain can bind to unmethylated histone H3 lysine4 
(H3K4), which releases the auto-inhibition of the DNMT3 enzymes and allows for the de novo 
methylation of C. When H3K4 is trimethylated (H3K4me3), marking active and poised promoters, 
this prevents the binding of the ADD domain and leads to the auto-inhibition of DNMT3A/B, as 
the ADD domain then binds and inhibits the MTase domain [7,8]. The PWWP domain can bind to 
H3K36me3, a mark that is found in the gene bodies of actively transcribed genes, resulting in the 
methylation of these regions as well [9]. 
The maintenance methyltransferase DNMT1 cooperates with UHRF1, which recognizes hemi-
methylated CpG dyads via its SET- and RING-associated (SRA) domain in order to ensure the 
inheritance of 5mC after DNA replication [10]. UHRF1 also harbors a tandem TUDOR-PHD 
domain, which binds to H3K9me2 and H3K9me3, two epigenetic marks associated with 
transcriptional repression [11]. UHRF1 recruits DNMT1 via its ubiquitin-like (UBL) domain, which 
can bind to the Replication foci targeting sequence (RFTS) of DNMT1 [12,13]. Without binding of 
UHRF1, the RFTS of DNMT1 folds into its MTase domain and inhibits the catalytic activity. The 
binding of UHRF1 promotes the binding of the RFTS to ubiquitinated H3 tails, which releases the 
auto-inhibition of DNMT1 to allow for the maintenance of symmetrical methylation of CpGs [14].  
3.1.2 Molecular mechanisms of DNA demethylation 
Originally, 5mC was associated with transcriptional repression, and now also has established 
roles in imprinting, X chromosome inactivation, embryonic development, tissue-specific gene 
expression, and cancer [15]. Due to the stable nature of the carbon-carbon bond, it was long 
thought that DNA methylation is an irreversible process that can only be removed in a passive 
manner, i.e. by dilution and de novo DNA synthesis in the absence of DNA methylation [16]. 
However, at the beginning of the new millennium, the first evidence emerged to support the 
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existence of an active removal pathway for 5mC: Mayer and colleagues showed that the mouse 
paternal genome is demethylated within 6-8 hours of fertilization, before the onset of DNA 
replication, thus proposing the existence of a DNA demethylation machinery [17]. 
DNA demethylation can occur in a passive manner, by inhibiting the maintenance of 5mC by 
DNMT1 during DNA replication. In the absence of functional DNMT1 or its cofactor UHRF1, DNA 
methylation will be successively lost over multiple rounds of DNA replication. This is how, for 
example, 5mC is erased in the maternal genome during mouse preimplantation development 
[10,18,19]. 
Various different mechanisms of active DNA demethylation have been proposed in mammals, 
which include: 1) DNA demethylation by nucleotide excision repair (NER) [20], 2) base-excision 
repair (BER) upon 5mC deamination by Activation-induced deaminase (AID) [21], and 3) 5mC 
oxidation mediated by the Ten-Eleven Translocation (TET) family enzymes followed by BER or 
passive dilution [22–26].  
DNA demethylation by NER was initially proposed to occur via Growth arrest and DNA-damage-
inducible protein 45 alpha (GADD45A). In this model, GADD45A is first targeted to sites of DNA 
demethylation and then recruits the DNA repair machinery through the endonuclease XPG. In 
this process, methylated cytosines are excised and repaired with unmethylated cytosines [20]. 
However, the details of this mechanism are a matter of debate [27] and rather, alternative 
functions for GADD45 proteins in DNA demethylation have been proposed, which will be 
discussed in chapter 3.2. 
AID was shown to deaminate 5mC to thymidine in vitro, suggesting a possible role of DNA 
deaminases in active DNA demethylation [28]. Still, the direct in vivo evidence for a role of 
deaminases is missing and a subject of debate, as some studies have suggested a role of AID-
mediated 5mC deamination in DNA demethylation [29–31], while others did not find any evidence 
for the involvement of AID in DNA demethylation and reprogramming [31–33]. One model 
proposes that AID could play an indirect role in DNA demethylation, by inducing lesions at nearby 
unmethylated C, leading to the replacement of 5mC in the vicinity [16,34]. 
The breakthrough in the field of active DNA demethylation came in 2009, when mammalian Ten-
eleven translocation 1 (TET1), a protein originally identified as a fusion partner of the mixed 
lineage leukaemia (MLL) gene in acute myeloid leukaemia (AML) [35], was discovered to convert 
5mC to 5-hydroxymethylcytosine (5hmC) [22,24]. Later, also TET2 and TET3 were shown to 
convert 5mC to 5hmC [36] and ultimately, all TET proteins were shown to further convert 5hmC 
into 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC) (Figure 3.1) [23,37]. Following TET-
mediated oxidation of 5mC, unmethylated C can be restored via passive or active mechanisms: 
passively by DNA replication-dependent dilution [38–40] or actively via removal of 5fC and 5caC 
by Thymine DNA glycosylase (TDG) [23,25]. Analogous to 5mC, its oxidative derivatives – 5hmC, 
5fC and 5caC – can also be removed in a passive manner via replication-dependent dilution, as 
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no maintenance machinery is known to exist for these bases. This process is known as active 
modification (by TET enzymes) followed by passive dilution [26].  
Arguably, the most accepted mechanism of active DNA demethylation is the active modification 
by TET enzymes and the subsequent removal of 5fC and 5caC by TDG [41]. The removal of 5fC 
and 5caC by TDG generates an abasic (AP) site, which is restored to unmethylated C by BER 
(Figure 3.1). This process has been biochemically reconstituted by Weber and colleagues, who 
demonstrated that base excision by TDG is coupled to BER [42]. After TDG recognizes 5fC or 
5caC, it cleaves the N-glycosylic bond between the DNA base and the sugar phosphate bone, 
generating an AP site. Subsequently, the DNA-(apurinic or apyrimidinic site) lyase (APEX1) 
cleaves the phosphodiester bond 5’ to the AP site, creating a single-strand break. The single-
strand break, containing a hydroxyl residue at the 3’-end and a deoxyribose phosphate at the 5’ 
end, is then recognized by DNA polymerase β (Pol β), which fills the gap with an unmodified C. 
At the same time, Pol β removes the 5’-deoxyribose phosphate and recruits XRCC1 and DNA 
ligase 3 (LIG3) to seal the DNA ends [43].  
 
 
Figure 3.1 TET-TDG mediated active DNA demethylation 
Cytosine (C) is methylated by DNMT1 (maintenance methyltransferase) or DNMT3A/B (de novo methyl-
transferases) at the 5’ position. TET enzymes (TET1/2/3) oxidize the methyl group in an iterative manner to 
5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC). 5fC and 5caC are 
then excised by TDG, which generates an abasic (AP) site. Unmethylated C is finally restored by the base 
excision repair (BER) machinery. Modifications of C are highlighted in red. Figure based on [44]. 
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3.1.3 Biological functions of DNA demethylation 
DNA demethylation plays a role in numerous biological contexts, among them pre-implantation 
and primordial germ cell (PGC) development, embryonic stem cell (ESC) differentiation, neuronal 
functions, genomic stability and DNA damage repair, as well as cancer [41].  
In mouse development, TET3 acts on the paternal genome of the fertilized zygote and oxidizes 
5mC to 5hmC, to initiate active DNA demethylation [45]. This is followed by passive DNA 
demethylation of the paternal and maternal genome due to exclusion of DNMT1 from the nucleus 
during the subsequent cell divisions [19]. However, there are studies that argue with this model. 
First of all, it was proposed that also the maternal genome can undergo active DNA demethylation 
[46]. Second, it was demonstrated that the majority of global DNA demethylation occurs 
independently of replication [46,47]. Instead, the paternal genome could be demethylated 
independently of TET3, via an additional, yet unknown mechanism. In fact, it was shown that 
DNMT1 and DNMT3A are indeed active in the zygote and provide the substrate for TET3-
mediated hydroxylation [47].  
After implantation of the blastocyst, de novo methylation of the epiblast genome is rapidly restored 
by DNMT3A and DNMT3B [3]. Those stem cells, which eventually will form the later germline, 
undergo two additional rounds of DNA demethylation: one passive round and one active round, 
which is mediated by TET1 and TET2 [38,48,49]. Later, both male and female gametes are de 
novo methylated by DNMT3 enzymes to give rise to the gamete specific DNA methylation 
patterns. In general, TET proteins are not thought to be the drivers of active demethylation in the 
embryos and the germline, but rather the guardians of erroneous DNA methylation [3].  
Mouse ESCs (mESCs), which are derived from the inner cell mass of the embryonic day 3.5 
blastocyst, are a popular model system to study DNA methylation and demethylation dynamics, 
as they express both Tet1 and Tet2 [41]. Accordingly, they have detectable levels of 5hmC 
(~0.13 % of total C), 5fC (~0.002 % of total C) and 5caC (~0.0003 % of total C) [37]. Tet1/2/3 
triple-knockout mESCs have no detectable 5hmC levels. As expected, they display 
hypermethylation, especially at distal enhancers [50], and differentiation and developmental 
defects [51]. The finding that Tet triple-knockout mouse embryos display gastrulation defects 
further underlines the importance of the TET enzymes and DNA demethylation for proper early 
differentiation and embryonic development [52]. Importantly, the gastrulation defects are indeed 
due to impaired DNA demethylation, as in Tet triple-knockout embryos the Lefty1 promoter and 
Lefty2 enhancer are hypermethylated, which leads to impaired Nodal signaling, a core signaling 
pathway required for gastrulation. In this process, the catalytic activity of TET3 is essential for 
normal Lefty-Nodal signaling, as a catalytically inactive mutant of TET3 could not rescue the 
gastrulation defects. 
In addition to stem cells, 5hmC is also highly abundant in neuronal tissues, such as the brain [24]. 
The neuronal defects observed in TET-deficient mice suggest that DNA demethylation plays an 
important role in neuronal functions. For example, TET1 deficiency leads to impaired hippocampal 
neurogenesis, as well as poor learning and memory formation [53]. Moreover, neuronal activity-
INTRODUCTION 
7 
regulated genes including Npas4 are downregulated, most likely due to promoter 
hypermethylation [54]. TET3 in primary cortical neurons of mice, on the other hand, was shown 
to be necessary for fear extinction learning by establishing 5hmC accumulation around extinction-
related genes [55]. Recently, 5hmC generated by TET3 was also suggested to protect mice 
against ischemic injuries in the brain [56]. 
TET enzymes and DNA demethylation contribute to DNA repair and genomic stability in several 
ways. For example, at DNA damage sites, 5hmC colocalizes with the damage response proteins 
phosphorylated histone H2AX (γH2AX) and p53-binding protein 1 (53BP1). Moreover, TET 
enzymes are required for efficient repair after Aphidicolin-induced DNA damage, and a loss of 
TET enzymes leads to inaccurate chromosome segregation [57]. A loss of all TET enzymes in 
mESCs also leads to telomere abnormalities, increased sister chromatid exchange and 
chromosomal fusion in two additional studies [50,58]. In vivo, Tet1 heterozygous knockout mice 
are more sensitive to X-ray exposure than wild-type mice, as they display a severe deterioration 
of the coat [59].  
Lastly, defective DNA demethylation has been connected to cancer in various respects and 
especially the disruption of TET2’s enzymatic activity can lead to myeloid tumorigenesis [60]. 
Numerous solid tumors display a reduction of 5hmC levels. The reduction of 5hmC originates 
either directly from TET mutations, or from mutations of TET regulators, such as Isocitrate 
dehydrogenase (IDH) 1/2 or Wilms tumor protein 1 (WT1) [41]. IDH1 and 2 catalyze the formation 
of α-ketoglutarate (α-KG), a cofactor of TET enzymes. Common mutations of IDH1 and 2 in AML 
and brain tumors can lead to a neomorphic enzyme activity that catalyzes the reduction of α-KG 
to 2-hydroxyglutarate, which ultimately inhibits TET enzymatic activity [61]. Wild-type WT1 can 
recruit TET2 to target genes, but AML-associated mutations or loss of WT1 lead to impaired 
hematopoietic differentiation and decreased 5hmC levels, probably due to failure of proper TET2 
recruitment [62,63]. Paradoxically, also the widespread hypomethylation observed in cancer 
genomes was recently connected to TET loss of function. TET1 deficiency results in the 
relocalization of DNMT3A1 from heterochromatic to euchromatic regions that were previously 
occupied by TET1, thereby leading to hypomethylation in heterochromatic regions [64]. 
3.1.4 Molecular functions of TET proteins 
TET proteins are iron(II)/α-KG-dependent dioxygenases, which iteratively oxidize 5mC to 5hmC, 
5fC and 5caC (Figure 3.1). All three mammalian TET protein family members (TET1, 2 and 3) 
share a common C-terminal catalytic dioxygenase domain, consisting of a double-stranded β-
helix domain (DSBH), which is split into two parts by a low complexity insert region and preceded 
by a cysteine-rich region (Figure 3.2) [41].  
The analysis of the crystal structure of human TET2 bound to DNA gave important insights into 
the catalytic function of the C-terminal domain: the cysteine-rich and DSBH domains form a 
compact catalytic domain, brought together by two zinc fingers. Whereas the cysteine-rich domain 
stabilizes the DNA above the DSBH domain, the DSBH domain binds to iron(II) and α-KG and 
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oxidizes 5mC, 5hmC and 5fC, which can be inserted in the catalytic cavity by a base-flipping 
mechanism [65,66]. 
The N-terminal region and the low complexity region are mostly uncharacterized, except for a 
CXXC-type zinc finger at the N-terminus of TET1 and TET3 [41]. The CXXC domain can mediate 
binding to CpG-rich regions, as demonstrated by the crystal structure of the CXXC domain of 
Xenopus Tet3: It contains eight conserved cysteine residues, which coordinate two zinc ions. The 
zinc ions hold the mainly unstructured CXXC domain together, creating a crescent-shaped 
architecture to bind DNA [67]. However, the CXXC domains of TET1 and TET3 prefer different 
substrates: the TET1 CXXC domain can bind to unmodified C as well as 5mC and 5hmC in a 
CpG-rich context [68], whereas the TET3 CXXC domain requires an unmodified cytosine to bind 
to DNA, but not necessarily in a strict CpG context [67]. TET2 has evolutionarily lost its putative 
CXXC domain as a result of a chromosomal gene inversion, which created the gene IDAX. IDAX 
can bind to unmethylated CpGs and also interacts with the catalytic domain of TET2. Surprisingly, 
it does not recruit TET2 to CpGs in order to promote TET2-mediated oxidation of 5mC, 5hmC and 
5fC, but instead it mediates caspase-dependent degradation of TET2. In fact, a similar mode of 
regulation was proposed for the CXXC domain of TET3 [69]. 
TET1 and TET3 have additional isoforms, termed TET1 short (TET1s) and TET3s, which lack the 
CXXC domain (Figure 3.2) [70,71]. The different TET isoforms likely play different roles in mouse 
development: while the full-length isoform of TET1 (TET1FL) is expressed in early embryos, ESCs 
and PGCs, TET1s is restricted to somatic cells. Interestingly, TET1s can still bind CpG islands 
despite lacking the CXXC domain, but its global chromatin affinity and DNA demethylation activity 
are reduced. In addition to the CXXC domain, also the first 131 amino acids (a.a.) of TET1FL can 
mediate global chromatin binding [70].  
 
 
Figure 3.2 Structure of mouse TET proteins 
TET family members share a common catalytic domain, consisting of a cysteine-rich region and a double-
stranded β-helix domain (DSBH) domain, which is split in two parts by a low complexity insert region. Only 
full-length TET1 (TET1FL) and full-length TET3 (TET3FL) also have a CXXC domain, which can mediate 
CpG binding. a.a., amino acids, s, short. Figure based on [41].  
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Unexpectedly, TET enzymes are not exclusively binding to sites enriched for the oxidized 5mC 
products of TET, 5hmC, 5fC and 5caC. On the contrary, TET binding sites are more enriched at 
active promoters (marked by H3K4me3), bivalent promoters (marked by H3K4me3 and 
H3K27me3) and CpG islands, but not at distal regulatory elements [70,72–75]. In this respect, a 
study by Zhang and colleagues found no correlation of TET1 binding sites and TET1-mediated 
DNA demethylation sites, neither at distal DNase I hypersensitivity regions, which are indicative 
of regulatory elements, nor at promoters [70].  
In addition to their catalytic functions, TET proteins also have non-catalytic functions. For 
example, TET1 contributes to transcriptional repression by interacting with the SIN3A-co-
repressor complex [74]. TET1 can also form a complex with the histone acetyltransferase MOF, 
preventing the auto-acetylation of MOF. This increases the chromatin affinity of MOF, leading to 
higher H4K16 acetylation and ultimately allowing DNA repair and the maintenance of genome 
stability [59]. TET2 can interact with and recruit the Histone deacetylase 2 (HDAC2) to mediate 
repression of interleukin-6 transcription during inflammation [76]. Moreover, all TET proteins can 
regulate transcription via the recruitment of O-linked N-acetylglucosamine transferase (OGT) 
[73,77,78]. The downregulation of TET2 reduces the the addition of N-acetylglucosamine (O-
GlcNAcetylation) of H2B serine 112, which in turn diminishes the transcription of target genes of 
OGT, H2B Ser 112 GlcNAc and TET2 [73]. In addition, both TET2 and TET3, in co-operation with 
OGT, promote binding of the H3K4 methyltransferase SETD1A to chromatin, to activate gene 
expression [78].  
In vivo, catalytically inactive mutants of TET proteins can exert some biological functions. For 
example, a catalytically inactive mutant of TET1 remains able to regulate memory-related genes 
in mice [79] and a Tet3 mutant in Xenopus laevis can partially rescue developmental defects 
caused by a Tet3 depletion [67]. A recent study has shed more light on TET2’s non-catalytic 
functions in hematopoiesis and revealed that the catalytic activity mainly regulates the myeloid 
lineage, while the non-catalytic functions are important for the lymphoid lineage [80]. 
3.1.5 Genomic distribution of the oxidative derivatives of 5mC 
The oxidative derivatives of 5mC are present at highly variable levels, depending on the tissue 
and cell type. 5hmC is present at high levels in the central nervous system and embryonic tissues, 
but has low levels in most other tissues [41]. 5fC and 5caC levels are much less abundant than 
5hmC, one reason being their active removal by TDG. In TDG-deficient mESCs, 5fC levels are 
about 6-fold increased, and 5caC levels are about 8-fold increased [81].  
Several studies have shed light on the genomic distribution of 5hmC, 5fC and 5caC in mESCs. 
5hmC is mostly located in gene-rich areas and increases in density from transcription start sites 
to transcription termination sites. 5hmC levels at promoters are generally low, whereas 5hmC is 
enriched at distal regulatory elements, especially at poised enhancers containing H3K4me1, and 
DNase I hypersensitivity sites. Interestingly, 5hmC levels are high near, but not directly at 
transcription factor binding sites [68,82–85]. 5fC and 5caC are found at major satellite repeats 
and poised enhancers in wild-type mESCs. Upon TDG depletion, 5fC and 5caC accumulate at 
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distal regulatory elements, TET binding sites, DNase I hypersensitivity regions, CCCTC-binding 
factor (CTCF) and p300 binding sites [81,86,87]. 
3.1.6 Regulation of TET proteins 
3.1.6.1 Regulation of TET proteins by substrates and cofactors 
The cofactors of TET proteins closely link TET enzymes to metabolism. α-KG is essential for TET 
enzymatic activity and is produced from isocitrate by the enzyme IDH as one step of the citric acid 
cycle. In the next steps, α-KG is converted to succinyl-coenzyme A by α-KG dehydrogenase, and 
further converted to succinate by the succinyl-coenzyme A synthetase. In mESCs, high levels of 
α-KG induce TET-dependent hypomethylation and support self-renewal while high levels of 
succinate promote differentiation [88]. Likewise, the modulation of the involved enzymes, such as 
overexpression of IDH1 or IDH2, can boost 5hmC levels in cells [89].  
Vitamin C can interact with the catalytic domain of TET enzymes and thereby enhance their 
activity towards 5mC oxidation [90]. In mice, a gestational Vitamin C deficiency mimics a TET1 
deficiency with regard to germline reprogramming, transcriptional profile, meiosis and fecundity. 
Specifically, Vitamin C deficiency leads to DNA hypermethylation at meiosis regulators and 
transposable elements in the embryonic germline, leading to failures in meiotic initiation and 
progression in fetal female germ cells [91]. Lastly, also iron(II) [92] and oxygen availability can 
influence TET activity, although the effects of oxygen on TET activity vary in cells and animals 
[41]. 
3.1.6.2 Post-translational modifications of TET proteins 
TET proteins can be regulated by various post-translational modifications, which can affect 
chromatin binding as well as the catalytic activity. All three TET proteins can be monoubiquitinated 
by the E3 ubiquitin ligase complex cullin-ring finger ligase-4 (CRL4). Ubiquitination occurs on a 
highly conserved lysine (K) residue (human TET1 K1589, TET2 K1299 and TET3 K859) within 
the catalytic domain. The monoubiquitination is promoted by the binding of the DDB1- and CUL4-
associated factor 1 (VprBP) to the catalytic domain of TET. VprBP is a binding partner of 
Damaged DNA binding protein 1 (DDB1), which itself is a member of the CRL4 complex. This 
monoubiquitination promotes the binding of TET to DNA and is essential for proper 5hmC 
production [93,94]. 
Furthermore, TET2 can be acetylated by the acetyltransferase p300 in the N-terminal region of 
TET2 at K110, and can be deacetylated by HDAC1 and HDAC2. Acetylation increases TET2 
activity, possibly by preventing polyubiquitination and thereby protein degradation. Interestingly, 
TET2 acetylation also enhances DNMT1 binding, which also promotes TET2 protein stability. In 
addition, a DNMT1 knockdown reduces TET2 tightening to chromatin during oxidative stress [95]. 
This suggests that DNA methylation and DNA demethylation could be directly coupled. 
All three TET family members are highly phosphorylated, mostly at the N-terminus and the low 
complexity insert region, whereas only a few phosphorylation sites have been identified in the 
catalytic domain. While the impact of phosphorylation on TET activity has only been scarcely 
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studied so far, it is known that phosphorylation can be suppressed via O-GlcNAcetylation of 
serines and threonines by the glycosyltransferase OGT [96]. O-GlcNAcetylation was shown to be 
required for both TET1-mediated 5hmC production and TET1-mediated target gene repression 
[97].  
Furthermore, human TET1 can be modified by addition of poly [ADP-ribose] (PAR), a negatively 
charged polymer. PARylation of TET1 is catalyzed by poly [ADP-ribose] polymerase 1 (PARP1) 
and enhances TET1 activity [98]. 
3.1.6.3 Interaction partners of TET proteins 
Several interaction partners of TET proteins have been identified, most of which help to target 
TET proteins to genomic loci. Several different transcription factors can target TET proteins to 
their binding sites. For example, NANOG physically interacts with TET1 and TET2 and recruits 
them to NANOG binding sites in mESCs, where TET1/2-mediated 5hmC production is required 
for proper somatic cell reprogramming [99]. In a similar manner, PR domain zinc finger protein 14 
(PRDM14) physically interacts with TET1/2 and recruits them to its target loci in mESCs in order 
to induce DNA demethylation at pluripotency-associated genes, germline-specific genes and 
imprinted loci [100]. Recently, Early growth response protein 1 (EGR1) was discovered to recruit 
TET1 in order to induce DNA demethylation and the activation of downstream genes during 
postnatal mouse development [101]. 
LIN28A, a protein that can bind both DNA and RNA, can recruit TET1 to transcription start sites 
in mESCs to induce DNA demethylation, linking LIN28A and TET1 specifically to active 
transcription [102]. In addition, TET proteins also interact with repressive protein complexes in 
mESCs, for example with two subunits of the Polycomb Repressive Complex 2 (PRC2): 
Suppressor of zeste 12 protein homolog (SUZ12) and Enhancer of zeste homolog 2 (EZH2). 
These interactions are in line with the finding that 5hmC correlates with the histone mark 
H3K27me3, which is generated by PRC2. Accordingly, a SUZ12 knockdown reduces 5hmC levels 
at H3K27me3 positive regions, especially within bivalent (H3K4me3 and H3K27me3 positive) 
promoters. This finding combines both roles of TET1, its activating function via DNA 
demethylation, and its repressive function via PRC2. These two opposing functions of TET 
proteins could be important to maintain developmental genes in a poised state [103]. 
TET1 also physically interacts with other DNA demethylation factors, such as TDG [42] and 
GADD45A [104] (see chapter 3.2.2). An in vitro study demonstrated that TET1 can interact with 
TDG via an N-terminal domain containing the CXXC domain, and the C-terminal catalytic domain 
of TET1. The two enzymes closely work together in promoting 5mC oxidation and excision, 
suggesting a closely coupled DNA demethylation pathway [42].  
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3.2 The role of GADD45A in active DNA demethylation 
3.2.1 Molecular functions of GADD45A 
GADD45A belongs to a family of small (18 kDa), stress-inducible acid nuclear proteins with three 
members: GADD45-alpha (GADD45A), -beta (GADD45B), and –gamma (GADD45G). GADD45 
proteins play a role in diverse processes such as cell cycle control, apoptosis and DNA repair 
[105]. In 2007, GADD45A was discovered to play a role in active DNA demethylation, which was 
proposed to occur via DNA repair through the recruitment of the endonuclease XPG [20]. 
Although other studies have confirmed a role of GADD45 proteins in active DNA demethylation, 
how and if GADD45 proteins mediate active DNA demethylation remains to be a matter of debate 
in the field, one reason being perhaps the lacking enzymatic activity of GADD45 proteins 
[27,31,33,106]. Since then, several mechanisms of GADD45-mediated DNA demethylation have 
been proposed: In zebrafish, Gadd45 proteins were shown to promote DNA demethylation via 
the recruitment of the deaminase AID, followed by thymine base excision by Methyl-CpG-binding 
domain protein 4 (Mbd4) [31]. However, this mechanism has been challenged [33]. More evidence 
for the involvement of GADD45 proteins in DNA demethylation emerged with the understanding 
of how GADD45 can be recruited to sites of DNA demethylation, and with the discovery of TET-
TDG mediated active DNA demethylation (see chapters 3.1.2 and 3.2.2). 
GADD45A can be directed to chromatin and mediate DNA demethylation by interacting with 
different chromatin factors. TAF12, a subunit of RNA Polymerase I and II-specific TBP-TAF 
complexes, can recruit GADD45A to the promoters of active genes [107]. The H3K4me3 reader 
Inhibitor of growth protein 1 (ING1) can recruit GADD45A to H3K4me3 positive regions via its 
PHD domain [108], and the long noncoding RNA TARID can recruit GADD45A to the TCF21 
promoter [109]. GADD45A-mediated locus-specific DNA demethylation was further corroborated 
by a recent study, which showed that Gadd45a/b/g triple-knockout mESCs display 
hypermethylation at ~ 7000 sites, but only minor global hypermethylation. The hypermethylated 
sites correlate with loci undergoing TET-TDG-dependent oxidation and are enriched for 
enhancers and coding exons [110]. Overall, these studies suggest that GADD45A has a role in 
gene-specific DNA demethylation rather than global DNA demethylation, as originally proposed 
[20]. 
In 2015, two studies consolidated GADD45A-mediated DNA demethylation and the TET-TDG 
pathway by discovering that GADD45A can interact with both TET1 [104] and TDG [111] (Figure 
3.3). First of all, GADD45A physically interacts with TET1 to enhance 5hmC formation [104]. 
Second, GADD45A physically interacts with TDG to increase 5fC and 5caC removal in transfected 
HEK293T cells [111]. In addition, Gadd45a/b double- and Gadd45a/b/g triple-knockout mESCs 
displayed hypermethylation at loci that are also affected by TDG depletion [110,111]. Still, the 
exact mechanism by which GADD45A enhances TDG activity has not been resolved to date.  
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3.2.2 Interaction of GADD45A and TET1 in active DNA demethylation 
Recent work in our research group linked the roles of GADD45A and TET1 in active DNA 
demethylation. As shown for TDG, GADD45A can also physically interact with TET1 to enhance 
TET1 activity. In particular, GADD45A enhances the formation of 5hmC by TET1. On the other 
hand, it reduces 5fC and 5caC levels, which is probably linked to its interaction with TDG (Figure 
3.3). Importantly, GADD45A also interacts with the isolated catalytic domain of TET1 to enhance 
5hmC production. In contrast, the enhanced removal of 5fC and 5caC mediated by GADD45A 
also requires the N-terminus of TET1. Moreover, GADD45A and full-length TET1 can 
synergistically activate a number of GADD45A target genes in HEK293T cells, which also requires 
the catalytic activity of TET1 [104]. Overall, this points to a dual function of GADD45A, namely to 
activate TET1 and also to enhance 5fC/5caC removal by TDG [104,111]. However, the 
mechanism by which GADD45A enhances TET1 activity and 5fC/5caC removal by TDG is still 
unresolved.  
 
 
Figure 3.3 TET-TDG mediated active DNA demethylation and the role of GADD45A 
Cytosine (C) is methylated by DNMT1 (maintenance methyltransferase) or DNMT3A/B (de novo methyl-
transferases) at the 5’ position. TET enzymes (TET1/2/3) oxidize the methyl group in an iterative manner to 
5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC). 5fC and 5caC are 
then excised by TDG, which generates an abasic (AP) site. Unmethylated C is finally restored by the base 
excision repair (BER) machinery. Modifications of C are highlighted in red. GADD45A (G45A) has a dual 
function in this process, as it can 1) interact with TET1 to enhance TET1 oxidation activity and 2) interact 
with TDG to enhance the removal of 5fC and 5caC.  
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3.3 Mitogen-activated protein kinases (MAP kinases) as interaction 
partners of GADD45 proteins 
3.3.1 Molecular functions of MAP kinases 
As stress response proteins, GADD45 proteins have various interaction partners, among them 
members of the Mitogen-activated protein kinase (MAP kinase) family [112]. MAP kinase 
signaling pathways are highly conserved and ubiquitous mechanisms of eukaryotic cell regulation 
and respond to various stimuli such as hormones, growth factors, cytokines, agents acting 
through G protein-coupled receptors, Transforming growth factor β-related agents, pathogen-
associated molecular patterns, and environmental stresses. MAP kinase signaling consists of a 
cascade comprised of three steps, which includes a MAP kinase kinase kinase, a MAP kinase 
kinase, and a MAP kinase (Figure 3.4). MAP kinases are proline directed kinases, which 
phosphorylate serines and threonines of protein targets only if they are followed by prolines. 
Substrate specificity is established through docking sites on the substrates [113,114]. 
3.3.2 Activation of MAP kinases by GADD45 proteins 
In response to stress, GADD45 proteins can mediate the activation of Mitogen-activated protein 
kinase kinase kinase 4 (MAP3K4/MTK1/MEKK4) by directly binding to an N-terminal region of 
MAP3K4. The binding of GADD45 proteins interrupts the auto-inhibition of the C-terminal kinase 
domain of MAP3K4, caused by the interaction with the N-terminus of MAP3K4. Upon GADD45 
binding, MAP3K4 can dimerize, allowing the autophosphorylation and activation of MAP3K4 
[115]. An activation of MAP3K4 activates downstream kinases such as MAP2K3, MAP2K4 and 
MAP2K6, which in turn activate MAPK14 (p38α) and MAPK11 (p38β) [114]. In addition, 
GADD45A can directly bind to p38 (MAPK11,12,13,14) and mediate oncogenic H-Ras-induced 
activation of p38 in a MAP3K4-independent manner [116].  
 
Figure 3.4 Overview of mammalian MAP kinase signaling and its interaction with GADD45A 
MAP kinase signaling forms a cascade, where a MAP kinase kinase kinase (MAP3K) phosphorylates a MAP 
kinase kinase (MAP2K), which in turn phosphorylates a MAP kinase (MAPK). MAP kinases can activate 
additional kinases. Solid lines indicate an activation via direct phosphorylation by an upstream kinase, while 
dashed lines indicate an activation via GADD45A (G45A).  
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3.4 The 3D genome architecture 
Beyond the regulation of active DNA demethylation via TET interaction partners such as 
GADD45A, also the three-dimensional (3D) genome architecture has been implicated in shaping 
the DNA (de)methylome [41]. Human diploid cells contain roughly 6 billion base pairs of DNA. 
This corresponds to about 2 meters of DNA per cell [117]. However, human cells only have a 
diameter of about 10-100 µM. The answer to how the entire DNA fits into the cell nucleus is: the 
eukaryotic DNA is packaged into chromatin, a complex of DNA, associated proteins and RNA. 
The first level of chromatin packaging is the nucleosome, which was discovered in the 1970s 
[118]. Nucleosomes are further organized into the 11 nm chromatin fiber, which folds at the 
submegabase scale into higher-order domains called topologically associating domains (TADs) 
(Figure 3.5 A) [119]. TADs have a high frequency of self-interaction and are separated from other 
TADs by boundary elements, such as the zinc finger protein CTCF and the Cohesin complex. 
Whereas TADs are conserved across tissues, sub-TADs (finer scale separation) and meta-TADs 
(larger scale separation) differ across cell types [120]. The sub-TADs, also known as intra-TADs, 
constrain promoter-enhancer interactions [121]. At the megabase scale, chromatin separates 
further into an active, so-called compartment A, and an inactive compartment B [122].  
 
 
Figure 3.5 Hierarchical model of chromatin organization 
A) The eukaryotic DNA is wrapped around histones, forming nucleosomes, which are organized into the 
11 nm chromatin fiber. At the submegabase scale, chromatin folds into TADs, regions that display a high 
frequency of self-interaction. TADs are separated by domain boundaries. These domain boundaries are 
created by CTCF and the Cohesin complex, which form so-called loop anchors. TADs can be further 
separated into sub-TADs, which are regions with a higher interaction frequency (dark red), and can also 
form meta-TADs, regions with an overall lower interaction frequency than the sub-TADs or TADs (light red). 
The lower panel represents interaction signals as obtained from Hi-C data. B) The loop extrusion model 
proposes a dynamic process of chromatin structuring, in which the Cohesin complex moves along the 
chromatin until it reaches CTCF binding sites. In this extrusion process, additional loop domains, also called 
sub-TADs, are formed and enhancers can be brought into close proximity to promoters. The arrows indicate 
movement of the Cohesin complex along chromatin.  
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TADs have been mainly defined by the so-called Hi-C method, a method based on chromosome 
conformation capture that was first described in 2009 by Lieberman-Aiden and colleagues. In this 
method, DNA fragments that are originally in close spatial proximity are ligated. Subsequently, 
interactions between DNA fragments are identified via next generation sequencing [122]. Today, 
the existence of TADs has been supported by alternative methods such as high resolution 
microscopy [123]. Yet, whereas the original Hi-C method gives an overview over the 3D structure 
in a population of cells and found that TADs are highly conserved, high resolution microscopy and 
also the more recent single-cell Hi-C identified a large number of cell-specific TADs [123,124]. 
3.4.1 Establishing TADs and promoter-enhancer contacts 
3.4.1.1 The role of the Cohesin complex in chromatin looping 
Cohesin is a multi-unit, ring-shaped protein complex that is highly conserved in eukaryotes (Figure 
3.6) [125]. Originally, it was discovered as an essential factor in cell division, during which it 
promotes sister chromatid cohesion, thus ensuring proper chromatid segregation during 
anaphase [126]. Cohesin’s ring-shaped structure is formed by the coiled-coil domains of the 
Structural maintenance of chromosomes subunits 1 and 3 (SMC1 and SMC3), which form a 
heterodimer. SMC1 and SMC3 contain ATPase domains, which are connected by a protein called 
RAD21. This tripartite ring has a diameter of about 40 nm, which can enclose one or two 
chromatin strands [127]. The fourth subunit, SA1 or SA2, contacts RAD21 and additional Cohesin 
subunits transiently associate with the complex, such as PDS5 and WAPL. SA1/2, PDS5 and 
WAPL are necessary to remove Cohesin complexes from chromatin [125]. 
 
 
Figure 3.6 The Cohesin Core Complex 
The ring-shaped Cohesin complex consists of the Structural maintenance of chromosomes subunits 1 and 
3 (SMC1 and SMC3), which form a heterodimer. SMC1 and SMC3 contain ATPase domains, which are 
connected by RAD21, closing the ring structure. The fourth subunit, SA1 or SA2, contacts RAD21 and plays 
a role in the first part of Cohesin release. Additional Cohesin subunits associate transiently with the complex, 
such as PDS5 and WAPL, which are essential for Cohesin removal. 
 
In 2008, Wendt and colleagues discovered a new function of Cohesin: shaping the 3D chromatin 
structure. Their study showed that the binding sites of Cohesin greatly overlap with the binding 
sites of CTCF, a factor already known to be important for transcriptional insulation [128]. Today, 
the loop extrusion model is the most accepted model that describes how Cohesin and CTCF 
cooperate to shape the 3D genome. Cohesin is loaded onto chromatin by the NIPBL-MAU2 
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complex and moves along the chromatin until it is blocked by CTCF bound to convergent CTCF 
binding sites [129]. The extrusion process can occur actively via the motor activity of the ATPase 
domains of SMC1 and SMC3 [130], via constant Cohesin loading and diffusion [131], or via RNA 
Polymerase II during transcription [129]. Through this process, Cohesin and CTCF form loop 
domains. During the extrusion process, regulatory regions such as enhancers and promoters are 
brought into close proximity (Figure 3.5 B). Conversely, enhancers and promoters lying within 
different TADs can be isolated from one another by boundary elements, such as the loop anchors 
consisting of CTCF and Cohesin [120]. 
Evidence for Cohesin’s importance in loop domain formation comes from several studies all 
published in 2017, in which either the Cohesin subunit RAD21, the Cohesin loading factor NIPBL, 
or the release factors WAPL and PDS5 were depleted. Rao and colleagues acutely depleted 
RAD21 in HCT116 cells using the auxin-inducible degron system. Already 40 min of RAD21 loss 
depleted the loop domains, whereas auxin withdrawal could restore the majority of loops within 
60 min [132]. Moreover, the Cre-driven conditional deletion of Rad21 in mouse oocytes also 
depleted loops in the one-cell embryo [133]. In a study by Schwarzer and colleagues, Nipbl was 
deleted in mice, specifically in non-dividing hepatocytes, using a tamoxifen-inducible Cre driver. 
The depletion of NIPBL led to a strong reduction of chromatin-bound Cohesin; more notably, 
TADs disappeared globally [134]. Finally, also the release factors WAPL and PDS5 were shown 
to play a role in proper loop formation: by depleting WAPL in HAP1 cells, Haarhuis and colleagues 
found that WAPL restricts chromatin loop extension [135]. This finding was also confirmed in 
mouse zygotes by Gassler and colleagues [133]. Accordingly, PDS5 depletion by RNAi in HeLa 
cells decreased TAD numbers but increased TAD sizes [136]. Interestingly, the above-mentioned 
studies also show that Cohesin restricts compartmentalization, i.e. the separation of chromatin 
into an active compartment A, and an inactive compartment B. In addition, Cohesin loss causes 
superenhancers to co-localize, thereby allowing aberrant transcription of nearby genes [132]. 
Overall, Cohesin has a complex role in the 3D genome organization; to allow distant genomic 
regions to interact, but also to insulate genomic regions from one another. 
3.4.1.2 The role of additional factors in promoting promoter-enhancer contacts 
Although the Cohesin complex can bring together enhancers and promoters, and CTCF can act 
as a boundary to restrict aberrant promoter-enhancer interactions outside of TADs, promoter-
enhancer contacts are not directly mediated by Cohesin and CTCF. Instead, additional factors 
have been implicated in the promotion of promoter-enhancer contacts. These include Mediator, 
a transcriptional co-activator complex of RNA polymerase II transcription [137], its interactor 
Estrogen-related receptor b (ESRRB) [138], the transcription factors Yin Yang 1 (YY1) [139], 
ZNF143 [140] and OCT4 [141], long noncoding RNAs [142], and the CHD4-ADNP-HP1 (ChAHP) 
complex [143]. 
Mediator can form a complex with Cohesin, and loops are formed between sites co-occupied by 
both Mediator and Cohesin. In contrast to CTCF and Cohesin co-bound sites, which tend to be 
more conserved, Mediator-Cohesin co-bound sites were found to be cell-type specific [137]. YY1 
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is a zinc-finger transcription factor, which is ubiquitously expressed and can promote structural 
chromatin interactions by forming dimers, in a similar manner as CTCF. To monitor promoter-
enhancer contacts after YY1 depletion, Weintraub and colleagues used the degradation tag 
(dTAG) system to deplete YY1 in mESCs and performed HiChIP, a protein-centric chromatin 
conformation method, for H3K27ac. YY1 depletion led to a decreased interaction frequency of 
enhancers and promoters, which was accompanied by significant expression changes of 60 % of 
the genes connected by YY1 promoter-enhancer loops [139]. Another zinc-finger protein, ZNF143 
was also shown to bind to promoter-enhancer loops in human cancer cell lines and also mouse 
sperm [140,144]. Some ZNF143 binding sites only co-localized with Cohesin, but not CTCF 
binding sites. Interestingly, these were preferentially short-range interactions, implicating that 
ZNF143 might play a role in the regulation of sub-TADs [144]. A recent preprint discovered 
another transcription factor that can target Cohesin to CTCF-unbound sites: OCT4. The authors 
propose a model by which the pioneer transcription factor OCT4 can create open chromatin 
regions, which allows Cohesin to bind [141]. Cohesin was also found to be enriched at a new 
class of long noncoding RNA loci, called trait-relevant intergenic long noncoding RNAs. As these 
long noncoding RNA loci are also enriched for enhancer-like chromatin signatures, this study 
suggests an involvement of long noncoding RNAs in shaping promoter-enhancer interactions 
[142]. Recently, the ChAHP complex, a complex comprised of the zinc finger transcription factor 
ADNP, the chromatin remodeler CHD4 and the heterochromatin binding protein HP1, was 
demonstrated to counteract chromatin looping by competing for CTCF binding sites [143].  
However, how Cohesin, CTCF and the various regulators act together in promoting promoter-
enhancer contacts has not been studied in detail. Furthermore, yet uncharacterized or cell-type 
specific factors might play additional roles. In fact, a study by Rubin and colleagues proposed that 
there might be Cohesin-independent promoter-enhancer loops, which are formed during 
differentiation. During epidermal differentiation, one class of promoter-enhancer contacts 
established contacts, while the second class already existed in undifferentiated cells. Notably, 
while the second class was associated with Cohesin, the first class was Cohesin independent. 
Instead, the newly established promoter-enhancer contacts were bound by the differentiation 
induced transcription factors KLF4 and ZNF750. Since these two factors also bind to other 
regions, they do not globally regulate promoter-enhancer looping, but rather are cell-type specific 
regulators of promoter-enhancer contacts [145].  
In contrast, Matthews and Waxman computationally predicted and experimentally validated that 
CTCF and Cohesin also form anchor loop structures within TADs, which they refer to as intra-
TAD loops. These intra-TAD loops constrain promoter-enhancer contacts and show conservation 
among various mouse and human tissues [121]. A recent preprint has further underlined the 
importance of Cohesin in mediating promoter-enhancer contacts. Depletion of the release factor 
WAPL resulted in decreased contact frequency between promoters and regulatory elements 
[141]. In conclusion, tissue invariant, i.e. CTCF/Cohesin as well as tissue specific mechanisms, 
e.g. transcription factors, likely cooperate to promote and also to constrain promoter-enhancer 
contacts. 
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3.4.2 The role of promoter-enhancer looping in gene regulation 
It has long been proposed that enhancers regulate promoters via looping [146]. However, only in 
recent years more light has been shed on the relationship between chromatin structure and gene 
regulation. While disturbances of the local chromatin structure can have an immense impact on 
the regulation of individual genes, disturbances of global players, such as CTCF and Cohesin, 
have a surprisingly small effect [132,147].  
An example for the regulation of an individual locus is the thoroughly studied β-globin locus, which 
contains several β-globin genes. In erythroid cells, a distal enhancer, referred to as the locus 
control region, physically contacts different β-globin promoters at different developmental stages 
to stimulate transcription of the appropriate β-globin. By artificially targeting the promoter of the 
repressed fetal β-globin gene to the distal enhancer, transcription of the fetal β-globin gene could 
be greatly enhanced in human erythroblasts [148]. 
Still, existing promoter-enhancer contacts do not necessarily lead to active transcription. 
Developmental studies in flies and mice have demonstrated that many promoter-enhancer 
contacts persist during different developmental stages, although the transcriptional programs are 
quite different [144,149]. In fact, many promoter-enhancer contacts are even associated with 
paused RNA polymerase [149]. Thus, chromatin structure seems to be important for gene 
regulation, but is not the only mode of regulation. 
In this context, manipulation of conserved regulators of chromatin looping does not greatly affect 
gene expression. Depletion of the Cohesin subunit RAD21 leads to a loss of loops in HCT116 
cells, but only to minor gene expression changes. Out of 12,222 genes that were expressed in 
untreated cells, only 66 genes showed a ≥ 2-fold change [132]. Two recent preprints found 
similarly modest, although slightly more widespread, reductions in gene transcription in mESCs 
[141,150]. In addition, Rhodes and colleagues discovered a new role for Cohesin in counteracting 
long-range polycomb chromatin domain interactions. Out of 365 downregulated genes after 
RAD21 depletion, 251 genes were bound by the PRC1 member RING1B [150].  
Manipulating Cohesin loading via NIPBL deletion in mouse hepatocytes led to differential gene 
expression of about a thousand genes, with more genes downregulated than upregulated. 
Exogenic regions, i.e. intergenic or antisense intragenic regions, were more often upregulated 
than downregulated [134]. When Cohesin release was inhibited by WAPL deletion in HAP1 cells, 
a similar number of genes was misregulated [135]. Although these numbers are higher than the 
number of differentially expressed genes after RAD21 depletion, the genes misregulated after 
NIPBL and WAPL depletion still only correspond to a subset of genes. In addition, even in regions 
where loop length increased after WAPL depletion, genes were still identified for which gene 
expression did not change [135]. 
Loss of CTCF in mESCs disrupted TAD insulation, giving rise to ectopic contacts across TAD 
boundaries. However, effects on gene transcription were also modest, with 370 differentially 
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expressed genes after 1 day of CTCF depletion. A subset of genes was upregulated, possibly 
due to loss of CTCF’s insulator function, and resulting ectopic activation by enhancers [147].  
In summary, disrupting 3D chromatin structuring factors does affect gene expression, but to a 
very limited extent. A reason could be that multiple factors shape the 3D chromatin in concert to 
ensure a fine-tuned gene regulation. Thus, the factors still intact in the described experimental 
conditions might compensate for the loss of one or only a few of these factors. 
3.4.3 The interplay between chromatin structure and DNA (de)methylation 
3.4.3.1 Chromatin structure as a regulator for active DNA (de)methylation 
The direct impact of disturbing promoter-enhancer looping on gene expression is rather modest. 
Hence, the question arises what other functions promoter-enhancer looping might have. The 
oxidation products of TET – 5hmC, 5fC and 5caC – are largely found at distal elements, whereas 
TET enzymes themselves are usually found at promoters. One model to explain this conundrum 
is that TET enzymes are recruited to enhancers via promoter-enhancer looping [41]. A 
mechanistic proof of this model is still missing, but several independent studies have formed a 
basis of support for this model.  
A study by Song and colleagues found that 5hmC and 5fC are enriched especially at enhancers 
predicted to link to promoters, suggesting that the loop structure might be important to mediate 
5mC oxidation [86]. In addition, two studies by Sun and colleagues showed that 5hmC and 5fC 
are located at CTCF-bound regions, i.e. regions that are important for constraining promoter-
enhancer contacts. At these regions, 5hmC and 5fC are distributed in a symmetrical and regularly 
spaced oscillating manner. The distance between neighboring 5hmC and 5fC peaks correlates 
with the unit length of the DNA wrapped around one nucleosome, ~150 bp. Thus, the nucleosome 
structure is likely important for TET regulation, perhaps by affecting the accessibility of 5mC and 
5hmC, the substrates for TET enzymes [83,84].  
A recent study discovered GADD45A and ING1 as novel factors involved in organismal aging via 
DNA demethylation of C/EBPβ-dependent superenhancers. This local DNA demethylation was 
dependent on long-range chromatin looping. While the TET1 interactor GADD45A was found to 
occupy mostly superenhancers, the second key protein, ING1, occupied promoters. As not only 
GADD45A, but also ING1 can interact with TET1, long-range chromatin looping was proposed to 
bring all of these factors together in order to induce DNA demethylation [151].  
Lastly, at distal regulatory regions, DNA binding factors have been implicated in shaping the 
methylome. Of note, CTCF binding itself was suggested to initiate local DNA demethylation [152]. 
3.4.3.2 DNA (de)methylation as a regulator for chromatin structure 
In a converse fashion, DNA (de)methylation can also regulate CTCF/Cohesin binding. CTCF itself 
is methylation sensitive and upon hypermethylation of its binding sites, CTCF binding is reduced 
[153]. In addition, DNA methylation was recently suggested to regulate CTCF/Cohesin-mediated 
chromatin interactions via the Methyl-CpG-binding protein 2 (MeCP2). A loss of DNMT3B reduced 
RAD21-mediated chromatin interactions in human ESCs. Xu and Corces proposed that this is 
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due to a loss of hemimethylation, likely because of an altered physical interaction with MeCP2 
[154]. MeCP2 can, as described by its name, bind to methylated C occurring in a CpG context, 
but also binds to 5hmC [155]. In addition, it can alter the chromatin state, e.g. by affecting histone 
H1 binding [156] or by recruiting the chromatin remodeler ATRX in order to allow CTCF binding 
[157]. Moreover, MeCP2 interacts with SMC1 and SMC3, two members of the Cohesin complex, 
and MeCP2’s interactor ATRX was shown to be required for the chromatin occupancy of Cohesin 
and CTCF [158].  
Whether DNA (de)methylation regulates chromatin structure, or if the chromatin structure 
determines the distribution of 5mC, 5hmC, 5fC and 5caC is unclear. It is possible that both control 
each other in a feedback mechanism to ensure the proper regulation of the genome, as was 
proposed by a recent study by Wiehle and colleagues [159]. On the one hand, they established 
CTCF as an insulator against the spreading of DNA methylation and proposed that CTCF sites 
could act as “bookmarks” for DNA demethylation. On the other hand, they showed that TET1/2 
deficiency leads to a gain of DNA methylation and increased nucleosome occupancy, and thereby 
to an altered chromatin structure. Uniting both regulatory pathways, the increased nucleosome 
occupancy itself can affect CTCF binding, which in turn changes DNA methylation patterns. 
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3.5 Aim of the thesis 
Research of the past 10 years has revealed many milestones regarding the understanding of 
active DNA demethylation in vertebrates. Today we comprehend the details of the biochemical 
mechanism of TET-mediated oxidation of 5mC and its oxidative derivatives in considerable detail. 
The regulation of TET enzymes by post-translational modifications and interacting proteins has 
also been widely studied; however, how post-translational modifications and interactors directly 
affect the enzymatic activity of TET remains uncertain. The small protein GADD45A is required 
for TET1 induced 5mC oxidation and DNA demethylation [104]. Yet, the mechanism by which 
GADD45A enhances TET1 activity and 5fC/5caC removal is still unresolved. In addition, a 
conundrum in the field of DNA demethylation has not been solved thus far: whereas TET binding 
sites are mostly found at promoters, the oxidation products of TET, 5hmC, 5fC and 5caC are 
mostly enriched at enhancers. My thesis addresses two TET-related topics: 1) TET1 regulation 
by GADD45A and 2) TET regulation by RAD21-dependent chromatin looping. 
In order to unravel the mechanism of GADD45A-mediated TET1 regulation, I explored several 
different possibilities. I considered that GADD45A could affect post-translational modifications of 
TET1 and monitored GADD45A-mediated changes of TET1-phosphorylation, -ubiquitination and 
-SUMOylation and their impact on TET1 activity. In addition, I focused on a few potential 
GADD45A-dependent interactors of TET1 and analyzed their roles in regulating TET1.  
To address the discrepancy between the location of TET binding sites and 5hmC, 5fC and 5caC 
sites, I first generated a system where chromatin loops could be globally depleted. I used mESCs 
as a model system and CRISPR/Cas9 to establish a conditional RAD21-knockout system. To 
investigate whether the loss of promoter-enhancer loops leads to a loss of 5fC at enhancers, I 
depleted the loops by depleting RAD21 and monitored 5fC levels via DNA immunoprecipitation 
followed by sequencing. 
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4 Results 
4.1 Investigating mechanisms of GADD45A-mediated TET1 regulation 
Our laboratory recently showed that GADD45A is required for TET1 induced 5mC oxidation and 
DNA demethylation [104]. However, at the start of my PhD project, the mechanism by which 
GADD45A enhances TET1 activity and 5fC/5caC removal was still unresolved. In the following 
chapters, I explored various possible mechanisms by which GADD45A could enhance TET1 
activity: by the interaction with MAP kinases (4.1.2), by enhancing ubiquitination (4.1.3) or 
SUMOylation (4.1.4) and by the recruitment of interactor proteins (4.1.5 and 4.1.6).  
4.1.1 Activity of a GADD45A-TET1 fusion protein 
In order to study the functional interaction between GADD45A and TET1 in more detail, I 
generated a fusion construct of GADD45A and the catalytic domain of TET1 (TET1CD), with an 
N-terminal FLAG-HA tag and a flexible glycine-serine (GS)-linker between GADD45A and 
TET1CD (Figure 4.1 A, top). I transfected HEK293T cells with two GADD45A-TET1CD fusion 
constructs (originating from two different bacterial clones), as well as three control TET1CD 
constructs, in three different concentrations, and monitored the protein expression by Western 
blotting (Figure 4.1 A, bottom). The GADD45A-TET1CD fusion proteins could be detected both 
with an HA and a GADD45A-antibody, and they were similarly or better expressed than the 
TET1CD proteins.  
To test the enzymatic activity of the GADD45A-TET1CD fusion proteins, genomic DNA was 
purified from HEK293T cells overexpressing the constructs and subjected to quantitative mass 
spectrometry. When TET1CD was transfected at the highest concentration (2 µg/well in a 12-well 
dish in a total volume of 600 µl), 5hmC levels were increased 18-fold compared to empty vector 
transfection (Figure 4.1 C, compare “TET1CD” to “Control”, black bars). However, 5hmC levels 
were only 6-fold enriched using the GADD45A-TET1CD fusion protein (Figure 4.1 C, compare 
“GADD45A-TET1CD” to “Control”, black bars). This effect was more pronounced for 5fC and 
5caC levels, as they could barely be detected after overexpression of the GADD45A-TET1CD 
fusion protein, whereas they were easily detectable after TET1CD transfection (Figure 4.1 D and 
E). Thus, instead of the expected enhanced activity, the GADD45A-TET1CD fusion construct had 
a reduced activity towards 5mC oxidation. One reason could be that the 10-amino acid linker 
(GGGGSGGGGS) between GADD45A and TET1 is not sufficiently long and flexible, and the 
fusion protein had a reduced activity because of steric hindrance. Consequently, I did not use the 
GADD45A-TET1 fusion constructs in further experiments to study the functional interaction 
between these two proteins. 
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Figure 4.1 The GADD45A-TET1CD fusion protein has a reduced catalytic activity 
HEK293T cells were transfected for 48 h with empty vector (Control), TET1CD, or GADD45A-TET1CD 
fusion constructs. (A) Top: Scheme of the GADD45A-TET1CD fusion construct. Bottom: Western blot 
showing expression levels of TET1CD and GADD45A-TET1CD. Plasmids were transfected in 3 different 
concentrations, 0.5 µg, 1 µg and 2 µg (per well of a 12-well dish in a total volume of 600 µl) represented by 
the triangle above. MW, molecular weight; Co, control. (B-E) Quantitative mass spectrometry measurements 
of genomic cytosine modifications. Mass spectrometry data by Dr. Michael Musheev.  
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4.1.2 GADD45A and MAP kinase mediated TET1 regulation 
Unpublished data from our laboratory suggested that the MAP kinase MAP3K4, a known 
interactor of GADD45A [160], might play a role in enhancing TET1 activity in a GADD45A-
dependent manner (Dr. Andrea Schäfer, personal communication). The binding of GADD45A to 
MAP3K4 mediates the autophosphorylation of MAP3K4, thereby activating the kinase [115]. 
Thus, TET1 could be a potential phosphorylation target of MAP3K4 or its downstream kinases 
and I investigated how GADD45A, MAP kinases and TET1 functionally interact. 
4.1.2.1 GADD45A and MAP3K4 decrease TET1 oxidation products 
To study the effect of GADD45A and MAP3K4 on TET1 enzymatic activity, these proteins were 
transiently overexpressed in different combinations in HEK293T cells. The cell line HEK293T was 
chosen as it is easy to manipulate and cost-efficient. However, it has very low endogenous TET1 
expression levels, and consequently, very low 5hmC, 5fC and 5caC levels. Therefore, also TET1 
has to be overexpressed to increase the levels of oxidized 5mC derivatives.  
The overexpression of TET1, GADD45A and MAP3K4 was confirmed by Western blot analysis 
(data not shown). 5mC and its oxidative derivatives – 5hmC, 5fC and 5caC – were measured by 
quantitative mass spectrometry (Figure 4.2 A-D). Whereas 5mC levels were not affected by the 
overexpression of the different proteins on a genomic scale, TET1 overexpression led to a 6-fold 
and 50-fold increase in 5hmC and 5fC, respectively, and raised 5caC levels to a detectable level 
(Figure 4.2 B-D, compare dark grey bars to light grey bars). Co-expression of GADD45A and 
TET1 significantly increased 5hmC levels (compared to TET1 overexpression alone, p<0.005), 
while 5caC levels were reduced (p<0.0005), consistent with previous reports [104,111]. MAP3K4, 
TET1 and GADD45A co-expression reduced 5hmC levels compared to TET1 overexpression 
alone (Figure 4.2 B, compare green bar to dark grey bar). Of note, the observed differences in 
5hmC levels did not arise from different TET1 protein expression levels (data not shown). This 
observed reduction is surprising, as it is opposite to the increase in 5hmC levels caused by 
GADD45A and TET1 co-expression. Moreover, it mimics the depletion of GADD45A, which also 
leads to a decrease in 5hmC levels [104].  
5fC and 5caC levels were also reduced when MAP3K4 was co-expressed with TET1 and 
GADD45A (p<0.0005) (Figure 4.2 C and D, compare green bars to dark grey bars). Also, the co-
expression of MAP3K4 and TET1, without GADD45A, decreased 5caC levels (p<0.0005) 
(compare blue bars to dark grey bars). The decrease in global 5hmC, 5fC and 5caC levels by the 
co-expression of GADD45A and MAP3K4 can be interpreted in contrasting ways: First, TET1 
enzymatic activity could be inhibited by MAP3K4. However, it is also possible that GADD45A and 
MAP3K4 might enhance TET1-mediated 5mC oxidation, as the reduction of 5hmC, 5fC and 5caC 
might be the result of an increased TET1 enzymatic activity coupled to an accelerated removal of 
5fC and 5caC by TDG. In addition, it also has to be considered that active MAP3K4 might solely 
affect the removal of 5fC and 5caC by TDG, and not TET1 activity directly. 
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Figure 4.2 GADD45A and MAP3K4 decrease TET1 oxidation products  
Quantitative mass spectrometry measurements of genomic levels of 5mC (A), 5hmC (B), 5fC (C) and 5caC 
(D) in HEK293T cells, which were transiently transfected for 48 h with plasmids encoding the indicated 
proteins or empty vector (Control). N/D, non detectable. Data shown as mean ± SD, n=3, ** = p-value < 
0.005, *** = p-value < 0.0005, according to student’s t-test. Mass spectrometry data by Dr. Michael Musheev. 
 
4.1.2.2 siRNA knockdown of selected MAP kinases does not rescue the MAP3K4-
induced reduction of 5hmC, 5fC and 5caC levels 
MAP3K4 is part of a complex network of MAP kinases, with many kinases being redundant (see 
Figure 3.4) [113]. In order to unravel whether MAP3K4 is directly responsible for the reduction of 
5hmC, 5fC and 5caC levels (see Figure 4.2), or if downstream kinases of MAP3K4 or other MAP 
kinases are involved, I performed siRNA knockdowns of candidate MAP kinases followed by 
quantitative mass spectrometry to monitor oxidized 5mC levels. I also overexpressed TET1, 
GADD45A and MAP3K4 to monitor if the siRNA knockdowns rescued the above-mentioned 
reduction of oxidized 5mC derivatives. 
Successful knockdown of the MAP kinases was confirmed via reverse transcription followed by 
quantitative PCR (RT-qPCR), showing siRNA knockdown efficiencies between 40 and 80 %. For 
one kinase, MAP3K6, the siRNA knockdown was not successful (data not shown). The 
overexpression of TET1, GADD45A and MAP3K4 was confirmed by Western blot analysis and 
of note, their expression levels were not affected by the siRNA knockdowns (data not shown).  
None of the transfected siRNAs rescued the reduction of 5hmC, 5fC and 5caC levels by MAP3K4 
(Figure 4.3 B-D, compare green bars to blue bars). This suggests that none of the tested MAP 
kinases is required for the reduction of 5hmC, 5fC and 5caC levels by MAP3K4 and GADD45A. 
Alternatively, higher knockdown efficiencies might be required to affect 5hmC, 5fC and 5caC 
levels. 
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Figure 4.3 siRNA knockdown of selected MAP kinases does not rescue the MAP3K4-induced 
reduction of 5hmC, 5fC and 5caC levels 
Quantitative mass spectrometry measurements of the levels of 5mC (A), 5hmC (B), 5fC (C) and 5caC (D) in 
HEK293T cells. Cells were transfected with control or specific siRNAs 24 h prior to DNA transfection with 
empty vector (Control), or a combination of TET1, GADD45A or MAP3K4 and harvested 72 h post siRNA 
transfection. N/D, non detectable. Mass spectrometry data by Dr. Michael Musheev. 
 
As many MAP kinases are redundant, the knockdown of only one kinase might not have any 
effects on target proteins. Thus, I also performed combined knockdowns of selected MAP 
kinases. Depletion of the MAP kinases was again monitored via RT-qPCR, showing siRNA 
knockdown efficiencies between 40 and 60 %, with the exception of MAPK12, MAP2K6 and 
MAP3K6, for which the knockdown was not successful (data not shown). The overexpression of 
TET1, GADD45A and MAP3K4 was confirmed by Western blot analysis and similar to the single 
MAP kinase siRNA knockdowns, the combined knockdowns did not affect the expression levels 
of TET1, GADD45A and MAP3K4 (data not shown).  
Considering 5mC oxidation, the combined knockdowns of MAP kinases also did not rescue the 
reduction of 5hmC, 5fC and 5caC levels by MAP3K4 and GADD45A (Figure 4.4 B-D, compare 
green bars to blue bars). This suggests that the tested MAP kinases are most likely not involved 
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in reducing 5hmC, 5fC and 5caC levels in a MAP3K4-dependent manner. Still, since the siRNA-
mediated knockdowns did not lead to a complete depletion of the mRNA levels, it does not fully 
exclude a possible role of the tested kinases in TET1 regulation. Also, additional downstream 
MAP kinases could be involved, which were not tested in these experiments. 
 
Figure 4.4 Combined siRNA knockdown of MAP kinases does not rescue the MAP3K4-induced 
reduction of 5hmC, 5fC and 5caC levels  
Quantitative mass spectrometry measurements of the levels of 5mC (A), 5hmC (B), 5fC (C) and 5caC (D) in 
HEK293T cells. Cells were transfected with control or a combination of specific siRNAs targeting MAP 
kinases 24 h prior to DNA transfection with plasmids encoding the indicated proteins, and harvested 72 h 
post siRNA transfection. N/D, non detectable. Data shown as mean ± SD, n=3, *** = p-value < 0.0005, 
according to student’s t-test. Mass spectrometry data by Dr. Michael Musheev. 
 
4.1.2.3 The p38 inhibitor SB202190 reduces TET1 activity 
An alternative approach to reducing the MAP kinase activity is using specific MAP kinase 
inhibitors. I used two different inhibitors, SB202190 and U0126: SB202190 inhibits MAPK11 
(p38B) and MAPK14 (p38A) [161], and U0126 inhibits MAP2K1 (MEK1) and MAP2K2 (MEK2) 
[162]. Similar to previous siRNA knockdown experiments (see 4.1.2.2), TET1, MAP3K4 and 
GADD45A were overexpressed in HEK293T cells, this time with the addition of the inhibitor 
treatments.  
The U0126 inhibitor treatment did not lead to any change in 5mC levels or 5hmC levels (Figure 
4.5 A and B, compare dark blue bars to grey bars). Since the success of the U0126 inhibitor 
treatment was not tested, e.g. by determining the phosphorylation levels of downstream 
MAP2K1/MAP2K2 target proteins, it cannot be excluded that a higher concentration of the 
inhibitor would have been necessary to cause effects. However, other studies have shown that a 
concentration of 10 µM of the U0126 inhibitor depletes the phosphorylation of downstream 
MAP2K1/MAP2K2 proteins [163,164], which is a lower concentration than the 25 µM used in this 
study. Assuming that the U0126 inhibitor treatment was successful, this suggests that MAP2K1 
and MAP2K2 are not involved in MAP3K4-mediated regulation of TET1.  
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The SB202190 inhibitor also did not affect 5mC levels. When only TET1 was overexpressed, 
SB202190 treatment slightly decreased 5hmC levels, although not significantly (Figure 4.5 B, 
compare light blue bar to grey bar). When GADD45A was co-expressed, however, 5hmC was 
significantly reduced (p<0.0005) (compare light blue bar to grey bar). Thus, SB202190 treatment 
blocked the increase of 5hmC levels by GADD45A. When MAP3K4 and TET1, or MAP3K4, 
GADD45A and TET1 were co-expressed, there was also a reduction of 5hmC by the SB202190-
treatment (compare light blue bars to grey bars).  
If MAP3K4 acted on TET1 via its downstream kinases MAPK11 (p38B) and MAPK14 (p38A), the 
use of the SB202190 inhibitor should block the effect of MAP3K4, i.e. increase 5hmC levels to 
the levels produced by TET1 overexpression alone. This, however, was not observed here. In 
contrast, the results suggest that MAPK14 and MAPK11 might enhance TET1 activity 
independently of MAP3K4. Therefore, GADD45A could regulate TET1 via MAP3K4 and 
MAPK11/14 via two independent pathways and with opposing effects. 
MAP kinases can affect the activity of their target proteins via phosphorylation [113]. Thus, to 
further address MAP3K4-mediated TET1 regulation, experiments had been performed in our 
laboratory by Dr. Andrea Schäfer to determine phosphorylation sites of TET1 via quantitative 
proteomics, in collaboration with the research group of Dr. Petra Beli (IMB Mainz). GADD45A and 
constitutively active MAP3K4 enhanced the phosphorylation of three common serine residues of 
TET1, namely serine 322, serine 871 and serine 1851. Furthermore, the siRNA knockdown of 
MAP3K4 impaired GADD45A-enhanced TET1 phosphorylation at two of these residues, serine 
322 and serine 871 (Dr. Andrea Schäfer, personal communication).  
To investigate which downstream MAP kinases are involved in these phosphorylation changes, I 
decided to also use a quantitative proteomics approach: Stable Isotope Labeling with Amino acids 
in Cell culture (SILAC) was used to quantitatively compare TET1 phosphorylation sites from 
inhibitor-treated cells vs. DMSO-treated controls. The SB202190 inhibitor reduced 
phosphorylation of two TET1 phosphorylation sites, serine 116 and serine 871, to a SILAC ratio 
of 0.5, compared to control treatment (Figure 4.5. C, light blue bars). Interestingly, 
phosphorylation of serine 871 was enhanced by the overexpression of GADD45A or constitutively 
active MAP3K4 (Dr. Andrea Schäfer, personal communication), indicating that this 
phosphorylation site might play a role in GADD45A-MAP3K4-mediated regulation of TET1.  
The U0126 inhibitor reduced the phosphorylation of serine 45 to a SILAC ratio of 0.6, and 
enhanced serine 1303 phosphorylation to a ratio of 1.5. However, the latter was only enhanced 
in one of two replicates (Figure 4.5. C, dark blue bars) and these phosphorylation sites were not 
affected by GADD45A depletion or overexpression (Dr. Andrea Schäfer, personal 
communication). 
To further elucidate the role of phosphorylation in regulating TET1 activity, TET1 mutants lacking 
one, two or three phosphorylation sites were generated by mutating serines to alanines. These 
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included mutations of serines 116 and 871; however, the TET1 mutants did not affect TET1 
enzymatic activity (Dr. Andrea Schäfer, personal communication). 
 
 
 
Figure 4.5 The p38-inhibitor SB202190 reduces TET1 activity 
(A and B) Quantitative mass spectrometry measurements of the levels of 5mC (A), and 5hmC (B) in 
HEK293T cells, which were transiently transfected for 48 h with plasmids encoding the indicated proteins or 
empty vector (Control). At the time of transfection, cells were treated with DMSO, 25 µM SB202190 
(MAPK11/MAPK14-inhibitor) or 25 µM U0126 (MAP2K1/MAP2K2-inhibitor). Data shown as mean ± SD, 
n=3, ns = non significant, ** = p-value < 0.005, *** = p-value < 0.0005, according to student’s t-test. Mass 
spectrometry data by Dr. Michael Musheev. (C) TET1 phosphorylation site changes upon SB202190 or 
U0126 treatment in relation to control (DMSO) treatment, identified and quantified by SILAC and 
phosphoproteomic analysis. Experiment was performed in duplicates, bars display the mean of the two 
experiments and individual data points are shown. Phosphoproteomic analysis by Andrea Voigt and Dr. 
Petra Beli. 
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4.1.2.4 GADD45A and MAP3K4 reduce TET1 activity 
Since the cooperation of GADD45A and MAP3K4 in the regulation of TET1 activity can be 
interpreted in two ways: 1) impairing TET1 activity and 2) enhancing TET1 activity, an additional 
method was required to resolve the dynamics of 5mC oxidation.  
I performed metabolic labeling of HEK293T cells followed by mass spectrometry to differentiate 
between newly produced and previously formed 5mC oxidation products. To label 5mC and its 
derivatives in cells, “labeled” L-Methionine-(methyl-13C,D3) can be added to the cell culture 
medium. This is then metabolized to labeled methionine-derived SAM within cells, which in turn 
is the substrate for DNMTs, therefore generating labeled 5mC [4]. 
HEK293T cells were “labeled” for 14 days with L-Methionine-(methyl-13C,D3), achieving a labeling 
efficiency of 97 % (data not shown). Then, cells were transfected with TET1, GADD45A or 
MAP3K4. At the time of transfection, the label was withdrawn, i.e., the “labeled” medium was 
replaced with medium containing “nonlabeled” L-Methionine. Cells were harvested after different 
time points and the ratios of “nonlabeled”, i.e. newly produced 5mC, 5hmC, 5fC, and 5caC vs. 
“labeled”, i.e. old 5mC, 5hmC, 5fC and 5caC, were determined via quantitative mass 
spectrometry.  
In general, the ratios of nonlabeled vs. labeled 5mC, 5hmC, 5fC and 5caC increased over time, 
as 5mC and its oxidative derivatives were newly generated (Figure 4.6). The ratios of nonlabeled 
vs. labeled 5hmC did not change upon the co-expression of GADD45A and MAP3K4, compared 
to TET1 overexpression alone (Figure 4.6 B, compare green bars to dark grey bars). GADD45A 
without MAP3K4, however, slightly increased the ratios of nonlabeled/labeled 5hmC, although 
not significantly (Figure 4.6 B, compare blue bars to dark grey bars). If GADD45A and MAP3K4 
indeed enhanced TET1 enzymatic activity, as would have been one possible conclusion from the 
experiments depicted in Figure 4.2, one would expect an increase of nonlabeled 5hmC and a 
strong decrease in labeled 5hmC, resulting in an increased ratio of nonlabeled/labeled 5hmC. 
Since this was not the case, it indicates that active MAP3K4 does not increase the turnover of 
5hmC, but rather reduces TET1 activity.  
Unexpectedly, the ratios of nonlabeled vs. labeled 5fC decreased when TET1 was overexpressed 
(Figure 4.6 C, compare dark grey bars to light grey bars). One possible explanation is that TET1 
preferentially oxidizes the parental, i.e. labeled 5mC, to 5hmC and further to 5fC. In addition, in 
order to produce nonlabeled 5fC, nonlabeled 5mC and 5hmC have to be generated first, which 
would explain the decrease of the nonlabeled vs. labeled ratio. When GADD45A and MAP3K4 
were co-expressed, the nonlabeled vs. labeled ratios of 5fC significantly increased compared to 
TET1 overexpression alone (p<0.05) (Figure 4.6 C, compare blue and green bars to dark grey 
bars). Still, the increase of the ratios was only modest. For 5caC, the results were similar, although 
here the increase of the ratio of nonlabeled vs. labeled 5caC by the co-expression of GADD45A 
and MAP3K4 (p<0.0005) was more pronounced than for 5fC (Figure 4.6 D).  
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The results for 5fC and 5caC suggest that GADD45A alone, and GADD45A in combination with 
MAP3K4 indeed increase the turnover of these modifications. However, since GADD45A and 
MAP3K4 do not increase the turnover of 5hmC, GADD45A and MAP3K4 in combination do not 
generally enhance TET1 activity. The increased 5fC and 5caC ratios might rather be due to an 
enhanced removal by TDG, perhaps because TDG is recruited preferentially to the parental, i.e. 
labeled 5fC and 5caC by GADD45A and TET1. Considering all the data, I conclude that 
GADD45A and MAP3K4 together reduce the activity of TET1. Consequently, MAP3K4 does not 
play a role in enhancing TET1 activity in a GADD45A-dependent manner. 
 
 
 
Figure 4.6 GADD45A and MAP3K4 do not change the ratio of nonlabeled/labeled 5hmC 
(A-D) Quantitative mass spectrometry measurements of genomic DNA in HEK293T cells, which were 
transiently transfected for 24 h, 48 h, or 72 h with plasmids encoding the indicated proteins. Cells were 
incubated with “labeled” L-Methionine-(methyl-13C,D3) for 14 days and medium was replaced with 
“nonlabeled” L-Methionine at the time of transfection. Displayed are the ratios of “nonlabeled” 5mC vs. 
“labeled” 13C,D3-5mC (A), “nonlabeled” 5hmC vs. “labeled” 13C,D2-5hmC (B), “nonlabeled” 5fC vs. “labeled” 
13C,D1-5fC (C), and “nonlabeled” 5caC vs. “labeled” 13C-5caC (D). Data shown as mean ± SD, n=3, * = p-
value < 0.05, *** = p-value < 0.0005, according to student’s t-test. N/D, non detectable. Mass spectrometry 
data by Dr. Michael Musheev. 
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4.1.3 The role of GADD45A in TET1 ubiquitination  
4.1.3.1 GADD45A decreases TET1 ubiquitination  
As TET1 is known to be ubiquitinated and this promotes DNA binding [94], GADD45A could also 
regulate TET1 activity via affecting TET1 ubiquitination. In order to investigate if GADD45A affects 
the ubiquitination of TET1, I performed Co-Immunoprecipitations (Co-IPs) of Ubiquitin and TET1 
in the presence or absence of GADD45A. The Co-IPs were done with overexpressed proteins in 
HEK293T cells, using an antibody against HA-tagged Ubiquitin to co-immunoprecipitate FLAG-
tagged TET1. 
Ubiquitinated TET1 could be successfully co-immunoprecipitated with the HA (Ubiquitin)-
antibody, as a smear in the IP fraction was detected for FLAG-TET1 (Figure 4.7 A, “TET1+UB”). 
Interestingly, GADD45A co-expression reduced the ubiquitination of TET1, while GFP co-
expression, serving as a control, had no effect on the ubiquitination (compare lane 
“TET1+GADD45A+UB” to lane “TET+GFP+UB”).  
Using another experimental approach to validate this finding, GFP-tagged TET1 was affinity 
purified with GFP-trap beads, allowing high salt washes under denaturing conditions to reduce 
unspecific background. Here, Ubiquitin was not ectopically expressed, in contrast to the 
experiment described above. In line with the previous results, GADD45A reduced the 
ubiquitination of TET1 in the IP fraction (Figure 4.7 B, compare lane “GFP-TET1+GADD45A” to 
lane “GFP-TET1”). As monoubiquitination of TET1 K1589 enhances TET1 activity [94] and 
GADD45A also enhances TET1 activity, the GADD45A-mediated decrease of TET1 ubiquitination 
likely has a different role. Perhaps, GADD45A has a stabilizing role on TET1, by preventing its 
ubiquitination and subsequent proteasomal degradation.  
 
Figure 4.7 GADD45A decreases TET1 ubiquitination  
(A) HA-affinity purification of whole cell extracts from HEK293T cells that were transiently transfected for 
48 h with HA-Ubiquitin (UB), FLAG-TET1, GADD45A, GFP or a combination thereof. Proteins were 
separated via SDS-PAGE, subjected to Western blotting and detected using antibodies indicated on the 
right. (B) GFP-affinity purification of whole cell extracts from HEK293T cells that were transiently transfected 
for 48 h with GFP-TET1, GADD45A or GFP using GFP-Trap Agarose. MW, molecular weight.  
RESULTS 
34 
To identify GADD45A-dependent TET1 ubiquitination sites, affinity purification of TET1 followed 
by quantitative mass spectrometry was performed in collaboration with Matthias Ostermaier and 
Dr. Petra Beli. However, several experimental optimization approaches with different digestion 
enzymes and using both mouse or human TET1 only yielded a 50 % coverage of the TET1 protein 
sequence. Only one GADD45A-dependent ubiquitination site, K328 in mouse TET1, was 
discovered when GADD45A was depleted (data not shown). Unfortunately, this site could not be 
reproduced in another pulldown. Mainly because of the low sequence coverage, we decided to 
not further explore TET1 ubiquitination via quantitative mass spectrometry. 
4.1.3.2 GADD45A increases TET1 protein stability 
To test if GADD45A stabilizes TET1 by preventing TET1 ubiquitination and subsequent 
degradation, I performed cycloheximide (CHX) chase assays of ectopic and endogenous TET1 
in human HEK293T and mESCs, respectively, in the presence and absence of GADD45A. CHX 
inhibits protein biosynthesis by blocking translational elongation and can therefore be used to 
monitor the stability of a protein over time [165].  
In HEK293T cells, 6 h of CHX treatment reduced ectopic TET1 protein levels to 20 % (Figure 4.8 
A and B, “Control”). When GADD45A was co-expressed, no reduction of TET1 protein levels was 
observed after 6 h (Figure 4.8 A and B, “GADD45A”), suggesting that GADD45A indeed stabilizes 
TET1 protein levels.  
To exclude any unspecific effects due to the overexpression of TET1 in HEK293T cells, I repeated 
the CHX assay in a knock-in CRISPR/Cas9 mESC line, which contains an HA-tag at the 
endogenous TET1 locus, enabling the detection of TET1 protein with an HA antibody [166]. 
Indeed, GADD45A overexpression in mESCs reduced the depletion of endogenous TET1 protein 
levels to 42 % after 12 h, compared to 4 % remaining protein levels without GADD45A co-
expression (Figure 4.8 C and D, compare “GADD45A”).  
To test whether GADD45A prevents the proteasomal degradation of TET1, the proteasome was 
inhibited with MG132. Surprisingly, MG132 treatment did not prevent degradation of TET1 in the 
CHX-chase assay (data not shown). Since CALPAIN1, a calcium-dependent protease, was 
reported to target TET1 for degradation [46], I tested if the Calpain inhibitor Calpeptin would 
stabilize TET1 protein levels similarly to GADD45A. Indeed, when Calpeptin was added to the 
HEK293T cells, TET1 protein levels were only reduced to 70 % after 6 h, compared to 20 % 
without Calpeptin (Figure 4.8 A and B, compare “CHX+Calpeptin” to “CHX”). Importantly, 
GADD45A did not further stabilize TET1 protein levels in the presence of Calpeptin. This was only 
the case for HEK293T cells, however, as in mESCs this effect of Calpeptin was not observed 
(data not shown). In conclusion, GADD45A stabilizes TET1 protein levels independently of the 
proteasome. This could be one mechanism of how GADD45A enhances TET1 activity. 
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Figure 4.8 GADD45A increases TET1 protein stability 
(A) CHX chase assay in HEK293T cells that were transiently transfected for 48 h with HA-TET1, GADD45A 
or empty vector (Control) and treated with 100 µg/ml CHX or 100 µg/ml CHX + 20 µM Calpeptin for the 
indicated times. Whole cell protein lysates were harvested, separated via SDS-PAGE, subjected to Western 
blotting and detected using antibodies indicated on the right. MW, molecular weight. (B) Quantification of 
TET1 protein levels in (A), normalized to TUBULIN as loading control. (C) CHX chase assay in HA-TET1 
mESCs that were transiently transfected for 48 h with GADD45A or empty vector (Control) and treated with 
50 µg/ml CHX for the indicated times. Nuclear protein lysates were harvested, separated via SDS-PAGE, 
subjected to Western blotting and detected using antibodies indicated on the right. Representative images 
of 2 independent experiments are shown. (D) Quantification of TET1 protein levels in (C), normalized to 
HNRNPA1 as loading control.  
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4.1.4 The role of GADD45A in TET1 SUMOylation  
4.1.4.1 GADD45A affects TET1 SUMOylation 
As SUMOylation is a well-known post-translational modification, which regulates protein activity 
[167], GADD45A-dependent SUMOylation of TET1 could be another mechanism of how 
GADD45A regulates TET1.  
To explore if TET1 is SUMOylated, Co-IPs of HA-tagged SUMO and FLAG-tagged TET1 were 
performed in the presence or absence of GADD45A. Indeed, when HA-SUMO2 and FLAG-TET1 
were overexpressed in HEK293T cells, the HA-antibody could immunoprecipitate FLAG-TET1, 
indicating that TET1 is indeed SUMOylated (Figure 4.9 A, “TET1+SUMO2”). GADD45A reduced 
the SUMOylation of TET1 (Figure 4.9 A, compare lane “TET1+GADD45A+SUMO2” to lane 
“TET1+GFP+SUMO2”).  
To corroborate these findings with endogenous SUMO, GFP-tagged TET1 was affinity purified 
with GFP-trap beads, and endogenous SUMO was detected by Western blotting. The GFP-affinity 
purification confirmed the results obtained with ectopic SUMO (data not shown). To test whether 
the SUMOylation lies within the catalytic domain of TET1, I overexpressed a GFP-tagged 
TET1CD, and performed a GFP-pulldown. 
Whereas GADD45A reduced the SUMOylation of full-length TET1, GADD45A increased the 
SUMOylation of TET1CD in the IP fraction (Figure 4.9 B). This difference seems peculiar at first, 
but it could be possible that decreased SUMOylation of the full-length protein masks the increased 
SUMOylation of the catalytic domain. As GADD45A can also enhance the activity of the isolated 
catalytic domain of TET1 [104], the functional interplay between GADD45A and the catalytic 
domain of TET1 will be further explored in the following chapter. 
 
 
Figure 4.9 GADD45A affects TET1 SUMOylation 
(A) HA-affinity purification of whole cell extracts from HEK293T cells that were transiently transfected for 
48 h with FLAG-TET1, HA-SUMO2/3, GADD45A, GFP, empty vector (Control) or a combination thereof. 
Proteins were separated via SDS-PAGE, subjected to Western blotting and detected using antibodies 
indicated on the right. (B) GFP-affinity purification of whole cell extracts from HEK293T cells that were 
transiently transfected for 48 h with GFP-TET1CD, GADD45A or GFP using GFP-Trap Agarose. MW, 
molecular weight.  
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4.1.4.2 Predicted TET1 SUMOylation-deficient single mutants do not affect the functional 
cooperativity with GADD45A 
To further explore the effect of SUMOylation on TET1 activity, SUMOylation sites in the catalytic 
domain of TET1 were predicted using the SUMOplotTM tool. This tool predicts SUMOylation sites 
according to a match with the SUMO-consensus sequence BKxD/E, where B is a hydrophobic 
residue, K is the lysine conjugated to SUMO, x is any amino acid, and D/E stands for aspartic 
acid or glutamic acid. Four potential SUMOylation sites were found in the catalytic domain of 
human TET1 that were conserved in mouse and rat: K1813, K1842, K1863, and K2067. The 
conservation gives more confidence that the predicted SUMOylation sites indeed play a role in 
TET1 protein regulation. 
Using site-directed mutagenesis, I generated lysine to alanine and lysine to arginine mutants of 
the predicted and conserved SUMOylation sites in the catalytic domain of TET1, and tested the 
activity of the mutants, first by quantitative mass spectrometry. However, none of the mutations 
had an impact on global 5mC oxidation in HEK293T cells upon TET1CD overexpression, as the 
mutants produced similar levels of 5hmC, 5fC and 5caC as wild-type TET1CD (Figure 4.10 B-D, 
grey bars). Moreover, the ability of GADD45A to enhance TET1CD-mediated 5hmC, 5fC and 
5caC production was not affected in the mutants (Figure 4.10 B-D, compare blue bars to grey 
bars). The only exception was a lacking increase of 5caC by GADD45A in the TET1 K2067R 
mutant, although there was still a slight trend.  
As a more direct assay to monitor the activity of the TET1CD mutants, I employed an in vitro 
TET1 oxidation assay, where I tested the effect of a K2067R mutation and the effect of GADD45A 
overexpression on 5mC oxidation. I FLAG-affinity purified wild-type FLAG-TET1CD or mutant 
FLAG-TET1CD from HEK293F suspension cells that had been transfected with expression 
constructs for these proteins. Subsequently, the in vitro TET1 oxidation assay was performed 
using an isotopically labeled methylated amplicon as a substrate, which allows the discrimination 
from contaminating genomic DNA that could have been immunoprecipitated with the proteins. 
TET1 oxidation products originating from the labeled methylated amplicon – 5hmC+3, 5fC+3 and 
5caC+3 – were then measured by quantitative mass spectrometry (where +3 indicates the 
increased molecular weight of the isotopes). 
In the in vitro TET1 oxidation assay, the addition of wild-type TET1CD decreased 5mC levels of 
the labeled methylated amplicon (originally 48 % 5mC+3) to 28 % 5mC+3 after 24 min (Figure 
4.10 E, “wt+GFP”). At the same time, 5hmC+3, 5fC+3 and 5caC+3 were produced (Figure 4.10 
F-H). When GADD45A was added to the reaction, production of 5hmC+3, 5fC+3 and 5caC+3 
slightly increased (compare green curves to black curves). 
Similar to what was observed for global 5mC oxidation (Figure 4.10 B-D), the K2067R mutant did 
not affect TET1CD activity in the in vitro TET1 oxidation assay (compare grey curves to black 
curves), and more importantly, the slight increase in 5mC oxidation by GADD45A was still 
observed (Figure 4.10 F-H compare blue curves to grey curves).  
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Figure 4.10 TET1 SUMOylation-deficient mutants do not affect the functional cooperativity with 
GADD45A 
(A-D) Quantitative mass spectrometry measurements of the levels of 5mC (A), 5hmC (B), 5fC (C) and 5caC 
(D) in HEK293T cells. Cells were transfected with wild-type (wt) or mutant (K1813A, K1842R, K1863A, 
K2067R) TET1CD, in addition to empty vector (Control) or GADD45A, and harvested after 48 h. Data shown 
as mean ± SD, n=3, ns = non significant, * = p-value < 0.05, ** = p-value < 0.005, *** = p-value < 0.0005, 
according to student’s t-test. (E-H) In vitro TET1 oxidation assay. HEK293F cells were transfected with wild-
type (wt) or mutant (K2067R) FLAG-TET1CD, in addition to GFP (Control) or GADD45A, and harvested after 
48 h. FLAG-TET1CD was affinity purified and the in vitro TET1 oxidation assay was performed using an 
isotopically labeled methylated amplicon as a substrate. DNA was purified and subjected to quantitative 
mass spectrometry. Data shown as mean, n=2. Mass spectrometry data by Dr. Michael Musheev.  
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In this study, only single lysine mutants were generated and double or multiple lysine to arginine 
mutants might be necessary to completely abolish SUMOylation of the catalytic domain of TET1. 
Moreover, additional lysines, which were not selected for mutation, might play a role in GADD45A-
mediated TET1 regulation. Still, I could not find any strong evidence that GADD45A enhances 
TET1 activity via SUMOylation. 
4.1.4.3 GADD45A enhances the SUMOylation of TDG 
GADD45A can not only interact with and enhance TET1 activity in active DNA demethylation. In 
fact, Li and colleagues showed that GADD45A also physically interacts with TDG and thereby 
enhances 5fC and 5caC removal [111]. Since it was also shown that TDG can be SUMOylated 
and this increases its substrate turnover [168], GADD45A could enhance TDG activity, and 
thereby 5fC and 5caC removal, by promoting SUMOylation of TDG. In this mechanism, GADD45A 
could act as the SUMO donor, as GADD45A itself can be SUMOylated [169]. 
To explore if the SUMOylation of TDG is affected by GADD45A, I performed Co-IPs of HA-tagged 
SUMO and FLAG-tagged TDG with or without GADD45A overexpression. When SUMO and TDG 
were co-expressed, an additional protein band appeared for TDG in the input as well as in the IP 
fraction, which represents SUMOylated TDG (Figure 4.11, compare lanes “SUMO” to “Control”). 
GADD45A strongly enhanced the SUMOylation of TDG, and even a third band appeared in the 
IP fraction, probably representing the conjugation of two SUMO molecules to TDG (Figure 4.11, 
compare lanes “SUMO+GADD45A” to “SUMO+GFP”). Therefore, GADD45A enhances the 
SUMOylation of TDG and this could be the mechanism by which GADD45A enhances 5fC and 
5caC removal. 
 
Figure 4.11 GADD45A enhances the SUMOylation of TDG 
HA-affinity purification of whole cell extracts from HEK293T cells that were transiently transfected for 48 h 
with FLAG-TDG, HA-SUMO2, GADD45A, GFP or combination thereof. Proteins were separated via SDS-
PAGE and subjected to Western blotting and detected using antibodies indicated on the right. TDG-S, 
SUMOylated TDG. MW, molecular weight.  
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4.1.5 GADD45A and the TET1 interactome 
In order to identify possible GADD45A-dependent TET1 interactors involved in ubiquitination or 
SUMOylation, TET1 was affinity purified in the presence or absence of GADD45A and subjected 
to quantitative mass spectrometry (in collaboration with Dr. Petra Beli). Unfortunately, four 
independent replicates only had a small overlap (only 18 common TET1 interactors), and 
GADD45A-dependet interactors were even more variable between replicates. Some of these few 
top candidates, which were also found in previous pulldowns performed by Dr. Andrea Schäfer 
(personal communication), were proteins involved in post-translational modifications, e.g. E3 
ligases (Table 4.1). The candidates included members of the superfamily of tripartite motif-
containing (TRIM) E3 ligases. These proteins all contain a RING domain, which enables them to 
conjugate Ubiquitin, SUMO, or Ubiquitin-like protein ISG15 (ISG15) to target proteins [170]. The 
interaction of GADD45A, TET1 and members of the TRIM family will be explored in the following 
chapter. 
Protein Function 
TRIM24 E3 Ubiquitin Ligase 
TRIM25 E3 Ubiquitin/ISG15 Ligase 
TRIM28 E3 Ubiquitin/SUMO Ligase 
TRIM33 E3 Ubiquitin Ligase 
HUWE1 E3 Ubiquitin Ligase 
STUB1 E3 Ubiquitin Ligase 
 
Table 4.1 Selection of candidate TET1 interactors identified via quantitative mass spectrometry 
 
4.1.6 Interplay between TET1, GADD45A and the E3 Ligases TRIM25 and TRIM28 
4.1.6.1 TRIM25 and TRIM28 knockdown decreases TET1 activity 
In chapters 4.1.3 and 4.1.4, I showed that GADD45A affects the ubiquitination and SUMOylation 
of TET1. Since GADD45A lacks any known enzymatic activity, additional co-factors are needed 
to affect these post-translational modifications of TET1. In this chapter, I will explore whether 
potential TET1 interactors with an E3 ligase activity, which were identified via quantitative mass 
spectrometry (Table 4.1), play a role in GADD45A-dependent regulation of TET1.  
First, the effect of the potential interactors on global 5mC oxidation was tested in loss of function 
experiments in HEK293T cells, followed by quantitative mass spectrometry. Depletion of selected 
TRIM family members was monitored via RT-qPCR, showing siRNA knockdown efficiencies 
between 40 and 70 % (data not shown). The overexpression of TET1 and GADD45A was 
confirmed by Western blot analysis and expression levels were not affected by the knockdown of 
the TRIM family members (data not shown). 
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Depletion of GADD45A via siRNA on a background of TET1 overexpression significantly 
decreased 5hmC levels compared to siControl-knockdown (p<0.05) (Figure 4.12 B, grey bars). 
The siRNA knockdowns of TRIM25 and TRIM28 decreased 5hmC levels even further (p<0.05 
and p<0.005, respectively). In contrast, the depletion of TRIM24 and TRIM33, which together with 
TRIM28 form the Tif1 protein family, did not affect 5hmC levels.  
When GADD45A was co-expressed with TET1 and no specific siRNA was transfected (mock or 
siControl), 5hmC levels significantly increased (p<0.05), as previously observed. However, when 
siRNAs against TRIM25 and TRIM28 were transfected, this increase by GADD45A was not 
observed (Figure 4.12 B, compare blue bars to grey bars).  
Regarding 5fC and 5caC, the effect of the GADD45A, TRIM25 and TRIM28 knockdowns were 
similar to the effects observed towards 5hmC levels: depletion of each of the three factors 
significantly decreased 5fC and 5caC levels, when compared to the non-specific siControl siRNA 
(Figure 4.12 C and D, grey bars). As for 5hmC, siRNA knockdowns of TRIM24 and TRIM33 had 
no effect. 
GADD45A co-expression with TET1 reduced the levels of 5fC and 5caC under control conditions 
(mock and siControl) (Figure 4.12 C and D, compare blue bars to grey bars). However, a 
combined knockdown of TRIM25 or TRIM28 together with overexpression of GADD45A did not 
reduce levels further than either knockdown of TRIM25 or TRIM28, or overexpression of 
GADD45A alone (compare blue bars to grey bars). In contrast, TRIM24 and TRIM33 knockdown 
in combination with GADD45A overexpression reduced 5fC and 5caC levels, similarly as control 
treatments (mock and siControl). Of note, siRNA knockdowns of TRIM25 and TRIM28 also 
reduced global 5hmC, 5fC and 5caC levels produced by the catalytic domain of TET, in the same 
way as a GADD45A siRNA knockdown (data not shown). These results suggest that TRIM25 and 
TRIM28 might be involved in enhancing TET1 activity in a GADD45A-dependent manner. 
In HEK293T cells, TET1 needs to be ectopically expressed in order to reach reliable and 
detectable 5fC and 5caC levels, which might introduce a bias due to variation in TET1 protein 
levels. Although the protein levels were always monitored via Western blot (data not shown) and 
the effects observed for the depletion of TRIM25 and TRIM28 cannot be simply explained by a 
reduction of TET1 protein levels, a system without TET1 overexpression is more reliable. Thus, I 
also performed knockdowns of the top candidates in mESCs. mESCs have higher endogenous 
TET1 expression levels compared to HEK293T and consequently, also higher 5hmC, 5fC and 
5caC levels.  
In mESCs, GADD45A depletion did not affect 5hmC levels, but like in HEK293T cells, slightly 
reduced 5fC and 5caC levels, although not significantly (Figure 4.12 F-H). TRIM25 and TRIM28 
depletion also only mildly decreased 5fC and 5caC levels (non significant), but the trend was 
similar as in HEK293T cells.  
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Despite the observed discrepancies in HEK293T cells and mESCs, TRIM25 and TRIM28 might 
be promising candidates involved in GADD45A-mediated TET1 regulation and will be further 
explored in the following chapter.  
 
Figure 4.12 TRIM25 and TRIM28 knockdown decreases TET1 activity 
(A-D) Quantitative mass spectrometry measurements of the levels of 5mC (A), 5hmC (B), 5fC (C) and 5caC 
(D) in HEK293T cells. Cells were transfected with control or specific siRNAs 24 h prior to DNA transfection 
with TET1 alone or TET1+GADD45A, and harvested after 72 h. In “mock” treated samples, cells were only 
treated with transfection reagent but no siRNA. (E-H) Quantitative mass spectrometry measurements of the 
levels of 5mC (E), 5hmC (F), 5fC (G) and 5caC (H) in mESCs. Cells were transfected with control or specific 
siRNAs and harvested after 48 h. All data are shown as mean ± SD, n=3, ns = non significant, * = p-value < 
0.05, ** = p-value < 0.005, *** = p-value < 0.0005, according to student’s t-test. Mass spectrometry data by 
Dr. Michael Musheev. 
 
4.1.6.2 TRIM25 and TRIM28 knockdown does not affect TET1 activity in vitro  
To corroborate the roles of TRIM25 and TRIM28 in regulating TET1 activity, I performed a more 
direct assay investigating the functional interaction between TRIM25/TRIM28 and TET1, an in 
vitro TET1 oxidation assay (see chapter 4.1.4.2). The FLAG-tagged catalytic domain of TET1 was 
transiently overexpressed in HEK293T cells and TRIM25 or TRIM28 were depleted using siRNAs. 
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FLAG-TET was purified from cell extracts and the in vitro TET1 oxidation assay was performed 
using an isotopically labeled methylated amplicon.  
Addition of wild-type TET1CD sligthly decreased 5mC+3 levels of the isotopically labeled 
methylated amplicon purified from siControl-treated cells, whereas 5hmC+3 production increased 
over time, as expected (Figure 4.13 A and B, black curves). 5hmC production after 3 and 12 min 
was not affected by either, TRIM25 or TRIM28 knockdown (Figure 4.13 B, compare blue and 
green curves to black curve). After 24 min, 5hmC production seemed decreased by TRIM25 
knockdown; however, Western blot data (not shown) indicated that this was probably due to 
decreased TET1CD protein levels in the samples. Hence, while the depletion of TRIM25 and 
TRIM28 decreased 5hmC levels on a global scale, the depletion of the two factors did not affect 
TET1CD oxidation activity in this in vitro TET1 oxidation assay.  
These results suggest that TRIM25 and TRIM28 might indirectly, rather than directly, regulate 
TET1. For example, they could be involved in modifying and targeting TET1 to genomic loci, 
analogous to the ubiquitination by CRL4 that enhances TET1 binding to DNA [94]. Such effects 
might require a chromatin context, whereas these effects might not be observed in an in vitro 
assay using an amplicon as a TET1 substrate. Still, also off-target effects of the siRNAs cannot 
be excluded. In addition, overexpression of TRIM25 or TRIM28 did not affect TET1 activity, 
neither on a global scale nor in the in vitro TET1 oxidation assay (data not shown). Furthermore, 
an interaction between TRIM25 or TRIM28 and TET1 could not be confirmed via Co-IPs (data not 
shown). This makes it unlikely that TRIM25 or TRIM28 are directly involved in the regulation, and 
specifically the GADD45A-mediated regulation, of TET1. 
 
 
Figure 4.13 TRIM25 and TRIM28 knockdown does not affect TET1 activity in vitro  
In vitro TET1 oxidation assay. HEK293T cells were transfected with control or specific siRNAs 24 h prior to 
DNA transfection with the catalytic domain of FLAG-TET1 and harvested after 72 h. FLAG-TETCD was 
affinity purified and the in vitro TET1 oxidation assay was performed using an isotopically labeled methylated 
amplicon as a substrate. DNA was purified and subjected to quantitative mass spectrometry to quantify 5mC 
(A) and 5hmC (B). Data shown as mean, n=2. Mass spectrometry data by Dr. Michael Musheev.   
RESULTS 
44 
4.2 Linking TET activity to distal regulatory elements 
A yet unresolved question in the demethylation field is why TET binding sites are mostly found at 
promoters, whereas the oxidation products of TET – 5hmC, 5fC and 5caC – are largely found at 
distal elements. One explanation could be that TET proteins are targeted to distal elements via 
promoter-enhancer looping [41]. In the following chapters, I will present how I tested this 
hypothesis by depleting promoter-enhancer loops and measuring if this leads to a loss of oxidized 
5mC derivatives at enhancers. Promoter-enhancer loops can be abolished via depletion of 
RAD21, a core component of the Cohesin complex [132]. However, since RAD21 is an essential 
protein for cell division, as it is involved in sister chromatid cohesion [126], a system in which 
RAD21 can be depleted in a controlled manner was needed. Therefore, I used the Auxin-inducible 
degron (AID) system, which allows fast depletion of proteins, shortening the half-life of AID-tagged 
proteins to only 10-20 min [171]. As a model system, I chose mESCs, because they have high 
endogenous TET1 and TET2 expression levels, and thus, high 5hmC, 5fC and 5caC levels [41]. 
4.2.1 Auxin-Inducible Degron tagging of Rad21 in mESCs 
In order to establish a conditional RAD21 depletion system in mESCs, I first replaced the stop 
codons of both Rad21 alleles with C-terminal AID-tags. Second, I stably introduced a transgene 
encoding the Tir1 F-box (OsTIR1) protein from Oryza sativa (rice). OsTIR1 can bind to AID in the 
presence of the plant hormone auxin and triggers a proteasome-dependent degradation of the 
AID-tagged protein [171]. 
RAD21-degron cell lines were generated by transfecting E14tg2a mESCs with three different 
plasmids: one plasmid containing the guide RNA (gRNA) (targeting the C-terminus of the Rad21 
gene) and the Cas9 endonuclease sequence, and two plasmids containing an AID-3xHA-tag and 
either a hygromycin or a neomycin resistance gene, flanked by Rad21 homology arms. This 
allowed for antibiotic selection of cells containing an AID-3xHA-tag at both Rad21 alleles (Figure 
4.14 A, top). 144 single clones were picked and analyzed for homozygous AID-3xHA integration 
at the Rad21 locus, using genotyping PCRs (data not shown). The genotyping PCRs revealed 37 
double positive clones for an insertion of the hygromycin and the neomycin resistance genes at 
the Rad21 locus. These clones were expanded, protein lysates were prepared, and lysates were 
subjected to Western blotting. A successful AID-3xHA insertion at the Rad21 locus is expected 
to translate to an approximately 10 kDa larger protein compared to the wild-type RAD21 protein. 
The Western blot analysis revealed two clones (A1 and F5), which had homozygous AID-3xHA 
insertions, as indicated by a single 130 kDa protein band being detected using an HA-antibody, 
and by the detection of the same sized band using a RAD21-antibody (Figure 4.14 B, lanes 1 and 
14). For four other clones, the HA-antibody also detected a band at this size (A3, F7, C7_2 and 
D10_2); however, the RAD21-antibody detected a second lower band. This suggests that the 
AID-3xHA-tag was only inserted at one of the two Rad21 alleles, where the lower band 
corresponds to the endogenous, untagged RAD21 protein, and the higher band corresponds to 
the AID-3xHA-tagged RAD21 protein.  
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In a second transfection and selection round, OsTir1 was integrated at the Tigre (tightly regulated) 
locus [172] in the two positive Rad21-AID-3xHA cell lines (Figure 4.14 A, bottom). The Tigre locus 
was chosen as it allows for a robust transgene expression in mESCs, and transgenes inserted at 
this locus were observed to have higher expression levels than if inserted at the Rosa26 locus or 
randomly [147,173]. Thus, the two clones A1 and F5 were once more transfected with two 
plasmids: one containing a gRNA (targeting the Tigre locus to allow for insertion of the OsTir1 
transgene) and the Cas9 endonuclease sequence, and one containing a V5-tagged OsTir1 
expression cassette and a puromycin resistance gene flanked by arms homologous to the Tigre 
locus. Following puromycin selection, a total of 192 single clones were picked and analyzed for 
successful OsTir1 integration at the Tigre locus, using genotyping PCRs (data not shown). The 
genotyping PCRs revealed 29 OsTir1-positive clones, which were further expanded to test for a 
depletion of RAD21 after auxin addition.  
Acute RAD21 depletion was induced by treating cells with 500 µM of the auxin analog Indole-3-
acetic acid sodium salt (referred to as “auxin” henceforth) for 6 h. Afterwards, protein lysates were 
subjected to Western blot analysis, using antibodies against HA and RAD21 to monitor the 
depletion of RAD21, and V5 to analyze the expression of OsTir1. This analysis revealed 10 
conditional RAD21 depletion cell lines (data not shown). Of these, four clones with the most 
efficient RAD21 depletion upon auxin addition were selected and more thoroughly tested in time-
course experiments.  
 
 
Figure 4.14 Auxin-Inducible Degron tagging of Rad21 in mESCs 
(A) Scheme showing the transgenic loci of the Rad21-AID-3xHA cell lines. (B) Western blot of whole cell 
protein lysates of the indicated mESC-clones, which originated from two different 96-well plates (#1 and #2), 
using antibodies indicated on the right. MW, molecular weight. 
  
RESULTS 
46 
4.2.2 Acute Protein Depletion of RAD21 in mESCs 
The dynamics of acute RAD21 depletion were monitored using auxin treatment intervals ranging 
from 0.5 - 24 h followed by Western blotting and immunofluorescence staining, using four different 
Rad21-AID-3xHA cell lines (A1_B4, A1_B6, F5_D4 and F5_F6). A short auxin treatment of 0.5 h 
already reduced RAD21 levels by more than 50 %, and 1 h was enough to almost completely 
reduce RAD21 levels (Figure 4.15 A, “α-HA”, and B, “RAD21”). After 2 h of treatment, cell 
morphology started to change compared to untreated cells, as the cell colonies became smaller 
and started detaching from the culture dish (data not shown). After 4 h of auxin treatment, higher 
numbers of mitotic cells were found compared to untreated cells (Figure 4.15 B, “DAPI”, indicated 
by arrows). This could be the result of mitotic arrest, due to premature sister-chromatid separation 
after RAD21 depletion [174]. These experiments show that interpretation of data acquired after 
more than 4 h of auxin treatment will be compromised by interference with cell cycle and 
chromosome condensation. Of note, the same results were observed for all four tested cell lines 
(data shown only for cell line F5_F6). 
Next, quantitative mass spectrometry was performed to measure the levels of the oxidative 
derivatives of 5mC in the Rad21-AID-Tir1 mESC-lines. Cell lines F5_D4 and F5_F6 (originating 
from clone F5 from the first transfection round) had higher levels of 5hmC, 5fC and 5caC than cell 
lines A1_B4 and A1_B6 (originating from clone A1 from the first transfection round) (Figure 4.15 
C). To monitor if RAD21 depletion affects global levels of 5mC and its oxidative derivatives, 
genomic DNA was also isolated after auxin-mediated RAD21 depletion and similarly measured 
by quantitative mass spectrometry. After 24 h of RAD21 depletion, 5fC levels were almost 
reduced by half, suggesting that RAD21 depletion might affect 5fC globally (Figure 4.15 D). Yet, 
this might also be related to the mitotic arrest mentioned earlier. In fact, the enzyme responsible 
for the removal of 5fC, TDG, is controlled in a cell cycle dependent manner and is degraded in S-
phase, but highly expressed in the G2-phase [175]. To analyze cell cycle differences in more 
detail, flow cytometry of propidium iodide stained cells could be performed for future experiments. 
Cell lines F5_D4 and F5_F6 had comparable 5mC, 5hmC, 5fC and 5caC levels as wild-type 
mESCs (compare Figure 4.12 and Figure 4.14, also see [37]). Therefore, one of these cell lines 
containing higher levels of 5hmC, 5fC and 5caC – cell line F5_F6 – was selected for further 
downstream analyses. 
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Figure 4.15 Acute Depletion of RAD21 using the AID System in mESCs 
(A) Western blot of nuclear protein lysates from Rad21-AID-Tir1-mESC-line F5_F6, treated with 500 µM 
auxin for the indicated time, using antibodies indicated on the right. MW, molecular weight. (B) 
Immunofluorescence staining of cell line F5_F6 using a RAD21-antibody, DAPI was used to stain nuclei. 
The scale bar corresponds to 10 µM, arrows indicate mitotic cells. Experiment in (A) and (B) was performed 
with four different Rad21-AID-Tir1-mESC-lines (A1_B4, A1_B6, F5_D4 and F5_F6), representative data for 
cell line F5_F6 is shown. (C) Quantitative mass spectrometry measurements of the levels of 5mC, 5hmC, 
5fC and 5caC in the indicated Rad21-AID-Tir1-mESC-lines. (D) Quantitative mass spectrometry 
measurements of 5fC (normalized to 5hmC) in the four different Rad21-AID-Tir1-mESC-lines, treated with 
500 µM auxin for the indicated hours. Data shown as mean ± SD, n=4. Mass spectrometry data by Dr. 
Michael Musheev. Co, control.  
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4.2.2.1 Prolonged RAD21 depletion leads to a G2/M arrest and reduced 5fC accumulation 
To investigate if loop depletion affects the oxidation of 5mC at enhancers, I performed 5hmC and 
5fC DNA immunoprecipitation (DIP) followed by qPCR. Investigated regions and respective qPCR 
primers were bioinformatically selected and designed (in collaboration with Dr. Emil Karaulanov, 
IMB Mainz) according to the following criteria: The candidate regions for qPCR amplification 
overlap with annotated enhancers [176], are 5hmC and 5fC positive [81,177,178], and loop to a 
promoter with a TET1 binding site [166,179]. The promoters have low 5hmC and 5fC levels 
[81,177,178] and enhancers do not contain a TET1 binding site [166,179]. 
During the course of this study, Rhodes and colleagues published a RAD21-degron mESC-line 
similar to ours and showed that chromatin loops are depleted after 6 h of auxin treatment [150]. I 
decided to use the same time point for my experiments to ensure that also in my system, loops 
were completely depleted. This meant accepting the risk that some of the results I would obtain 
might result from the unintended impacts of RAD21 depletion on the cell cycle. A relatively short 
time of auxin-mediated RAD21 depletion would likely not affect already established 5hmC and 
5fC, unless these modifications are quickly removed. Hence, the effects of loop depletion on TET 
activity would be expected to be larger for newly established 5hmC and 5fC. To increase the 
amount of newly established 5hmC and 5fC after RAD21 depletion, TET activity can be enhanced 
by Vitamin C addition after RAD21 depletion. Vitamin C can interact with the catalytic domain of 
TET enzymes and thereby enhance their activity towards 5mC oxidation [90]. 
Genomic DNA was extracted and subjected to 5fC or 5hmC DIP followed by qPCR to quantify 
enrichment of TET oxidation products at candidate enhancer regions under four different 
experimental conditions: First, cells were treated with auxin for 6 h to induce depletion of loops; 
untreated cells served as control. Second, cells were treated with Vitamin C 2 h after auxin 
addition (for a total of 4 h) in order to temporarily enhance TET activity, untreated cells served as 
control (Figure 4.16 A).  
5hmC and 5fC DIP successfully enriched target regions. 5hmC was enriched 15-30-fold at the 
candidate enhancer regions, compared to a control region, while 5hmC enrichment at the 
corresponding promoters was much lower (up to 7-fold) (Figure 4.16 B, dark green bars). 5fC DIP 
enriched Cgnl1, a 5fC positive control region [81] 13-fold compared to a 5fC negative control 
region. The 5fC enrichment at the candidate enhancer regions was up to 4-fold compared to the 
negative control, and the enrichment at the corresponding promoters was up to 3-fold (Figure 
4.16 C, dark green bars).  
Vitamin C treatment increased 5hmC enrichment moderately at enhancer regions, but not at 
promoter regions (Figure 4.16 B, compare dark blue to dark green bars). Similarly, upon Vitamin C 
treatment, 5fC enrichment at enhancer regions was increased up to 14-fold compared to the 
control region, whereas the Vitamin C effect was more moderate at the promoter regions (Figure 
4.16 C, compare dark blue to dark green bars). On the other hand, auxin-mediated RAD21 
depletion had no effect on 5hmC and 5fC enrichment (Figure 4.16 B and C, compare light green 
to dark green bars).  
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The enrichment of 5hmC and 5fC in response to combined auxin and Vitamin C treatments 
differed: The 5hmC DIP revealed no differences of 5hmC enrichment between auxin treated and 
untreated cells upon Vitamin C treatment (Figure 4.16 B, compare light blue to dark blue bars). 
Vitamin C-induced 5fC enrichment, however, was significantly impaired at four candidate 
enhancer regions, whereas the same impairment was only observed at one promoter region 
(Figure 4.16 C, compare light blue to dark blue bars). 
This suggests that the depletion of RAD21, which leads to a subsequent depletion of chromatin 
loops, impairs the acute, Vitamin C-induced accumulation of 5fC at enhancer regions. However, 
a similar trend, although not significant, was also observed for the non-enhancer regions. This 
indicates that the reduced 5fC accumulation may not be enhancer-specific and therefore RAD21-
loop independent. 
To rule out unspecific effects caused by possible cell cycle perturbations, cell cycle profiles for 
the four different conditions were generated by flow cytometry of propidium iodide stained cells. 
Untreated cells displayed a cell cycle profile typical for mESCs with a small proportion of cells in 
G1-phase and a high proportion of cells in S-phase (Figure 4.16 D) [180]. The addition of 
Vitamin C did not alter the cell cycle profile, whereas the addition of auxin strongly did: after 6 h 
auxin treatment, no G1 peak could be detected, the S-phase was smaller than in the untreated 
cells, and most cells were found in G2/M, suggesting that auxin treatment led to a G2/M arrest.  
Considering the lack of 5fC accumulation at enhancers and the unimpaired 5hmC accumulation 
after combined auxin and Vitamin C treatment, it is possible that not the oxidation activity of TET 
enzymes was impaired, but rather that removal of 5fC by TDG was enhanced. In fact, TDG is 
degraded in S-phase, but highly expressed in the G2-phase [175]. This would explain why 5fC 
levels are lower in cells that were treated with both auxin and Vitamin C, compared to Vitamin C 
alone, as they arrested in G2/M-phase, where 5fC is excised by TDG. This explanation, however, 
is not supported by the unchanged enrichment of 5fC upon auxin treatment alone. Moreover, 
following Vitamin C treatment, the accumulation of newly generated 5hmC is much smaller than 
that of 5fC. Therefore, possible differences of 5hmC accumulation mediated by RAD21 depletion 
might be below detection limit. 
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Figure 4.16 Prolonged RAD21 depletion leads to a G2/M arrest and reduced 5fC accumulation 
(A) Experimental workflow and timeline depicting the combined auxin and Vitamin C treatment. Rad21-AID-
Tir1-mESCs were treated with 500 µM auxin, treated 2 h later with 40 µg/ml Vitamin C (VitC), and harvested 
after a total of 6 h. (B) qPCR of immunoprecipitated genomic DNA samples using a 5hmC-antibody. Co, 
control. (C) qPCR of immunoprecipitated genomic DNA samples using a 5fC-antibody. Data shown as mean 
± SD, n=3, * = p-value < 0.05, ** = p-value < 0.005, *** = p-value < 0.0005, according to student’s t-test. (D) 
Cell cycle profiles of propidium iodide stained cells, measured by flow cytometry. DNA content corresponds 
to propidium iodide intensity.  
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4.2.2.2 G1/S synchronization avoids cell cycle perturbations by RAD21 depletion 
To avoid cell cycle differences between RAD21-depleted and control cells, I controlled cell cycle 
progression by synchronizing the Rad21-AID-Tir1-mESCs at the G1/S boundary by double 
thymidine arrest. Since preliminary results from our laboratory suggested that TET enzymes are 
most active in S-Phase (Lorenz Hexemer and Dr. Andrea Schäfer, personal communication), cells 
were released by thymidine removal, thereby allowing for new production of 5hmC, 5fC and 5caC 
mediated by the activity of the TET enzymes. One hour before release from the thymidine arrest, 
auxin was added to deplete RAD21 and at the time of release, Vitamin C was added to the cells. 
Genomic DNA was isolated, and global 5mC, 5hmC, 5fC and 5caC levels were measured by 
quantitative mass spectrometry (Figure 4.17 A).  
The genomic levels of all monitored cytosine modifications – 5mC, 5hmC, 5fC and 5caC – 
increased after double thymidine arrest and decreased again after release (Figure 4.17 B-E, dark 
green bars). The addition of auxin alone had no effect on the levels of these modifications 
(compare light green bars to dark green bars). Vitamin C increased 5hmC levels 2-fold, 5fC levels 
6-fold, and 5caC levels 8-fold (compare dark blue bars to dark green bars). When auxin was 
added in combination with Vitamin C, only small changes could be detected. For the time points 
2 h and 3 h after release, 5hmC and 5fC levels were slightly reduced compared to non-auxin 
treated samples (Figure 4.17 C and D, compare light blue bars to light green bars). 
To monitor cell cycle perturbations, cell cycle profiles of the four different conditions were 
generated by flow cytometry of propidium iodide stained cells. Compared to untreated cells, most 
cells at time of release (“0 h”) were arrested at the G1/S boundary (Figure 4.17 F). In auxin non-
treated cells, the release enabled the cells to migrate through S-phase until most cells reached 
G2/M 4 h after release. At this time point, a small proportion of cells had already reached G1-
phase to start a new cell cycle. The addition of Vitamin C did not affect the dynamics of the cell 
cycle profiles. In contrast, the addition of auxin induced a G2/M arrest, starting to be visible 3 h 
after release, as was also observed in non-synchronized cells (Figure 4.16 D). However, 3 h after 
release, the cell cycle differences between auxin-treated and non-treated samples were still 
subtle. At the same time, the effects of auxin depletion in combination with Vitamin C treatment 
on global 5hmC, 5fC and 5caC levels were the largest.  
Therefore, I selected the 3 h interval as a good time point for DIP followed by sequencing (DIP-
seq). DIP-seq would allow investigating the site-specific effects of RAD21 depletion on 5mC 
oxidation globally and corroborating findings made earlier for selected enhancers using DIP 
followed by qPCR. In order to achieve greater effects of RAD21 depletion on 5hmC, 5fC and 5caC 
levels, auxin treatment during the thymidine block was further prolonged. By testing different time 
points, adding auxin 10 h before release of the thymidine block was determined to be the best 
time point (data not shown). 
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Figure 4.17 G1/S synchronization avoids cell cycle perturbations by RAD21 depletion 
(A) Experimental workflow and timeline. Rad21-AID-Tir1-mESCs were synchronized in the G1/S-phase by 
double thymidine block. Cells were treated with 500 µM auxin 1 h before release, and 40 µg/ml Vitamin C 
(VitC) was added at the time of release. Cells were harvested after the indicated times. (B-E) Quantitative 
mass spectrometry measurements of the levels of 5mC (B), 5hmC (C), 5fC (D) and 5caC (E). Mass 
spectrometry data by Dr. Michael Musheev. Co, control. (F) Cell cycle profiles of propidium iodide stained 
cells, measured by flow cytometry. DNA content corresponds to propidium iodide intensity.   
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4.2.3 Genome-wide identification of RAD21-dependent 5fC sites 
4.2.3.1 5fC DIP-Seq after acute RAD21 depletion  
To investigate whether loss of RAD21 leads to a loss of the oxidation products of 5mC at 
enhancers, I chose to focus on only one of the oxidation products – 5fC – for the following reasons: 
First, the depletion of RAD21 impaired the Vitamin C-induced accumulation of 5fC at enhancer 
regions after 6 h of auxin-mediated RAD21 depletion, whereas the accumulation of 5hmC was 
not significantly impaired at tested enhancers (Figure 4.16 B and C). Second, Vitamin C 
increased 5fC levels more than it increased 5hmC levels (Figure 4.16 B and C, Figure 4.17 B-E).  
First, Rad21-AID-Tir1-mESCs were synchronized at the G1/S boundary by double thymidine 
arrest before acute RAD21 depletion and Vitamin C treatment. RAD21 was depleted for a total of 
13 h, 10 h during the thymidine block, and 3 h after release. Next, Vitamin C was added for 11 h 
to enhance TET activity when RAD21 was depleted (8 h during the thymidine block and 3 h after 
release). Finally, genomic DNA was extracted and subjected to 5fC DIP-seq (see Figure 4.18 A 
for experimental outline).  
The efficient depletion of RAD21 was confirmed by Western blot (Figure 4.18 B), and cell cycle 
analysis showed only small differences between auxin treated and untreated samples (Figure 
4.18 C). To confirm an efficient enrichment of 5fC-positive regions by the 5fC-antibody, the 
enrichment of candidate enhancer regions was tested by qPCR. In addition, qPCRs were 
performed with samples immunoprecipitated by IgG, as a further negative control. In untreated 
samples, the 5fC antibody enriched the enhancer regions more than 80-fold, compared to IgG 
(Figure 4.18 D, compare dark green bars to striped dark green bars). In addition, there was a 
more than 10-fold enrichment of 5fC-immunoprecipitated enhancer regions compared to the 
negative control region, whereas promoter regions were not enriched (dark green bars). 
Vitamin C increased the enrichment of enhancer regions up to 2-fold, but not of promoter or 
control regions (compare dark blue bars to dark green bars). Yet, the addition of auxin did not 
affect the enrichment of the enhancers, neither without Vitamin C, nor with Vitamin C treatment. 
As only four enhancers were considered, however, we decided to proceed with the sequencing 
of the samples, as they might not be representative for the majority of enhancers in the cell. 
Paired-end sequencing of the samples yielded an average of 2.4x107 reads per sample. However, 
mapping of the paired-end reads resulted in many discordant and singleton reads in the DIP 
samples, but not in the Input samples. We think that this peculiarity originates from non-
homologous single-strand DNA hybridization during the DIP procedure and Library prep. In fact, 
other studies performed the adaptor-ligation with paired-end adaptors before the DIP procedure, 
which would decrease the number of discordant and singleton reads due to non-homologous 
single-strand DNA hybridization [181,182]. To overcome this problem, single reads (read 1 from 
each pair) were mapped to the mm10 mouse genome. Single read-mapping was also used in 
other 5fC DIP-seq studies in mESCs, and should therefore also give conclusive data about 5fC 
enrichment [81]. 
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Figure 4.18 Generation of samples for 5fC DIP-Seq 
(A) Experimental workflow and timeline. Rad21-AID-Tir1-mESCs were synchronized in the G1/S-phase by 
double thymidine block. Cells were treated with 500 µM auxin 10 h before release, and 40 µg/ml Vitamin C 
8 h before release. (B) Western blot of nuclear protein lysates showing the successful depletion of RAD21 
after auxin addition. Protein samples were harvested from the same dishes as DNA samples for DIP. MW, 
molecular weight. (C) Cell cycle profile of propidium iodide stained cells, measured by flow cytometry. DNA 
content corresponds to propidium iodide intensity. (D) qPCR of immunoprecipitated genomic DNA samples 
using a 5fC-antibody or IgG. Data shown as mean ± SD, n=3. Co, control. 
 
Our dataset yielded 203,404 common 5fC peaks (present in at least two DIP samples). This 5fC 
peak set showed a good overlap with 5fC peaks identified by Shen and colleagues, as 80 % of 
their identified 5fC peaks (approximately 20,000 peaks) were also found in our dataset (Figure 
4.19 A) [81]. Our identified 5fC peaks were enriched for TET1 binding sites [166], mESC 
enhancers [176], and Satellite and Simple Repeats, while LINE L1 elements were depleted 
(Figure 4.19 F, compare dark grey to light grey bars).  
Unexpectedly, differential analysis revealed no deregulated 5fC accumulation in the RAD21-
depleted (“auxin”) samples compared to the control samples, using DESeq2 [183] with a relaxed 
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FDR cut-off of 10 % (Figure 4.19 B). This result was further corroborated also with the tools 
EdgeR [184], DiffBind [185] and MEDIPS [186]. Moreover, RAD21 neither significantly affected 
any 5fC peaks in the cells treated with Vitamin C (Figure 4.19 C). Vitamin C treatment alone, on 
the other hand, affected thousands of peaks. DESeq2 differential enrichment analysis revealed 
that 3,732 5fC peaks were increased and 1,322 reduced at 10 % FDR (Figure 4.19 D). The 
Vitamin C-induced peaks were enriched at TET1 binding sites and mESC enhancers, while the 
Vitamin C-suppressed peaks were enriched at Satellite and Simple Repeats (Figure 4.19 F). A 
similar outcome was observed when analyzing Vitamin C effects in the presence of auxin, with 
even more induced 5fC peaks (5,985), but a similar number of suppressed 5fC peaks (1,283) as 
in the cells not treated with auxin (Figure 4.19 E). 
 
 
Figure 4.19 Depletion of RAD21 does not affect 5fC deposition in mESCs 
(A) Overlap of the 203,404 common 5fC peaks identified by 5fC DIP-seq with the 5fC peaks identified by 
Shen et al [81]. (B-C) MA-plots from differential enrichment analyses of auxin-treated vs. untreated cells in 
the absence (B) or presence (C) of Vitamin C using DESeq2. No differential peaks were found with a relaxed 
10 % FDR cut-off. Co, control. (D-E) MA-plots showing the effects of Vitamin C treatment in the absence (D) 
or presence (E) auf auxin, using DESeq2 with a 10 % FDR cut-off. Significantly changed peaks are 
highlighted red: 3,732 5fC peaks are increased and 1,322 reduced in the absence of auxin, and 5,985 
increased/1,283 reduced in the presence of auxin. RPM, reads per million. (F) Feature overlap of the 
203,404 common 5fC peaks, Vitamin C-induced (3,732) and Vitamin C-suppressed (1,322) 5fC peaks, as 
well as a shuffled interval set of the common 5fC peaks as a randomized control. Bioinformatic analysis and 
MA-plots by Dr. Emil Karaulanov.  
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I thus conclude that 5fC deposition at enhancers is RAD21-loop independent, at least under the 
experimental conditions used in this study (Figure 4.20). Although we did not investigate if all 
loops were indeed depleted, a recent study in mESCs, which uses a similar RAD21-degron 
mESC-line, showed that loops are depleted already 6 h after RAD21 depletion [150]. Of course, 
it is possible that by using another experimental set-up, e.g. using different time points, RAD21-
dependent changes of 5fC peaks might be revealed. Nevertheless, it is likely that TET activity is 
targeted to distal elements via other means, and not by promoter-enhancer looping. 
 
 
 
Figure 4.20 5fC deposition at enhancers is RAD21-loop independent 
Model showing that 5fC deposition at enhancers is not affected by RAD21 depletion. 
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4.2.4 Regulation of TET activity by PAR 
4.2.4.1 5hmC levels at selected enhancers are not altered by PAR depletion 
Recently, the enzyme Poly [ADP-ribose] polymerase 1 (PARP1) emerged as a player in shaping 
the 3D chromatin structure. PARP1 can add poly [ADP-ribose] (PAR), a negatively charged 
polymer, to target proteins and also itself, in a process termed PARylation [187]. Its role in shaping 
chromatin structure includes, amongst others, the interaction with and PARylation of CTCF, which 
mediates chromatin fiber interactions [188].  
To test if instead of RAD21, PARylation might play a role in regulating TET activity at enhancers, 
I inhibited PAR synthesis in mESCs using two PARP-inhibitors: Olaparib and PJ34. In order to 
determine if the inhibitor treatment was successful, a Western blot using a PAR-antibody was 
performed. Olaparib treatment caused a weak reduction of the PAR-signal in the cytoplasmic and 
nuclear fractions in a concentration dependent manner, while PJ34 at 10 µM completely depleted 
the PAR signal (Figure 4.21 A).  
The effects of PAR depletion on global levels of 5mC, 5hmC, 5fC and 5caC were monitored via 
quantitative mass spectrometry. While PARP inhibition did not affect 5mC and 5fC levels, 10 µM 
PJ34 significantly increased 5hmC and 5caC levels, compared to the control DMSO treatment 
(p<0.05) (Figure 4.21 B-E). Still, the increase was rather modest: 1.1-fold for 5hmC and 1.2-fold 
for 5caC. Conversely, 1 µM Olaparib treatment significantly decreased 5hmC levels, however, 
10 µM Olaparib treatment had no effect. Since the reduction of PAR levels according to the 
Western blot were actually weakest with 1 µM Olaparib treatment, this is most likely an unspecific 
effect.  
Although no strong great global changes of the oxidative products of 5mC could be detected, site-
specific changes at enhancers could still be possible. Hence, I performed 5hmC DIP-qPCR upon 
PARP inhibition. In control (DMSO)-treated samples, candidate enhancers were enriched about 
20-fold compared to the negative control upon 5hmC DIP (Figure 4.21 F, “DMSO”, grey bars). 
The treatment with the PARP-inhibitors did not affect 5hmC enrichment at any of the candidate 
enhancer regions tested (compare “Olaparib”, green bars, and “PJ34”, blue bars, with “DMSO”, 
grey bars). The enrichment of 5hmC levels at promoters was weaker than at the enhancers, as 
observed before (see Figure 4.16), and again, no effect by PARP-inhibition was observed. 
In summary, PARP inhibition did not lead to strong global changes of 5hmC, 5fC and 5caC. In 
addition, the enrichment of 5hmC at candidate enhancer regions was not altered by PARP 
inhibition. Thus, PARylation likely does not play a role in targeting TET to distal genomic elements. 
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Figure 4.21 5hmC deposition at enhancers is not affected by PAR depletion 
mESCs were treated with the indicated PARP inhibitors for 48 h. (A) Western blot of nuclear and cytoplasmic 
protein lysates, showing the depletion of PAR by the indicated inhibitors. RAD21 and TUBULIN antibodies 
were used as nuclear and cytoplasmic markers, respectively. MW, molecular weight. (B-E) Quantitative 
mass spectrometry measurements of the levels of 5mC (B), 5hmC (C), 5fC (D) and 5caC (E). (F) qPCR of 
immunoprecipitated genomic DNA using a 5hmC-antibody. Data shown as mean ± SD, n=3, * = p-value < 
0.05, according to student’s t-test. Mass spectrometry data by Dr. Michael Musheev. 
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5 Discussion 
5.1 Mechanisms of GADD45A-mediated TET1 regulation 
GADD45A and TET1 are both well-known players in the relatively young field of active DNA 
demethylation [20,22]. GADD45A physically interacts with TET1 and thereby enhances TET1 
activity [104]. However, the mechanism behind this cooperation is still poorly understood. 
GADD45A does not directly demethylate DNA, as it lacks any known enzymatic function. It rather 
promotes active DNA demethylation by acting as an adaptor protein and by bringing together 
different factors involved in this process [20,109,111,151]. Thus, it is likely that GADD45A also 
acts as an adaptor for TET1, bridging TET1 and a yet unknown additional effector.  
The first aim of my PhD thesis was to unravel the mechanism of how GADD45A enhances TET1 
activity. For this purpose, I explored different paths: studying a) a GADD45A-TET1 fusion protein, 
b) the interplay between MAP3K4, GADD45A and TET1, c) the role of GADD45A in altering post-
translational modifications of TET1, and d) the recruitment of additional interactors – members of 
the TRIM protein family – by GADD45A. 
Unfortunately, the generated GADD45A-TET1CD fusion protein was not functional and could not 
be used to further elucidate the mechanism by which GADD45A enhances TET1 activity. Very 
recently, Taghbalout and colleagues could target a GADD45A-TET1CD fusion protein to a 
methylation-silenced gene using a newly developed methylation editing toolbox called Casilio-
ME, which allows for recruitment of multiple effectors to a target site. Their fusion protein was 
active and could increase the expression of the methylation-silenced MLH1 gene. Moreover, their 
GADD45A-TET1CD fusion protein was 3-fold more active than TET1CD alone [189]. I only tested 
if my GADD45A-TET1CD fusion protein was active regarding global 5mC oxidation and cannot 
rule out that it still might be active at a single locus. Another possibility is that Taghbalout’s slightly 
longer GS-linker between GADD45A and TET1CD (16 amino acids compared to 10 amino acids) 
is necessary for the activity of the fusion protein. In any case, the GADD45A-TET1CD fusion 
protein by Taghbalout and colleagues will be of great interest to further unravel how GADD45A 
increases TET1 enzymatic activity. 
All three TET family members are highly phosphorylated, mostly at their N-terminus and low 
complexity insert region, whereas only a few phosphorylation sites have been identified in the 
catalytic domain [96]. The impact of phosphorylation on TET activity has only been scarcely 
studied so far; also, the involved kinases remain largely unknown. Recently, AMPK was 
established as a kinase phosphorylating TET2 at S99. Mutation of this phosphorylation site 
destabilizes TET2 and leads to reduced global 5hmC levels [190]. Yet, this phosphorylation site 
is not conserved in TET1 and thus probably represents a TET2 specific mode of regulation. 
In this study, the four identified MAPK-regulated phosphorylation sites were all located in the N-
terminus of TET1. Two of these sites, S116 and S871, showed reduced phosphorylation upon 
inhibition of MAPK11/MAPK14. In addition, the SB202190 inhibitor treatment abolished the 
enhancement of TET1 activity by GADD45A (Figure 4.5). The orthologous site to human TET1 
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S871, mouse TET1 S854, was also identified as a phosphorylation site by Bauer and colleagues 
[96]. Nevertheless, since GADD45A enhances not only the activity of full-length TET1, but also 
the C-terminal catalytic domain alone, relevant phosphorylation sites for GADD45A-dependent 
TET1 regulation would be expected to lie within the catalytic domain of TET1. Two TET1 
phosphorylation sites within the catalytic domain (S1605 and S1851) were indeed more heavily 
phosphorylated by the overexpression of GADD45A and MAP3K4. However, phosphorylation 
deficient serine to alanine mutations did not alter TET1 activity regarding global 5mC oxidation 
(Dr. Andrea Schäfer, personal communication), arguing against a role of these phosphorylation 
sites in regulating TET1 activity.  
Of course, the cooperation between GADD45A and MAP3K4 could also affect TET1 not directly 
via phosphorylation, but via indirect means, e.g. by the recruitment of additional TET1 interactors. 
However, the co-expression of GADD45A and MAP3K4 rather reduced TET1 activity, instead of 
enhancing it like expression of GADD45A alone (Figure 4.2 and Figure 4.6). Thus, MAP3K4 is 
not the co-factor of GADD45A that is responsible for enhancing TET1 activity. 
The role of phosphorylation in regulating TET1 activity remains elusive. We cannot exclude that 
GADD45A plays a role in the phosphorylation of TET1, but we could neither find any evidence 
that these phosphorylation changes affect TET1 activity on a global scale. The higher density of 
phosphorylation sites in the N-terminus of TET1 suggests that the recruitment to chromatin rather 
than the catalytic activity of TET1 could be affected by phosphorylation. In fact, the notion that 
TET1’s N-terminus mediates chromatin binding is supported by the discovery of two different 
isoforms of mouse TET1: a full-length isoform that is exclusive to embryonic tissues (TET1FL), 
and a truncated isoform of TET1 (TET1s). TET1s lacks large parts of the N-terminus including 
the CXXC domain and was only found to be expressed in somatic tissues. Furthermore, TET1s 
has a reduced global catalytic activity and reduced global chromatin binding [70].  
Perhaps, the N-terminus of human TET1 is also essential for the regulation by GADD45A, 
although this does not become evident with overexpressed proteins. Indeed, it is possible that the 
high non-physiological levels of TET1CD that were used in this study mask a possible deficiency 
of TET1CD in its global activity and chromatin binding. Thus, future studies should rather 
investigate TET1 phosphorylation in a physiological context, e.g. in embryonic tissues, to avoid 
unspecific effects caused by ectopic overexpression. In fact, whereas GADD45A increases 5hmC 
production via TET1FL as well as TET1CD, the enhanced removal of 5fC and 5caC is only 
observed for TET1FL, but not TET1CD (compare Figure 4.2 to Figure 4.10 and Figure 4.12) [104]. 
This argues that for GADD45A’s full role in DNA demethylation, also the N-terminus of TET1 is 
required. 
The third path that was explored to unravel how GADD45A enhances TET1 activity, was the role 
of GADD45A in altering ubiquitination or SUMOylation of TET1. All three TET proteins are 
monoubiquitylated by the E3 ubiquitin ligase complex CRL4 on a highly conserved lysine residue 
within the catalytic domain. This monoubiquitylation promotes the binding of TET to DNA and is 
essential for proper 5hmC production [93,94]. In this study, GADD45A reduced TET1 
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ubiquitination (Figure 4.7), which could indicate that GADD45A increases TET1 protein stability 
by preventing degradation via the proteasome, as it is well known that ubiquitin chains can target 
proteins to the 26S proteasome for degradation [191]. A CHX assay revealed that GADD45A 
indeed increases TET1 protein stability, but independently of the proteasome (Figure 4.8). 
Instead, a Calpain inhibitor stabilized TET1 protein levels to a similar extent as GADD45A, but 
only affected overexpressed human TET1 in HEK293T cells, not endogenous mouse TET1 in 
mESCs.  
Yet, a different study, conducted by Wang and Zhang, discovered that mouse TET1 was targeted 
by CALPAIN1-mediated degradation also in mESCs. This study also showed that Calpain1-
knockout cells had elevated 5hmC levels [46]. The discrepancy between the study by Wang and 
Zhang and ours could have different reasons. The main cause probably originates from the 
technical limitations of accurately quantifying proteins by Western blotting. The accurate 
quantification of proteins via Western blotting depends on many variables, such as protein 
isolation, membrane transfer, quality of the antibody, selection of a reference protein (serving as 
the “loading control”), and the method of quantification of band intensities [192]. Indeed, most of 
these variables differed in the two studies. For example, Wang and Zhang used TUBULIN as a 
reference protein for the relative quantification of TET1 protein levels. In this thesis, distinct bands 
of HA-TET1 could only be detected when nuclear protein lysates were used for Western blotting, 
requiring also a nuclear reference protein. HNRNPA1 was used for this purpose, as it gave more 
reliable signals than other tested loading controls (LAMINB1, Histone H3 and p68, data not 
shown). Still, Figure 4.8 shows that HNRNPA1 is not detected as a fully distinct band and this 
could affect protein quantification. As these technical limitations of Western blotting apply 
universally, any conclusions based solely on the Western blot method should be taken with 
caution.  
Despite the limitations described above, this thesis provides first hints that GADD45A increases 
TET1 stability, possibly by preventing Calpain-mediated decay. To further explore this in the 
future, GADD45A-degron mESC lines could be used to monitor how an acute depletion of 
GADD45A affects TET1 protein stability in an endogenous TET1 context. In addition, it would be 
interesting to know if GADD45A only increases protein stability of full-length TET1, or also 
stabilizes TET1CD.  
Still, the question of how GADD45A mediates stabilization of the TET1 protein remains 
unresolved. GADD45A has been shown to stabilize SMAD4 by preventing its ubiquitination and 
subsequent proteasomal degradation [193]. However, the proteasome inhibitor MG132 had no 
effect on TET1 stability in this study (data not shown). Another possibility would be that GADD45A 
does not directly affect protein stability, but rather increases mRNA stability. In fact, GADD45A 
was recently shown to stabilize memory-related mRNAs in mice, which requires the RNA-binding 
capacity of GADD45A [194]. Thus, GADD45A could also regulate TET1 activity by stabilizing its 
mRNA, for example via preventing binding and degradation by miRNAs. In this context, several 
miRNAs have been implicated in TET1 regulation, such as miRNA-22 [195], miRNA-26a [196], or 
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miRNA-29a [197]. Another RNA binding protein, Deleted in azoospermia-like (DAZL), has been 
shown to regulate TET1 by stabilizing its mRNA and enhancing its translation [198]. In the future, 
a possible stabilizing function of GADD45A on TET1 mRNA could be tested and compared to the 
effect of an RNA-binding deficient K45A mutant of GADD45A [199]. 
SUMOylation already has a proposed role in DNA demethylation: it enables TDG to be released 
from the DNA after excision; hence, increasing the turnover of TDG [168]. However, the role of 
SUMOylation has been a matter of debate and it may not be the only mechanism mediating 
product release [200,201]. Recently, SUMO was shown to not only coordinate TDG, but the whole 
TDG-base excision repair complex [202]. GADD45A was shown to interact with TDG and to 
promote removal of 5fC and 5caC by TDG, but the mechanism is yet unclear [111]. In fact, 
GADD45A itself can be SUMOylated, as recently shown by a mass spectrometry screen [169]. 
Therefore, GADD45A could help to assemble the DNA demethylation complex, for example by 
acting as a SUMO donor, similar to X‐ray repair cross‐complementing protein 1 (XRCC1), which 
acts as a SUMO donor for TDG during DNA demethylation [202]. 
In this light, I investigated if GADD45A promotes the removal of 5fC and 5caC by coordinating 
the SUMOylation of TDG and also TET1. Indeed, GADD45A strongly enhanced the SUMOylation 
of TDG (Figure 4.11), providing a first hint that this might be the mechanism by which GADD45A 
can enhance 5fC and 5caC removal by TDG. To my knowledge, TET1 had not been identified as 
a SUMO target at the beginning of this study, but TET3 had been found to be SUMOylated in a 
high resolution mass spectrometry screen [203]. Co-IPs of SUMO and TET1 revealed that also 
TET1 is SUMOylated. Surprisingly, GADD45A decreased the SUMOylation of full-length TET1, 
while it enhanced the SUMOylation of TET1CD (Figure 4.9).  
I decided to focus on GADD45A’s effect on the catalytic domain of TET1, as the activity of the 
isolated catalytic domain is also enhanced by GADD45A. Possible SUMOylation sites of TET1 
were predicted by an identification of SUMO-consensus motifs and the predicted SUMO sites 
were mutated from lysine to alanine or arginine. However, none of the four tested TET1 mutations 
affected TET1 activity or the functional cooperativity with GADD45A (Figure 4.10). A recent study 
confirmed that TET1 can indeed be SUMOylated, and three SUMO sites were identified in human 
HeLa and U2OS cell lines: K540, K784 and K792 [169]. Of note, none of these identified sites 
lies in a SUMO-consensus motif, nor in the catalytic domain of TET1. However, since TET1 
expression levels in somatic cell lines are generally low [41], less abundant SUMO sites might 
have been overlooked. Thus, it might be possible that 1) other SUMOylation sites exist in the 
catalytic domain, which lie outside of SUMO-consensus motifs and were thus not predicted and 
2) SUMOylation, like phosphorylation, is mainly confined to the N-terminus of TET1. This thesis 
cannot provide evidence that SUMOylation plays a role in GADD45A-mediated TET1 regulation, 
but it can neither exclude it. In vitro SUMOylation of TET1 followed by a TET1 in vitro oxidation 
assay would give more insights into the role of SUMOylation in coordinating TET1 activity. 
If not via post-translational modifications, how else could GADD45A regulate TET1? Interactors, 
regulating TET1 activity have been identified, which mostly affect TET1 activity by the recruitment 
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to specific loci (reviewed in [41]). In search for GADD45A-regulated TET1 interactors, the E3 
Ubiquitin/ISG15 ligase TRIM25 and the E3 Ubiquitin/SUMO ligase TRIM28 were found to be 
required for GADD45A to enhance global TET1 activity (Figure 4.12). However, these two factors 
most likely affect TET1 enzymatic activity only indirectly, e.g. by enhanced recruitment to genomic 
loci, as the depletion of these factors did not affect TET1 activity in an in vitro oxidation assay 
(Figure 4.13). Interestingly, the connection between TRIM28 and TET proteins has been made 
before. TET proteins are required for efficient binding of TRIM28 to MuERV-L in order to repress 
MuERV-L transcription [50]. This, however, involves the repressive function of TET proteins, 
which is uncoupled from the catalytic activity [74]. In summary, this thesis could not identify any 
new GADD45A-mediated interactors of TET1. As a result, the main question remains unresolved: 
How does GADD45A enhance TET1 activity? Other post-translational modifications, apart from 
the ones discussed here, might play a role in this mechanism, including: acetylation, which can 
enhance TET2 activity [95], O-GlcNAcetylation, which was shown to be required for proper TET1 
function [97], and PARylation, which also enhances TET1 activity [98]. 
Apart from recruiting co-factors to enhance the catalytic activity of TET1, GADD45A could also 
be involved in targeting TET1 to genomic loci. Several other proteins targeting TET1 to genomic 
loci have been identified, including NANOG [99], PRDM14 [100], PRC2 [103], LIN28A [102]. 
Indeed, GADD45A was recently shown to target TET1 to a subset of R-loops [166]. In addition, 
preliminary TET1 ChIP-seq results in wild-type vs. Gadd45a/b/g triple-knockout mESCs showed 
that a few hundred TET1 peaks were downregulated after GADD45A/B/G depletion (Dr. Khelifa 
Arab, personal communication). This suggests that GADD45 proteins are indeed involved in 
targeting TET1 to genomic loci.  
Both TET1 and GADD45A belong to protein families composed of two additional members, TET2 
and TET3; and GADD45B and GADD45G. In fact, those other family members are also involved 
in active DNA demethylation and can thus, at least partially, act redundantly [31,37,106,110]. The 
redundancy is also further stressed in vivo: single Tet3 mouse mutants are viable [45], Tet1/2 
double knockout mutants are partially lethal [204], whereas Tet1/2/3 triple-mutants are lethal due 
to gastrulation defects [52]. In addition, also GADD45 single knockouts of Gadd45a, -b or -g are 
viable [205–207]. One could envision that the functional interaction between GADD45A and TET1 
is not exclusive. Other combinations of GADD45 and TET proteins could also cooperate in 
promoting DNA demethylation, which, in its whole, regulates the epigenome. As a first proof of 
this concept, co-expression of GADD45B and TET1, as well as GADD45G and TET1 also boosted 
5hmC levels, similar to GADD45A co-expression (data not shown). 
A general problem when studying GADD45A’s role in TET1-mediated DNA demethylation is 
GADD45A’s dual role of enhancing 5hmC production by TET1 and enhancing 5fC and 5caC 
removal by TDG (see e.g. Figure 4.2). To uncouple these two functions of GADD45A, one can 
make use of TDG mutants. This could reveal whether GADD45A indeed enhances the removal 
of 5fC and 5caC by TDG, or if GADD45A rather affects the substrate preference and processivity 
of TET1. 
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5.2 The interplay between chromatin structure and DNA demethylation 
A remaining conundrum in the field of DNA demethylation is why TET binding sites are mostly 
found at promoters, whereas the oxidative derivatives of 5mC, which are generated by the TET 
enzymes, are mostly enriched at distal elements, such as enhancers. A simple model to explain 
this discrepancy is promoter-enhancer looping, as proposed by Wu and Zhang [41]. Interestingly, 
in a recent study ING1 (occupying promoters) was shown to promote local DNA demethylation 
via GADD45A (mostly bound at superenhancers), by long-range chromatin looping [151]. 
To test if promoter-enhancer looping plays a role in targeting TET activity to distal regulatory 
elements, I generated a RAD21-degron mESC-line, which was used to acutely and efficiently 
deplete RAD21 (Figure 4.15). Due to the complexity of identifying chromatin loops, I did not 
perform high-resolution genome-wide chromosome conformation capture (Hi-C) analysis to verify 
if the depletion of RAD21 resulted in a depletion of promoter-enhancer looping in the RAD21-
degron mESC-line. However, a thorough analysis of acute RAD21-loss in the context of chromatin 
structure has been performed by Rao and colleagues in human HCT116 cells, also using an 
auxin-inducible RAD21-degron cell line. Hi-C analysis showed that already 40 min of auxin 
treatment depleted loops, whereas auxin withdrawal could restore the loops accordingly [132]. In 
addition, a recent study in mESCs confirmed the loss of loops 6 h after auxin-mediated RAD21 
depletion [150], and another mESC study specifically detected a reduced contact frequency 
between the Sik1 promoter and its distal regulatory elements upon 24 h of RAD21 depletion [141]. 
For genome-wide analysis of 5fC deposition, I depleted RAD21 by auxin addition for a total of 
13 h, with auxin renewal after the first 10 h. Thus, although not proven, it can be assumed that 
promoter-enhancer loops in my system were also depleted.  
To test if the TET oxidation product 5fC is affected by loop depletion, specifically at enhancers, I 
performed a 5fC DIP-seq after RAD21 depletion. Surprisingly, differential 5fC peak analysis did 
not reveal any peaks that changed after RAD21 depletion (Figure 4.19 A and B). Yet, we are 
confident about having correctly mapped 5fC peaks, as 80 % of the peaks of a published 5fC 
dataset were also found in our dataset [81]. Also, the feature overlap analysis showed enrichment 
for 5fC in mESC enhancers and repetitive regions, which have been shown before to be enriched 
for 5fC (Figure 4.19 E) [81]. In addition, we were generally able to detect differential 5fC peaks in 
our experimental set-up, as revealed by 3,732 (-auxin) and 5,985 (+auxin) Vitamin C-induced 5fC 
peaks (Figure 4.19 C and D). The increase in the number of Vitamin C-induced peaks after 
RAD21 depletion (+auxin) is surprising. But since the additional peaks are random and are not 
enriched at any investigated genomic feature (data not shown), we think that this increase might 
just be a technical artefact. We thus conclude that RAD21 depletion, and therefore loop depletion, 
has no effect on 5fC distribution.  
There are several caveats of the above-described experimental setup, which could explain our 
results: First, the experiment was performed in cells that express TDG. Consequently, the majority 
of newly produced 5fC might have been already removed by TDG. In fact, a 5fC DIP-seq study 
has revealed a large increase in overall 5fC peaks after TDG depletion, especially in distal 
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regulatory elements [81]. Also alternative methods to detect 5fC, termed 5-formylcytosine-
selective chemical labeling (fC-Seal) or 5fC chemical modification-assisted bisulfite sequencing 
(fCAB-seq), revealed an increase in 5fC levels after TDG depletion, especially in poised 
enhancers, whereas the authors did not find any TDG dependent regulation for 5hmC [86]. Thus, 
it could be possible that 5fC distribution in the cell, in contrast to our model, is not mainly regulated 
by TET, but rather by TDG. In the future, one could study the distribution of 5fC after promoter-
enhancer loop depletion in a TDG-deletion background. This would make it possible to study only 
the effects of TET on 5fC distribution, without disturbances caused by TDG removal. It also has 
to be considered that promoter-enhancer loop depletion could have a greater effect on 5hmC 
distribution at enhancers, since 5hmC is not removed by TDG. Although I did not observe any 
effects after 6 h of auxin depletion on the 5hmC levels at selected enhancers, a longer auxin 
treatment might still reveal differences at other enhancer regions (Figure 4.16).  
Second, maybe the expected changes of 5fC peaks after loop depletion are too small to be 
detected by 5fC DIP-seq, although Vitamin C was added to enhance de novo 5fC formation. An 
average cell cycle of mESCs lasts 11 h [180]. Assuming there is no active removal of 5fC by TDG 
and no new production by TET enzymes, 50 % of “old” 5fC would still remain in the cell after 11 h 
due to DNA replication. In our experimental set-up, the cells underwent only one round of 
replication after loop depletion (Figure 4.18). Song and colleagues determined that 7 % of the 
total number of 5fC-containing peaks overlap with enhancers, which are predicted to link to 
promoters [86]. If 50 % of 5fC at these regions remained after DNA replication, only 3.5 % of the 
total 5fC, in the best scenario, would be predicted to change after RAD21 depletion, given our 
model is correct. In fact, “old” 5fC at the parental strand might serve as a mark to guide TET to 
the daughter strand during DNA replication, a concept similar to DNA methylation maintenance 
by DNMT1 [6]. This possible maintenance might make proper loop formation dispensable for new 
5fC production. For example, TET might be recruited to enhancers not via promoter-enhancer 
looping, but via DNMT3A/B recruitment. Although this might seem surprising as DNMT3A/B are 
mainly known as de novo DNA methyltransferases, they have also been implicated in 
maintenance DNA methylation [209]. This concept would fit to findings of Gu and colleagues, who 
showed that TET1 occupancy at enhancers in Dnmt3a knock-out mESCs was decreased [210]. 
At the same time, TET1 occupancy at promoters slightly increased, suggesting that diverse 
modes of TET1 regulation exist, depending on the genomic context. In addition, Zhang and 
colleagues found that all human TET proteins interact with DNMT1, and TET2 also associates 
with DNMT3B. Furthermore, they propose that DNMT1 could be essential for recruiting TET2 to 
chromatin during oxidative stress [95]. 
To discriminate between newly produced 5fC and old 5fC, one could perform nascent sequencing 
of 5fC, via pulse labeling with the nucleotide analog ethynyl-deoxyuridine (EdU), as described for 
5mC by Xu and Corces [154]. Using this method in combination with a base-resolution method to 
detect 5fC would also overcome the drawbacks of the 5fC DIP-seq method, of having a low spatial 
resolution, a strong density bias (discussed for 5mC- and 5hmC-antibodies in [82]) and the lack 
of absolute quantification [41]. An additional recently discussed problem of DIP-methods is off-
target binding of IgG to short unmodified DNA repeats, which increases the noise and complicates 
the identification of subtle alterations of the modifications [211]. In fact, this could have been a 
problem in the 5fC DIP-seq in our and other studies, as simple repeats were enriched in our called 
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5fC peaks (Figure 4.19). Alternative base-resolution methods for 5fC detection include e.g. 
M.SssI methylase-assisted bisulfite sequencing (MAB-seq), which measures 5fC and 5caC [87], 
reduced bisulfite sequencing (redBS-seq) [212], or fCAB-seq [86]. Using one of these methods 
would increase the sensitivity and thus, the possibility to detect also subtle changes of 5fC levels. 
A large number of TADs are cell specific [123,124] and in contrast to the population average, 
Cohesin depletion in single cells did not abolish domain separation [123]. Thus, perhaps also the 
changes of 5fC distribution are masked by cell-to-cell differences and single cell 5fC sequencing 
would be required to detect changes of 5fC distribution in individual cells. 
Supposing that experimental caveats indeed masked changes of 5fC levels after RAD21 
depletion, what evidence speaks for a relationship between the 3D chromatin structure and DNA 
demethylation? Xu and Corces discovered that a loss of DNMT3B reduces RAD21-mediated 
chromatin interactions in human ESCs. They propose that this is due to a loss of hemimethylation, 
perhaps because of an altered physical interaction with MeCP2 [154]. MeCP2 can interact with 
Cohesin and regulate chromatin looping [157,158]. Furthermore, a recent study by Wiehle and 
colleagues established CTCF as an insulator for DNA methylation spreading. They propose a 
methylation/nucleosome/CTCF switch, where TET1/2 deficiency leads to a gain of DNA 
methylation and increased nucleosome occupancy. This affects CTCF binding, which in turn 
changes DNA methylation patterns [159]. A study focusing on the role of CTCF in shaping the 3D 
chromatin also established CTCF as a boundary element, which is required for TAD insulation 
[147].  
This gives CTCF a distinct role from RAD21 and the Cohesin complex, which is required for loop 
domain formation [132]. Still, both CTCF and Cohesin are involved in shaping the 3D chromatin 
structure. If TET recruitment to enhancers was indeed dependent on promoter-enhancer looping, 
maybe only the disruption of both, CTCF and the Cohesin complex would affect TET activity at 
enhancers. Although promoter-enhancer contacts are depleted after Cohesin loss, TADs still 
persist and compartmentalization is even enhanced [132]. Perhaps, the compartmentalization 
alone is sufficient to recruit TET to enhancers.  
Another important question is also whether the 3D chromatin structure shapes the 
(de-)methylome as proposed by Xu and Corces [154], or whether the (de-)methylome shapes the 
3D chromatin structure, as proposed by Wiehle and colleagues [159]. In fact, Fang and colleagues 
revealed additional evidence suggesting that the (de-)methylome might shape the 3D chromatin 
structure by showing that a combined Tet2 and Tet3 depletion disrupts YY1 binding and long-
range chromatin interactions during mouse heart development [208]. 
Many recent studies propose that TADs and chromatin loops are dynamic structures [213]. 
Hence, it is not surprising that factors other than CTCF and Cohesin also play a role in shaping 
the 3D chromatin structure. In fact, Cohesin has many CTCF-independent binding sites, and 
CTCF is specifically not often found at promoter-enhancer elements, whereas Cohesin is 
[121,214]. Promoter-enhancer interactions might be mediated by Cohesin alone, by the 
interaction of Cohesin and the transcriptional co-activator complex Mediator [137], ESRRB [138], 
as well as the transcription factors YY1 [139], ZNF143 [140] and OCT4 [141], long noncoding 
RNAs [142] and the ChAHP complex [143]. Lately, also the histone chaperone Facilitates 
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chromatin transcription (FACT) was shown to contribute to the formation of Cohesin-dependent 
TADs in Saccharomyces cerevisiae, independently of transcription [215]. In addition, a recent 
preprint demonstrated that the acetyltransferase ESCO1 can contribute to boundary formation in 
chromatin looping, like CTCF [216]. Therefore, to completely abolish promoter-enhancer 
contacts, one would have to perhaps deplete far more proteins than only RAD21.  
Despite the possibility that other factors might be involved in forming promoter-enhancer loops, 
TET enzymes might also be recruited to enhancers via other means, for example by PAR. Both 
CTCF and TET1 are targets of PARylation, and thus, PARylation might bring these two factors 
together [98,188]. In addition, PAR chains have been shown to decondense higher-order 
chromatin structures [217] and have been proposed to cause phase separation and thereby 
reorganize the 3D chromatin structure [218]. Therefore, I tested a possible involvement of 
PARylation in regulating TET activity at enhancers by inhibiting PARylation with Olaparib and 
PJ34. However, the inhibitors did not affect the enrichment of 5hmC at candidate enhancers 
(Figure 4.21 F), suggesting that PARylation does not play a major role in the recruitment of TET 
to these enhancers. Surprisingly, the inhibition of PARylation by PJ34 slightly increased global 
5hmC levels (Figure 4.21 C). This is in contrast to what has been observed by Ciccarone and 
colleagues, who observed a decrease of global 5hmC after PJ34 treatment in HEK293T cells 
[98]. This difference might be due to the different cell types and different expression levels of TET 
proteins in mESC (high) and HEK293T (low), or different methods of 5hmC-detection (quantitative 
mass spectrometry used in this study vs. dot blot used by Ciccarone and colleagues). Although 
the PARylated Peroxisome proliferator-activated receptor γ (PPARγ) complex can recruit TET1 
to PPAR response elements [219], this mechanism is likely not transferable to TET1 recruitment 
to enhancers in general. 
As discussed in chapter 5.1, several other TET interactors could also be involved in the 
recruitment of TET to enhancers, among them GADD45A and the long noncoding RNA TARID 
[109,166]. This is consisent with the finding that GADD45A is bound at enhancers in mouse 
embryonic fibroblasts (MEFs) [151]. Transcription factor occupancy might also play an important 
role in TET recruitment, as transcription factors themselves bind to enhancers [220]. Examples 
include NANOG [99], PRDM14 [100] and EGR1 [101].  
Another possibility is that TET proteins are not readily detected at enhancers due to technical 
limitations of the ChIP-seq method. In ChIP-seq, transient binding of TET to the DNA (e.g. to 
enhancers) might be undetectable and more stable binding sites of TET (e.g. promoters) might 
mask the transient binding sites. This issue has been raised for repressive transcription factors, 
which only transiently bind DNA and then vacate their binding regions [221]. Other techniques, 
such as DNA adenine methyltransferase identification (DamID)‐seq might circumvent this 
problem, as DamID-seq does not only capture one snapshot of a protein binding to DNA, but 
monitors binding events over a specific timeframe. In addition, the method does not rely on 
protein-DNA crosslinking or antibody binding, which might introduce additional artefacts [222]. 
Recently, two new methods – Cleavage Under Targets and Release Using Nuclease (CUT&RUN) 
and Cleavage Under Targets and Tagmentation (CUT&Tag) – have been shown to have a better 
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resolution and a better signal-to-noise ratio than ChIP-seq; thus, also allowing detection of 
transient protein-DNA interactions [223,224]. As these methods have not been employed to 
investigate TET binding thus far, using these methods will give a more comprehensive 
understanding about TET binding sites in the future.  
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6 Material and Methods 
6.1 Material 
6.1.1 Equipment 
-150°C freezer (Sanyo); -80°C freezer (Sanyo); agarose gel chambers (Bio-Rad); Agilent 6490 
triple quadrupole mass spectrometer (Agilent Technologies); bacterial incubators (Thermo 
Scientific); bacterial shaker (Infors); balances (Sartorius); Bioanalyzer (Agilent); Bioruptor 
(Diagenode); cell counter (Bio-Rad); cell culture dishes and flasks (TPP); cell culture incubators 
(Thermo Scientific); centrifuges (Heraeus); ChemiDoc XR+ System (Bio-Rad), ChemiDoc XRS+ 
System (Bio-Rad), Confocal microscope TCS SP5 (Leica); coverslips (Thermo Fisher Scientific); 
Criterion TGX Precast Midi Protein Gels (Bio-Rad); Cryo-Safe Cooler (Belart); cryo tubes (Greiner 
Bio-One); DNA LoBind 1.5 ml Tubes (Eppendorf); DynaMag-2 Magnet rack (Invitrogen); E-Gel 
electrophoresis system (Invitrogen); extra thick blot filter paper (Bio-Rad); fridges (Liebherr); 
heating blocks (Eppendorf); laminar flow hoods (Dometic); LightCycler 480 (Roche); Low Binding 
1.5 ml tubes (Biozym); LSRFortessa SORP cell analyzer (BD Biosciences); magnetic stirrer 
(Heidolph); microcentrifuges (Heraeus); microscope (Leica); micro tube (Covaris); microwave 
oven (Sharp); multidispenser pipette (Eppendorf); Nanodrop 2000 spectrophotometer (Thermo 
Scientific); NextSeq500 (Illumina); orbital shaker (Neolab); PAGE midigel chambers (Bio-Rad); 
PCR thermocyclers (Biometra); pH meter (Mettler Toledo); pipet boy (Integra); pipettes 
(Eppendorf); power supplies (Bio-Rad); PVDF transfer membrane (Neolab); Qubit (Thermo 
Fisher); rotator (Neolab); SpeedVac concentrator (Eppendorf); SuperFrost Plus Adhesion slides 
(Thermo Fisher Scientific); test tubes (Eppendorf, Falcon, Sarstedt); test tube rotator (Kisker 
Biotech), TPX microtubes (Diagenode); Trans-Blot SD semi-dry transfer cell (Bio-Rad); Trans-
Blot Turbo (Bio-Rad); Trans-Blot Turbo Midi PVDF (Bio-Rad); tubes with cell-strainer cap 
(Falcon); ultrapure water purification system (Millipore); ultrasonicator S2/E210 (Covaris); 
vortexer (Scientific industries); water baths (Neolab) 
6.1.2 Chemicals and pre-made Buffers 
0.05 % Trypsin-EDTA (1x) (Gibco); 0.25 % Trypsin-EDTA (1x) (Gibco); 0.1 % gelatin in ultrapure 
water (Millipore); 15N dCTP (Silantes); agarose (Biozym); α-ketoglutaric acid disodium salt 
hydrate (Sigma-Aldrich); ammonium acetate (Sigma-Aldrich); ammonium iron(II) sulfate 
hexahydrate (Sigma-Aldrich); ampicillin (Sigma-Aldrich); ATP (NEB); boric acid (Sigma-Aldrich); 
bovine serum albumin (BSA) (Sigma-Aldrich); Buffer 2.1 (NEB); Calpeptin (Sigma); 
chloroacetamide (CAA) (Sigma-Aldrich); chloroform-isoamylalcohol (Roth); Cutsmart buffer 
(NEB); cycloheximide solution (Sigma-Aldrich); DAPI (Sigma-Aldrich); dialyzed FBS (Sigma-
Aldrich); dimethyl sulfoxide (DMSO) (Sigma-Aldrich); dithiothreitol (DTT) (Sigma-Aldrich); DMEM 
for SILAC (Thermo Fisher Scientific); DMEM, HEPES (Sigma-Aldrich); high glucose, pyruvate, 
no glutamine (Gibco); DMEM, high glucose, no glutamine, no methionine, no cysteine (Gibco); 
DPBS, no calcium, no magnesium (Gibco); EDTA (Sigma-Aldrich); EGTA (Sigma-Adlrich); ES-
grade FBS (PAN Biotech); ethanol (Sigma-Aldrich); ethidium bromide (Roth); fetal bovine serum 
(FBS) (Lonza); FLAG peptide (Sigma Aldrich); Fluorescence Mounting Medium (Dako); FreeStyle 
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293 Expression Medium (Gibco); gelatin (Sigma); GeneAmp PCR Buffer 1, 15 mM MgCl (Thermo 
Fisher Scientific); geneticin (Gibco); glycerol (Sigma-Aldrich); glycine (Sigma-Aldrich); 
hygromycin B (Sigma-Aldrich); hydrochloric acid (Sigma-Aldrich); indole-3-acetic acid sodium salt 
(Sigma-Aldrich); isopropanol (Sigma-Aldrich); L-ascorbic acid (Sigma-Aldrich); L-Cysteine 
(Sigma-Aldrich); LIF (Homemade cell supernatant); lithium chloride (Sigma-Aldrich); L-Glutamine 
100x 200 mM (Gibco); L-Methionine-(methyl-13C,d3) (Sigma-Aldrich); magnesium chloride 
(Sigma-Aldrich); MEM Non-essential amino acids 100x (Gibco); methanol (Sigma-Aldrich); 
MG132 (Tocris); N-Ethylmaleimide (NEM) (Sigma-Aldrich); Nonidet P 40 Substitute (Sigma-
Aldrich); nuclease-free water (Qiagen); NuPAGE LDS Sample Buffer (4X) (Invitrogen); Olaparib 
(AZD2281, Ku-0059436) (Selleckchem); Optimem (Gibco); paraformaldehyde (Merck Millipore); 
PEI MAX 4000 (Polysciences); penicillin/streptomycin 10,000 U/ml (PAN); phenol-chloroform-
isoamylalcohol (Roth); Phosstop (Roche); PJ-34 hydrochloride hydrate (Sigma-Aldrich); 
Plasmocin (Invitrogen); potassium hydroxide (Sigma-Aldrich); propidium iodide (Sigma-Aldrich); 
Protease inhibitor cocktail tablets EDTA-free (Roche); puromycin (Sigma-Aldrich); Quick Start 
Bradford 1x Dye Reagent (Bio-Rad); random primers (Invitrogen); SB202190 (Sigma-Aldrich); 
skim milk powder (Sigma-Aldrich); SAM (NEB); sodium acetate (Sigma-Aldrich); sodium chloride 
(Sigma-Aldrich); sodium citrate tribasic dihydrate (Sigma-Aldrich); sodium deoxycholate (Sigma-
Aldrich); sodium dodecyl sulfate (Sigma-Aldrich); sodium hydroxide (Sigma-Aldrich); sodium 
phosphate dibasic dihydrate (Sigma-Aldrich); sodium phosphate monobasic monohydrate 
(Sigma-Aldrich); sodium pyruvate 100 mM (Gibco); ß-mercaptoethanol (Sigma-Aldrich); 
thymidine (Sigma); Trizma base (Sigma-Aldrich); Trizma hydrochloride (Sigma-Aldrich); Triton X-
100 (Sigma-Aldrich); Tween-20 (Sigma-Aldrich); U0126 (Sigma-Aldrich); urea (Sigma-Aldrich); 
xylene cyanol (Sigma-Aldrich); yeast tRNA (Roche) 
6.1.3 Kits 
ANTI-FLAG M2 Affinity Gel (Sigma-Aldrich); DNAse I (Roche); DNeasy 96 Blood & Tissue kit 
(Qiagen); DNeasy Blood & Tissue kit (Qiagen); Dynabeads Protein A and G (Thermo Fisher 
Scientific); GFP-Trap Agarose (Chromotek); Gibson Assembly Master Mix (NEB); High Sensitivity 
DNA Assay (Agilent); LightCycler 480 Probes Master (Roche); LightCycler 480 SYBR Green I 
Master (Roche); Lipofectamine 2000 (Invitrogen); PCR Mycoplasma Test Kit I/C (Promokine); 
Plasmocin (ant-mpt-1) (InvivoGen); Protein A Agarose (Roche); PvuII (Promega); Qiaprep 
Maxiprep kit (Qiagen); Qiaprep Midiprep kit (Qiagen); Qiaprep Miniprep kit (Qiagen); Qiaquick 
Gel extraction kit (Qiagen); QIAquick PCR purification kit (Qiagen); QIAshredder (Qiagen); Qubit 
dsDNA HS Assay Kit (Thermo Fisher Scientific); QuikChange II XL Site-Directed Mutagenesis Kit 
(Agilent); Reverse Transcriptase (CF IMB); RNeasy 96 kit (Qiagen); RNeasy Mini Kit (Qiagen); 
Superscript II Reverse Transcriptase (Invitrogen); SuperSignal West Femto/Pico (Thermo Fisher 
Scientific); X-tremeGENE 9 (Roche) 
6.1.4 Enzymes 
AccuPrime Taq (Thermo Fisher Scientific); alkaline phosphatase (Fermentas); BamHI HF (NEB); 
CpG Methyltransferase (M.SssI) (NEB); MluI (NEB); NotI (NEB); nuclease P1 (Roche); Phusion 
High-Fidelity DNA Polymerase (NEB); Proteinase K (Roche); RNAse A (Qiagen); RNAse free 
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DNAse set (Qiagen); SacI (NEB); SalI (NEB); SmaI (Thermo Fisher Scientific); snake venom 
phosphodiesterase (Worthington), Taq (CF IMB); XbaI (NEB) 
6.1.5 Buffers and Solutions 
Solution Components 
Blastocyst Lysis 
Buffer 
100 mM Tris HCl pH 8, 100 mM KCl, 0.02% gelatin, 0.45% Tween-
20, 60 µg/ml yeast tRNA, 125 µg/ml Proteinase K 
Blotting Buffer 
(Bjerrum Schafer 
Nielsen) 
48 mM Tris, 39 mM glycine, pH 9.2, 20 % methanol 
CL Lysis Buffer 
150 mM NaCl, 50 mM Tris-HCl pH 7.5, 1 mM EDTA, 0.5 % Triton X-
100, 1x Protease inhibitor cocktail, 1x Phosstop, 1 mM Na3VO4, 
20 mM NaF 
Denaturing Lysis 
Buffer 
1x PBS, 1 % (wt/vol) SDS, 5 mM EDTA, 5 mM EGTA, 10 mM NEM, 
1x Protease inhibitor cocktail, 1x Phosstop, 1 mM Na3VO4, 20 mM 
NaF 
DNA loading buffer 
(5x) 
for 50 ml total volume in water: 25 ml glycerol, 0.5 ml EDTA (0.5 M), 
0.5 ml Tris-HCl pH 8 (0.5 M), pinch of xylene cyanol,  
dNTP mix 10 mM dATP, 10 mM dCTP, 10 mM dGTP, 10 mM dTTP 
FLAG elution buffer 
50 mM Tris-HCl pH 7.5,150 mM NaCl, 0.5 % Triton X-100, 100 µg/ml 
FLAG peptide; 1x Protease inhibitor cocktail, 1x Phosstop, 1 mM 
Na3VO4, 20 mM NaF 
GFP-Trap Dilution 
Buffer 
10 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.5 mM EDTA, 10 mM NEM, 
1x Protease inhibitor cocktail, 1x Phosstop, 1 mM Na3VO4, 20 mM 
NaF 
IP Buffer (1x) 
10 mM Na-phosphate buffer pH 7, 140 mM NaCl, 0.05 % Triton X-
100 
IVA3 Buffer 
150 mM NaCl, 20 mM Tris-HCl pH 7.5, 0.5 % Nonidet P 40 
Substitute, 10 % glycerol, 1x Protease inhibitor cocktail, 1 mM DTT 
IVA5 Buffer 
500 mM NaCl, 50 mM Tris-HCl pH 7.5, 1 % Nonidet P 40 Substitute, 
1x Protease inhibitor cocktail, 1 mM DTT 
Luria broth (LB) 
for 1 l total volume in water: 10 g bactotryptone, 5 g yeast extract, 
10 g NaCl pH 7.0, autoclaved 
Lysis Buffer A 
10 mM HEPES pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 1 mM DTT, 1x 
Protease inhibitor cocktail  
Lysis Buffer B 
20 mM HEPES pH 7.9, 1.5 mM MgCl2, 420 mM NaCl, 0.5 mM EDTA, 
25 % glycerol, 1 mM DTT, 1x Protease inhibitor cocktail  
Na-phosphate buffer 
(1 M) 
39 ml 2 M NaH2PO4 (276 g/L), 61 ml 2 M NaHPO4 (284 g/L), 100 ml 
H2O, pH 7 
4x NuPAGE+DTT 4x NuPAGE LDS sample buffer including 400 mM DTT 
PBS 
140 mM NaCl, 2.7 mM KCl, 1.5 mM KH2PO4, 8.1 mM Na2HPO4, pH 
7.4, autoclaved 
PBS-0.05 % Tween 1x TBS, 0.05 % Tween-20 
PBS-BSA 0.1 % 1x PBS, 0.1 % BSA 
PEI MAX (1 µg/µl) 1 µg/µl PEI MAX in H2O, pH 7.5, sterile filtered 
PEX-AS2 
150 mM NaCl, 20 mM Tris pH 7.5, 2 mM EDTA, 10 % Glycerol, 1 % 
Triton X-100, 1x Protease inhibitor cocktail  
Optional: 10 mM NEM, 1x Phosstop, 1 mM Na3VO4, 20 mM NaF 
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Proteinase K 
digestion buffer 
50 mM Tris HCl pH 8, 10 mM EDTA, 0.5 % SDS 
Reaction buffer 
7 ng/µl 15N-labeled methylated DNA substrate, 50 mM HEPES pH 
8.0, 75 µM ammonium iron(II) sulfate hexahydrate, 1 mM α-
ketoglutaric acid disodium salt hydrate, 2 mM L-ascorbic acid, 50 mM 
NaCl, 1 mM DTT, 1 mM ATP 
Reaction wash buffer 
50 mM HEPES pH 8.0, 2 mM L-ascorbic acid, 100 mM NaCl, 1x 
Protease inhibitor cocktail, 1 mM DTT 
RIPA buffer 
20 mM Na-phosphate buffer, 150 mM NaCl, 1 % (vol/vol) Triton-X 
100, 0.5 % (wt/vol) sodium deoxycholate, 0.1 % (wt/vol) SDS, 5 mM 
EDTA, 5 mM EGTA, 10 mM NEM, 1x Protease inhibitor cocktail, 1x 
Phosstop, 1 mM Na3VO4, 20 mM NaF 
RIPA dilution buffer 
20 mM Na-phosphate buffer, 150 mM NaCl, 1 % (vol/vol) Triton-X 
100, 0.5 % (wt/vol) sodium deoxycholate, 5 mM EDTA, 5 mM EGTA, 
10 mM NEM, 1x Protease inhibitor cocktail, 1x Phosstop, 1 mM 
Na3VO4, 20 mM NaF 
SDS-Running buffer 
10x 
for 1 l total volume: 10 g SDS, 30.3 g Tris, 144.1 g glycine 
TBE (10x) 1 M Trizma base, 1 M boric acid, 20 mM EDTA, autoclaved 
TBS (20x) 3 M NaCl, 53.7 mM KCl, 839 M Trizma hydrochloride, 160 mM 
Trizma base pH 7.4, autoclaved 
TBS-T 1x TBS, 0.1 % Tween-20 
TE buffer 10 mM Tris-HCl pH 8.0, 1 mM EDTA, autoclaved 
Wash Buffer 1  8 M urea, 1 % (wt/vol) SDS in 1x PBS 
Wash Buffer 2 1 % SDS in 1x PBS 
 
Table 6.1 Buffers and Solutions 
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6.1.6 Antibodies 
Antibody 
Host 
species 
Company Catalogue # Dilution WB 
5-Formylcytosine rabbit Active Motif 61227 - 
5-Hydroxymethylcytosine rabbit Active Motif 39791 - 
Alpha-Tubulin mouse Sigma T5168 1:5000 
FLAG mouse Sigma-Aldrich F3165 1:1000 
FLAG rabbit Sigma-Aldrich F7425 1:2000 
GADD5A (H-165) rabbit Santa Cruz sc-797 1:2000 
GFP rabbit 
Thermo Fisher 
Scientific 
A11122 1:2000 
HA, ChIP grade rabbit Abcam ab9110 1:4000 
HNRNPA1, clone 4B10 mouse Santa Cruz sc-32301 1:5000 
IgG ChIP grade control rabbit Abcam ab46540 - 
Mouse IgG, Alexa Flour 488 goat 
Thermo Fisher 
Scientific 
A11029 1:1000 (IF) 
Mouse HRP goat Dianova 115-035-146 1:10000 
Myc, clone 9E10 mouse Sigma-Aldrich M4439 1:2000 
PAR rabbit Trevigen 4336-BPC 1:2000 
PARP-1 N-terminal  rabbit Active Motif 39560 1:2000 
Rabbit HRP goat Dianova 111-035-144 1:10000 
RAD21 clone 53A303 mouse Merck Millipore 05-908 
1:2000 (WB)/ 
1:1000 (IF) 
SUMO 2,3,4 (C3) mouse  Santa Cruz Sc-393144 1:500 
TATA binding protein TBP  mouse Abcam ab818 1:2000 
Ubiquitin mouse Santa Cruz sc-8017 1:1000 
V5 mouse Invitrogen 46-1157 1:2000 
 
Table 6.2 Antibodies 
WB, dilution used for Western blot; IF, dilution used for immunofluorescence staining 
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6.1.7 Oligonucleotide sequences 
6.1.7.1 RT qPCR expression primers 
Target gene Forward primer (5’-3’) Reverse Primer (5’-3’) 
UPL 
Probe 
GADD45A 
(human) 
GCCAAGCTGCTCAACGTC CTCTGTCGTCGTCCTCGTC 40 
Gadd45a 
(mouse) 
GCTGCCAAGCTGCTCAAC TCGTCGTCTTCGTCAGCA 98 
GAPDH GCATCCTGGGCTACACTGAG AGGTGGAGGAGTGGGTGTC 82 
MAPK11 CATGCTCAACTGGATGCATTA CGCTTCAGCTGGTCAATGTA 37 
MAPK12 CTCCTTTGACGACGTTGACC TGAAGCTGAGCACCTCTTTGT 47 
MAPK13 CAGGACGTCAACAAGACAGC TTCTTGATGGCCACCTTCTC 24 
MAPK14 
TGGTCTGTTGGACGTTTTTAC
A 
CCATGAGATGGGTCACCAG 65 
MAP2K3 GAGGACATCCTTGGGGAGAT GTGGATCACCGACAGCTTG 1 
MAP2K4 
GGCCAAAGTATAAAGAGCTTC
TGA 
CAGCGATATCAATCGACATAC
AT 
33 
MAP2K6 CAAGGCTTGCATTTCTATTGG CCAGTTCCATTATAGGCTCCA 8 
MAP2K7 CGGAGGATCGACCTCAAC GGGAGCTCTCTGAGGATGG 24 
MAP3K5 
CACGTGATGACTTAAAATGCT
TG 
AGTCAATGATAGCCTTCCACA
GT 
89 
MAP3K6 GGCTCTGGATGCCTTCTACA ACAGGGAGGGCTGTACCA 67 
MAP3K7 AGCTTTATGGAGCCTGCTTG AGAGCCCCCTTCAGCATATT 47 
MTK1 GCCTTGAGAGTGACCCAAAG 
GCTTCATTCTTCATCTGTGCA
A 
17 
Tbp 
(mouse) 
GGGGAGCTGTGATGTGAAGT CCAGGAAATAATTCTGGCTCA 97 
TET1CD 
AATGGCTGTAAGTTTGGTAGA
AGC 
CGTGTAGCCAAACTCTGTAAG
TTATC 
45 
TRIM24 ACGGTCCAGTCACCAAATTC 
GGGGGTGTACACTAGTCATAG
TAACAG 
80 
TRIM25 
(human) 
TCGAGAGCACTGGATGATGT TTGTTGTAGCTGCTCCACCTT 18 
Trim25 
(mouse) 
CCCTACGACCCTAAGTCAAGC TGTGGCTGTGCATGATAGTG 85 
TRIM28 
(human) 
TGGTCAATGATGCCCAGA CTTGGTCATGGTCCAGTGC 1 
Trim28 
(mouse) 
CAACCAGCGGAAATGTGAG GGTACCACCAGGCTGCTC 2 
TRIM33 TGCCCTGTCTTCACTCCTTC GGGCACCGTATTACACCAAC 27 
 
Table 6.3 RT qPCR expression primers 
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6.1.7.2 Genotyping primers 
Genotyping PCR Forward primer (5’-3’) Reverse primer (5’-3’)  
mmRAD21_mAID_neo 
TATGACTGGGCACAACAG
AC 
CCTAGGCAGGTTTTCCTT
TC 
mmRAD21_mAID_neo_nested 
AGGATCTCCTGTCATCTC
AC 
AGTCTTCTGGGTTCTTGG
GC 
mmRAD21_mAID_hygro 
TGGCTGTGTAGAAGTACT
CG 
CCTAGGCAGGTTTTCCTT
TC 
mmRAD21_mAID_hygro_nest
ed 
GTCCGAGGGCAAAGGAA
TAG 
AGTCTTCTGGGTTCTTGG
GC 
OsTir_Tigre_Cterm 
TCACCTCGACCCATGGTA
ATA 
TGTACCACAGGGCGTTTC
A 
OsTir_Tigre_Nterm 
TCTGGCTAGACAGGGATC
TTACA 
ACTCCCACTGTCCTTTCC
TAATAA 
Tigre integration 1 
GCTTCCCCAACGGTCACT
TA 
CCCAGGAGGGACGGTTA
CTA 
Tigre integration 2 
GGGGTGGGAATCAAGCC
ATA 
GGCGTGAGTCGGAGAAC
TAA 
 
Table 6.4 Genotyping primers 
6.1.7.3 DIP-qPCR primers 
Target site Forward primer (5’-3’) Reverse Primer (5’-3’) 
UPL 
Probe 
Negative control 
GAAATCAAGGAGGCCTGA
AA 
TCTAAATAGCTCTGAGGG
ACCTG 
68 
Positive control 
CTGAGTGGCAGGCGTATT
C 
AATCTCAAAAGTTGCCAA
GCA 
33 
Adam15_enhancer 
CCCCGGATTTTATCCTCG
TA 
CAGATGCTGTCGACAATC
CA 
53 
Adam15_promoter 
TTTGGACACCACAAGACT
CG 
GTGAGCCGGAAGAACTG
G 
16 
Atxn7I3_enhancer 
CCCTCAGGCATTCTTGCT
AA 
GGTGAGGGTGCTGAAAA
GTC 
95 
Atxn7I3_promoter TCCCGACCCCACTAGGTC 
CCCCGGGACAATAGAGAC
A 
55 
Chd4_enhancer GCCGGCTCATCACACAGT GACCATCGGGGCCTATTC 69 
Chd4_promoter GGTGTTTCGGGCCCTTTA GTCTCGCCGGTGTCACTC 17 
Hsp90ab1_enhancer 
CGAGGTAGCCATTGGAGA
AG 
CTTTAAGCATGACGCCTG
GT 
46 
Hsp90ab1_promoter 
AGCCCACTTCTTGGGAGA
CT 
GTGGGAAGGGATTAAGAC
AGG 
88 
Myh9_enhancer 
TGCAGTCTCTGCATTTCC
TG 
AGGAGCCTCCCTTAGTCA
CAG 
99 
Myh9_promoter 
CTTCCGAGTGGACTTTCT
CG 
GCACGGAAGGCTCAAGAA
C 
62 
Ppp1r9b_enhancer TACGTGGCAGGCAGTTGA CTCTTCCAACCCGCTGAC 33 
Ppp1r9b_promoter 
TCCCTTTAGGACCCAGTG
GT 
TCTAGCTCTGCCCGAACC 70 
 
Table 6.5 DIP-qPCR primers 
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6.1.7.4 Cloning primers 
Plasmid 
name 
Fragment 
name 
Primer name Primer sequence (5’-3’) 
pEF FLAG-
HA TET1 
CD 
FLAG-HA 
FLAG_HA_fwd  
TGGCTAGGTAAGCTTGGTACATGGAC
TACAAGGACGACGATG  
FLAG_HA_rev 2 
AGGTGGGCAGTTCTGAGTCGAGTCCT
CCGGCGTA  
TET1CD 
TET1CD_fwd 2 
AGGACTCGACTCAGAACTGCCCACCT
GC  
TET1CD_rev  
GCTTACCTTCGAAGGGCCCTTCAGAC
CCAATGGTTATAGGG  
pEF FLAG-
HA 
GADD45A-
TET1 CD 
pEF 
pEF_fwd  TCTAGAGGGCCCTTCGAAG  
pEF_rev  GTCGAGTCCTCCGGCGTA  
GADD45A 
GADD45A_fwd  
  
GCCCGACTACGCCGGAGGACTCGACA
CTTTGGAGGAATTCTCGGCTGGAGAG  
GADD45A_rev 
GCAGTTCTGAATTCGACCCACCACCG
CCCGA  
TET1CD_3 
TET1CD_fwd  
CGGTGGTGGGTCGAATTCAGAACTGC
CCACC  
TET1CD_rev  
GCTTACCTTCGAAGGGCCCTCTAGAT
CAGACCCAATGGTTATAGG  
pEF GFP-
TEV TET1 
pEF_2 
pEF_fwd  TCTAGAGGGCCCTTCGAAG  
pEF_4_rev  GGTGGCGGTACCAAGCTT  
eGFP-TEV 
eGFP_TEV_2_fwd  
GCTAGGTAAGCTTGGTACCGCCACCA
TGGTGAGCAAGGGCGAG  
eGFP_TEV_2_rev  
GGCGGGATCGAGAGCGATCGCCTCG
AGATCT  
TET1 
TET1_2_fwd  
TCGAGGCGATCGCTCTCGATCCCGCC
ATGCA  
TET1_2_rev  
GCTTACCTTCGAAGGGCCCTCTAGAT
CAGACCCAATGGTTATAGGGCC  
pEF GFP-
TEV-
TET1CD 
TET1CD in 
pEF 
pEF_5_fwd  TCTGAACTGCCCACCTGC  
pEF_rev_4 GGTGGCGGTACCAAGCTTA  
eGFP_TEV 
eGFP_TEV3_fwd  
CTTGGTACCGCCACCATGGTGAGCAA
GGGCGAG  
eGFP_TEV3_rev  
GGTGGGCAGTTCAGAGCGATCGCCTC
GAGATCT  
pCS2 
FLAG-
TET1CD 
K1813A 
 TET1_K1813A_fwd 
AGACCGTGCAACCTGAAGTAGCAAGT
GAAACCGAACCCC 
 TET1_K1813A_rev 
GGGGTTCGGTTTCACTTGCTACTTCAG
GTTGCACGGTCT 
pCS2 
FLAG-
TET1CD 
K1842R 
 TET1_K1842R_fwd 
TCCGCTCCTCACCCAGTGAGAGAGGC
ATCT 
 TET1_K1842R_rev 
AGATGCCTCTCTCACTGGGTGAGGAG
CGGA 
pCS2 
FLAG-
TET1CD 
K1863A 
 TET1_K1863A_fwd 
CACACCAGCTCCACTGGCGAATGACG
CAACAGCC 
 TET1_K1863A_rev 
GGCTGTTGCGTCATTCGCCAGTGGAG
CTGGTGTG 
MATERIAL AND METHODS 
77 
pCS2 
FLAG-
TET1CD 
K2067R 
 TET1_K2067R_fwd 
CCCAACATGGTTTTGAACTAAACAAGA
TTAGGTTTGAGGCTAAAGAAG 
 TET1_K2067R_rev 
CTTCTTTAGCCTCAAACCTAATCTTGTT
TAGTTCAAAACCATGTTGGG 
 
Table 6.6 Cloning Primers 
 
6.1.7.5 Oligonucleotides used for CRISPR/Cas9 editing 
guide RNA Forward Oligo (5’-3’) Reverse Oligo (5’-3’) 
CRISPR_mmRad21_
mAID 
CACCGTTTTGGTGCCCTGCA
CACG 
AAACCGTGTGCAGGGCACCA
AAAC 
 
Table 6.7 guide RNA sequence 
 
Gene Synthesis 
fragment 
Sequence (5’-3’) 
CRISPR_mmRad21_
mAID 
ATGGTCTTCAGCGAGCTCTTGCTAAAACTGGAGCAGAGTCTATC
AGTTTGCTTGAGCTGTGTCGAAACACAAACCGAAAGCAGGCAGC
AGCAAAGTTCTACAGCTTTTTGGTTCTTAAGAAGCAGCAAGCCAT
CGAGCTCACACAGGAAGAGCCGTACAGTGACATCATTGCAACC
CCTGGACCACGGTTCCATATTATCGGATCCGGAGCTAGATGTGT
TCGAGCTAGTGATAACTCACTAGTACATACAAATTGCCCCCGAG
TCCAGTGCGCCTAAGCCCTTTAAGAAAGTTTTTAGATTTCTGTTT
GTACAAAAATCTTTGCCTTTTCTTTCTTCTTTTTCCCCCCAGTGTT
TCTAATTTTGTCAACCATATTTTTAAGGGAAACTGCTTATTTGGGT
TGGGT 
 
Table 6.8 Homology arm synthesis fragment 
 
6.1.7.6 Miscellaneous Oligonucleotides 
PCR reaction Forward Primer (5’-3’) Reverse Primer (5’-3’) 
IVO biotin 
[BtnTg]GATAAGCTTGGGATCTCT
ATAATCTCG 
[BtnTg]CAGCTTGTGCCCCAGGAT 
 
Table 6.9 Miscellaneous PCR Primers 
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6.1.8 siRNAs 
Target Gene siRNA ID Supplier  
GADD45A (human) VHS40261, stealth siRNA Thermo Fisher Scientific 
Gadd45a (mouse) 
Set of 3: MSS236318, MSS236319, 
MSS236320 
Thermo Fisher Scientific 
MAPK11 HSS183382, stealth siRNA Thermo Fisher Scientific 
MAPK12 HSS109467, stealth siRNA Thermo Fisher Scientific 
MAPK13 VHS40525, stealth siRNA Thermo Fisher Scientific 
MAPK14 VHS40416, stealth siRNA Thermo Fisher Scientific 
MAP2K3 VHS40371, stealth siRNA Thermo Fisher Scientific 
MAP2K4 HSS184677, stealth siRNA Thermo Fisher Scientific 
MAP2K6 HSS183392, stealth siRNA Thermo Fisher Scientific 
MAP2K7 HSS140876, stealth siRNA Thermo Fisher Scientific 
MAP3K5 VHS40812, stealth siRNA Thermo Fisher Scientific 
MAP3K6 VHS40987, stealth siRNA Thermo Fisher Scientific 
MAP3K7 VHS40542, stealth siRNA Thermo Fisher Scientific 
siRNA Negative 
Control, Med GC 
12935113, stealth siRNA Thermo Fisher Scientific 
Non-Targeting siRNA 
Pool #1 
D-001206-13-50, siGENOME Dharmacon 
TRIM24  HSS112966, stealth siRNA Thermo Fisher Scientific 
TRIM25 (human) HSS111608, stealth siRNA Thermo Fisher Scientific 
Trim25 (mouse) M-047483-01, siGENOME SMARTpool Dharmacon 
TRIM28 (human) HSS115468, stealth siRNA Thermo Fisher Scientific 
Trim28 (mouse) M-040800-01, siGENOME SMARTpool Dharmacon 
TRIM33 HSS122396, stealth siRNA Thermo Fisher Scientific 
 
Table 6.10 siRNAs 
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6.1.9 Plasmids 
Name Source Description  
pCAG-GFP-TEV-
mTET1 
Frauer et al 
[225] 
N-terminally GFP tagged mouse full-length TET1, 
with TEV Protease cleavage site between GFP 
and mTET1 
pcDNA3 HA-Ubiquitin 
Kamitani et 
al [226] 
HA-tagged Ubiquitin 
pcDNA3 HA-SUMO2 
Frauke 
Melchior 
HA-tagged SUMO2 
pCS2+_GFP 
Andrea 
Schäfer 
GFP overexpression plasmid 
pCS2FLAG/hTET1FL 
Lars 
Schomacher 
N-terminally 2x FLAG tagged full-length human 
TET1  
pCS2FLAG/hTET1CD 
Lars 
Schomacher 
N-terminally 2x FLAG-tagged catalytic domain of 
human TET1 (amino acids 1416-2136) 
pCS2 FLAG-TET1CD 
K1813A 
this study 
N-terminally 2x FLAG-tagged catalytic domain of 
human TET1 (amino acids 1416-2136) with a 
mutation at amino acid 1813 from lysine to alanine 
pCS2 FLAG-TET1CD 
K1842R 
this study 
N-terminally 2x FLAG-tagged catalytic domain of 
human TET1 (amino acids 1416-2136) with a 
mutation at amino acid 1842 from lysine to 
arginine 
pCS2 FLAG-TET1CD 
K1863A 
this study 
N-terminally 2x FLAG-tagged catalytic domain of 
human TET1 (amino acids 1416-2136) with a 
mutation at amino acid 1863 from lysine to alanine 
pCS2 FLAG-TET1CD 
K2067R 
this study 
N-terminally 2x FLAG-tagged catalytic domain of 
human TET1 (amino acids 1416-2136) with a 
mutation at amino acid 2067 from lysine to 
arginine 
pCS2FLAG/hTDG 
Lars 
Schomacher 
N-terminally 2x FLAG-tagged human TDG 
pCS2+myc-HsGadd45a Mathias Gierl N-terminally myc-tagged human GADD45A 
pCS2-myc-hMTK1 
Andrea 
Schäfer 
N-terminally myc-tagged human MTK (MAP3K4) 
Flag-HA-hTET1-pEF 
Tahiliani et al 
[22] 
Full-length human TET1 fused to a N-terminal 
Flag-HA tag 
pEF FLAG-HA TET1CD this study 
Expression plasmid for the catalytic domain of 
human TET1, amino acids 1416-2136, with an N-
terminal FLAG-HA tag 
pEF FLAG-HA 
GADD45A-TET1CD 
this study 
Expression plasmid for a fusion construct of 
human GADD45A and the catalytic domain of 
human TET1 (amino acids 1416-2136) with an N-
terminal FLAG-HA tag 
pEF GFP-TEV TET1 this study N-terminally GFP-tagged human full-length TET1 
pEF GFP-TEV-TET1CD this study N-terminally GFP-tagged human TET1CD 
pEN396_Tigre OsTir1 
Nora et al 
[147] 
Targeting vector to introduce an OsTir1 
expression cassette at the mouse Tigre acceptor 
locus using puromycin selection  
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pMA-
T_mmRad21_homology 
arms 
Thermo 
Fisher 
Scientific 
Homology arms of mmRad21 for C-terminal 
tagging with mAID-3xHA using CRISPR/Cas9 
pMK_mmRad21_mAID_
Neo 
Pia Schäfer 
Targeting vector for C-terminal tagging of 
mmRad21 with mAID-3xHA using CRISPR/Cas9, 
contains neomycin resistance gene 
pMK_mmRad21_mAID_
Hygro 
Pia 
Schäfer/this 
study 
Targeting vector for C-terminal tagging of 
mmRad21 with mAID-3xHA using CRISPR/Cas9, 
contains hygromycin resistance gene 
pX330_Cas9_gRNA 
Rad21 
Pia Schäfer 
Expression plasmid for Cas9 and Rad21 gRNA 
(5`-GTTTTGGTGCCCTGCACACG-3’) 
pX330_EN1201_Cas9_
gRNA Tigre 
Nora et al 
[147] 
Expression plasmid for Cas9 and Tigre gRNA  
(5’-ACTGCCATAACACCTAACTT-3’) 
 
Table 6.11 Plasmids 
 
6.2 Methods 
Unless stated otherwise, incubations were performed at room temperature (~20 °C). 
6.2.1 Molecular Biology methods 
Standard molecular biology methods including preparation of chemically competent XL1-blue 
Escherichia coli (E. coli) bacteria, plasmid amplification in E. coli, spectrophotometric 
quantification of DNA and RNA, restriction digests, PCR, agarose gel electrophoresis, and SDS-
PAGE were carried out as previously described [227]. All oligonucleotides used in this study were 
synthesized by Sigma-Aldrich or Integrated DNA Technologies (IDT). Plasmid DNA was 
sequenced by GATC Biotech or StarSEQ.  
6.2.1.1 Amplification and purification of plasmids from bacteria 
For plasmid amplification, 0.5 µg plasmid DNA was transformed into freshly thawed 50 µl XL-1 
blue E. coli chemically competent bacteria by a 30 s heat shock at 42 °C. This was followed by a 
2 min incubation on ice, subsequent incubation in 950 µl LB medium, which contained an 
appropriate selection antibiotic, for 1 h at 37 °C. 100 µl of bacteria suspension was plated on an 
LB-Agar plate (containing an appropriate selection antibiotic) and incubated at 37 °C overnight. 
The next day, a single clone was picked and used to inoculate LB medium (volume depending on 
downstream applications), containing an appropriate selection antibiotic, and incubated overnight. 
Plasmid DNA was purified using Qiagen Miniprep, Midiprep or Maxiprep kits according to the 
manufacturer’s recommendations. DNA amount and purity were measured on a Nanodrop 2000 
spectrophotometer. 
6.2.1.2 Cloning of plasmids 
Plasmids generated for this study were cloned using the Gibson Assembly kit from NEB, 
according to the manufacturer’s recommendations. In brief, PCR primers were designed using 
the NEBuilder Assembly Tool, PCRs were performed using Phusion polymerase, purified using 
Qiaquick Gel extraction kit, and ligated using the Gibson Assembly Master Mix. Plasmids were 
then amplified, purified, analyzed by restriction digest and sequenced to confirm correct insertion. 
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Site-directed mutagenesis was carried out using the QuikChange II XL Site-Directed Mutagenesis 
Kit, according to the manufacturer’s recommendations. 
6.2.1.3 Protein extraction and Western blot 
Cultured cells were harvested either by Trypsin digestion, or by cell scraping in PBS-0.05 % 
Tween, transferred to a 15 ml or 50 ml falcon tube, and pelleted by centrifugation for 5 min at 
300 g.  
For whole cell lysates, cell pellets were resuspended in RIPA buffer or PEX-AS2 buffer. Cells 
were incubated on ice, and cell disruption was achieved by 5 times needle homogenization using 
a 20 g needle or by sonication for 20 cycles 15 s on/off, high setting, using a Bioruptor. Samples 
were cleared by centrifugation for 10 min at 21,000 g at 4 °C. 
For nuclear and cytoplasmic fractionation, cells were resuspended in Lysis Buffer A and incubated 
for 10 min on ice, followed by centrifugation for 1 min at 21,000 g at 4 °C. The supernatant 
contained the cytoplasmic fraction and the pellet was resuspended in Lysis Buffer B, followed by 
a 20 min incubation on ice. Both fractions were sonicated for 20 cycles 15 s on/off, high energy, 
using a Bioruptor, followed by centrifugation for 10 min at 21,000 g at 4 °C to clear the lysates. 
Protein concentration was determined by Bradford Assay, by incubating 1-5 µl of protein lysate 
and 250 µl Quick Start Bradford 1x Dye for 5 min and measuring the absorption on a Nanodrop 
2000 spectrophotometer, which was compared to a standard curve of BSA samples with known 
protein concentrations, and was run in parallel to the samples of interest. 
Defined protein amounts of cell lysates were mixed with 4x NuPAGE+DTT and incubated for 
10 min at 70 °C. SDS-PAGE, transfer to PVDF membranes and Western blotting was performed 
according to standard protocols [227]. Signals were developed with SuperSignal West Pico or 
Femto Chemiluminescent Substrate and analyzed using a ChemiDoc with Image Lab software. 
Quantification of band intensity was performed using Image Lab Software. 
6.2.1.4 Immunofluorescence staining and Microscopy 
mESCs grown on coverslips in 12-well plates were rinsed with PBS and fixed for 15 min in 4 % 
paraformaldehyde on an orbital shaker at 45 rpm. Coverslips were washed 3 x 5 min in PBS + 
1 mg/ml BSA and permeabilized with 0.5 % Triton X-100 in PBS + 1 mg/ml BSA for 1 h. After 3 x 
5 min washes in PBS + 1 mg/ml BSA, the coverslips were blocked with 0.1 % Triton X-100 in PBS 
+ 1 mg/ml BSA for 1 h. Subsequently, incubation with 100 µl primary antibody RAD21 was 
performed overnight at 4 °C in a humid chamber, at a 1:1000 dilution in 0.1 % Triton X-100 in 
PBS + 1 mg/ml BSA. Coverslips were washed 3 x 10 min in PBS + 1 mg/ml BSA and then 
incubated with 1:1000 diluted Alexa Fluor 488-coupled secondary antibody in 0.1 % Triton X-100 
in PBS + 1 mg/ml BSA, followed by 3 x 10 min washes in PBS + 1 mg/ml BSA. To stain nuclei, 
coverslips were incubated with 1:10,000 DAPI in PBS + 1 mg/ml BSA for 1 h, followed by 2 x 5 
min washes in PBS. Coverslips were mounted on glass slides with Dako mounting medium and 
sealed with nail polish after 10 min. Immunofluorescence stainings were analyzed with a Leica 
SP5 confocal microscope and Leica LAS image software. 
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6.2.1.5 RNA isolation, reverse transcription and qPCR 
RNA was isolated using the QIAshredder and RNeasy Mini kits, or the RNeasy 96-well kit from 
Qiagen, according to the manufacturer’s instructions. The optional DNAse I on-column digestion 
was carried out and RNA was eluted in nuclease-free water and measured on a Nanodrop 2000. 
cDNA synthesis was carried out using Superscript II reverse transcriptase according to the 
manufacturer’s instructions. Briefly, 1000 ng RNA, 1 µl 10 mM dNTPs and 360 ng random primers 
were mixed in a final volume of 12 µl. After denaturation for 5 min at 65 °C the mixture was cooled 
on ice for 2 min. 4 µl 5x FS buffer, 2 µl 0.1 M DTT, 1 µl Ribolock and 1 µl Superscript II Polymerase 
were added and samples were incubated for 10 min at 25 °C, 90 min at 42 °C for cDNA synthesis 
and 15 min at 70 °C for enzyme inactivation. Resulting cDNA was diluted 1:5 in TE buffer. All 
incubation steps were carried out in a PCR thermocycler. 
For each 11 µl qPCR reaction, 5 µl cDNA, 5.5 µl 2x Probes Master, 0.11 µl 100 µM 
forward/reverse primer mixture, 0.11 µl UPL probe and 0.28 µl ddH2O were mixed. PCR reactions 
were performed in technical duplicates in a 384-well format in the Roche Light Cycler 480 using 
the following PCR program: 
Temperature 
(°C) 
Time Ramp rate  
95 10 min 4.8 °C/s  
95 10 s 4.8 °C/s 
50 x 60 20 s 2.5 °C/s 
72 1 s 4.8 °C/s 
4 1 min 2.5 °C/s  
 
Table 6.12 qPCR program 
 
Cp values were determined using the Roche LightCycler software and relative expression values 
were calculated according to the ddCp method [228], normalizing to GAPDH or Tbp as 
housekeeping genes and including normalization for primer efficiencies. UPL-compatible primers 
were designed using the Roche Assay Design center. 
6.2.1.6 Genotyping PCRs 
For CRISPR/Cas9 clone genotyping, cells from the equivalent of 1/2 well of a 96-well cell culture 
plate were transferred to a 96-well genotyping PCR plate and incubated in 50 µl blastocyst lysis 
buffer for 30 min at 37 °C, 10 min at 56 °C and 10 min at 95 °C. Afterwards, a PCR reaction was 
set up with the following components and PCR program: 
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Component 
Volume 
(µl) 
Cell lysate 5 
10x PCR Buffer 1 
including 15 mM MgCl2 
2 
dNTPs (10 mM) 0.5 
Primer forward (10 µM) 0.5 
Primer reverse (10 µM) 0.5 
Nuclease-free H2O 11 
Taq 0.5 
 
Table 6.13 Genotyping PCR components 
 
Temperature (°C) Time  
94 30 s  
94 20 s 
30 x 51-54 30 s 
72 1 min – 1 min 45 s 
72 10 min  
4 5 min  
 
Table 6.14 Genotyping PCR program 
 
6.2.1.7 Genomic DNA isolation for Mass Spectrometry 
DNA was isolated using the DNeasy Blood & Tissue kit or DNeasy 96 Blood & Tissue kit from 
Qiagen according to the manufacturer’s instructions with the following modifications:  
If intended for mass spectrometry, HEK293T cells were resuspended in 380 µl ATL and incubated 
with 20 µl Proteinase K for 2 h at 56 °C, shaking at 900 rpm. Next, 3 µl RNAse A + 27 µl ATL 
were added and incubated for 15 min. Subsequently, 820 µl premixed Buffer AL-Ethanol were 
added and further steps were performed as described in the kit.  
mESCs were resuspended in 100 µl PBS including 5 µl of RNAse A, vortexed, followed by 10 min 
of 21,000 g centrifugation at 4 °C, further incubated for 15 min on ice and afterwards mixed with 
100 µl of buffer ATL before proceeding with the kit’s standard instructions.  
After elution of DNA with AE buffer, DNA was precipitated with 3.3 volumes of 100 % ethanol, 0.1 
volume of 7.5 M ammonium acetate, followed by centrifugation at 21,000 g, 4 °C for 1 h. The DNA 
pellet was washed once with 70 % ethanol, the supernatant was removed and the pellet was dried 
for at least 30 min at room temperature and resuspended in nuclease-free water. DNA was 
degraded to nucleosides with nuclease P1, snake venom phosphodiesterase and alkaline 
phosphatase. Quantification of 5mC and its oxidative derivatives was carried out by Dr. Michael 
Musheev as described in [201], using an Agilent 1290 Infinity Binary LC system (Agilent 
Technologies) with a ReproSil 100 C18 column (Jasco) coupled to an Agilent 6490 triple 
quadrupole mass spectrometer (Agilent Technologies). 
6.2.1.8 Denaturing cell lysis followed by HA affinity purification 
To detect SUMOylated or ubiquitinated proteins using overexpressed HA-tagged SUMO or 
Ubiquitin, denaturing cell lysis followed by HA affinity purification was performed. One confluent 
15 cm dish of HEK293T cells was washed with cold PBS supplemented with 10 mM NEM and 
harvested in cold PBS supplemented with 10 mM NEM, using a cell scraper, and transferred to a 
15 ml falcon. After centrifugation for 5 min at 300 g at 4 °C, the cell pellet was resuspended in 
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1.5 ml denaturing lysis buffer, transferred to a 1.5 ml tube and kept at room temperature until the 
lysates were sonicated for 28 cycles, 15 s on/off, high energy using a Bioruptor. Afterwards, 75 μl 
of a 1 M DTT solution were added to the lysates (50 mM final concentration), the lysates were 
boiled in a water bath at 97 °C for 10 min, and transferred to a 15 ml falcon. Subsequently, the 
lysates were diluted with 13.5 ml of cold RIPA dilution buffer and supplemented with 75 µl 2 M 
NEM. For the “input” sample, 40 µl of lysate were transferred to a 1.5 ml tube and supplemented 
with 15 µl 4x NuPAGE+DTT and incubated for 10 min at 70° C.  
For each IP reaction, 70 µl Protein A Agarose beads were washed 3 times with 1 ml RIPA buffer 
for 10 min on a rotating wheel at 4 °C, followed by 3 min centrifugation at 300 g and 4 °C in a 
Heraeus centrifuge, and afterwards resuspended in 70 µl RIPA buffer. For pre-clearing, 20 µl 
beads were added to the lysates and incubated for 30 min at 4 °C on a rotating wheel. Lysates 
were cleared by centrifugation in a Heraeus centrifuge (using the same settings as above), and 
transferred to a new 15 ml falcon. The antibody incubation was performed overnight using 8 µl 
HA antibody on a rotating wheel at 4 °C, followed by incubation with 50 µl beads for 2 h on a 
rotating wheel at 4 °C. Subsequently, lysates were washed 3 times with 1 ml RIPA buffer for 
10 min on a rotating wheel at 4 °C, followed by 3 min centrifugation at 300 g and 4 °C in a Heraeus 
centrifuge. Elution was performed by adding 35 µl of 1x NuPAGE, including 100 mM DTT, 
followed by a 10 min incubation at 70 °C and clearing for 10 min at 21,000 g. To detect 
immunoprecipitated proteins, 12 µl of the lysates were loaded on an SDS-PAGE and detected via 
Western blotting (see chapter 6.2.1.3). 
6.2.1.9 GFP-Trap  
To detect SUMOylated or ubiquitinated proteins without overexpression of SUMO or Ubiquitin, 
GFP-Trap with denaturing washes was performed. One confluent 15 cm dish of HEK293T cells 
was washed twice with cold PBS supplemented with 10 mM NEM, and harvested in cold PBS 
supplemented with 10 mM NEM, using a cell scraper, and then transferred to a 15 ml falcon. After 
centrifugation for 5 min at 300 g at 4 °C, the cell pellet was resuspended in 500 µl CL lysis buffer, 
transferred to a 1.5 ml tube, incubated on ice for 10 min, and lysates were cleared by 
centrifugation at 21,000 g for 10 min at 4 °C. The supernatant was transferred to a new tube and 
for the “input” sample, 50 µl were transferred to another 1.5 ml tube and supplemented with 18 µl 
4x NuPAGE+DTT and incubated for 10 min at 70° C. Per IP reaction, 20 µl of GFP-Trap Agarose 
beads were washed 3 times with 1 ml CL lysis buffer for 10 min on a rotating wheel at 4 °C, 
followed by 1 min centrifugation at 1200 g and 4 °C, and afterwards resuspended in 20 µl CL lysis 
buffer. Afterwards, the beads were incubated with the lysates for 1 h on a rotating wheel at 4 °C. 
Washes were performed by inverting the tubes and spinning down at 1200 g and 4 °C, with 1 ml 
of the following wash buffers: 1x GFP-Trap dilution buffer, 3x Wash buffer 1, 1x Wash buffer 2. 
As a final step, 40 µl of 1x NuPAGE, including 100 mM DTT, were added to the beads, followed 
by a 10 min incubation at 70 °C and clearing for 10 min at 21,000 g. Samples were either used 
for SDS-PAGE and Western blotting or further processed for mass spectrometry. 
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For mass spectrometry, the last centrifugation step was omitted and instead, the samples were 
cooled down to room temperature and alkylated with 5.5 mM CAA for 30 min in the dark. Samples 
were then stored at -20 °C before being further processed by Matthias Ostermaier (Beli lab, IMB 
Mainz). 
6.2.1.10 FLAG-TET1 immunoprecipitation for proteomic mass spectrometry analysis 
To detect TET1 interacting proteins or phosphorylation sites of TET1, SILAC labeled HEK293T 
cells were transfected with plasmid encoding FLAG-TET1, as described in chapters 6.2.2.3 and 
6.2.2.6. For one condition, two dense 10 cm dishes were harvested using a cell scraper and 
transferred to one 15 ml falcon. Cells were pelleted by centrifugation for 5 min at 300 g and 
washed with 10 ml PBS. Afterwards, the cell pellet was resuspended in 500 µl PEX-AS2 buffer, 
transferred to a 1.5 ml tube and cell disruption was achieved by 5 times needle homogenization 
using a 27 g needle, and 5 times needle homogenization using a 23 g needle, followed by 
sonication for 28 cycles 15 s on/off, high setting, using a Bioruptor. Lysates were cleared by 
centrifugation at 21,000 g, for 15 min at 4 °C. The supernatant was transferred to a low binding 
1.5 ml tube and 30 µl pre-washed ANTI-FLAG M2 Affinity Gel (FLAG beads) were added to the 
supernatant. To wash the beads, 30 µl beads were washed 3 times with 1 ml PEX-AS2 buffer for 
10 min on a rotating wheel at 4 °C, followed by 3 min centrifugation at 300 g and 4 °C in a Heraeus 
centrifuge, and afterwards resuspended in 30 µl PEX-AS2 buffer. Incubation of FLAG beads with 
the lysates was performed for 3 h on a rotating wheel at 8 rpm at 4 °C. Subsequently, lysates 
were washed 4 times with 1 ml PEX-AS2 buffer for 10 min on a rotating wheel at 4 °C, followed 
by 4 min centrifugation at 300 g and 4 °C in a Heraeus centrifuge. For phosphoproteomic analysis 
of TET1, the 4 washes were performed with 1 ml PEX-AS2 buffer containing 750 mM NaCl, 
followed by 1 wash with regular PEX-AS2 buffer. Then, “Light”, “Medium”, and “Heavy” conditions 
were combined by adding 100 µl PEX-AS2 to each condition and transferring the beads to one 
1.5 ml tube. Samples were centrifuged again using the same settings as above and the last traces 
of buffer were removed using a gel loading tip. For elution, 100 µl FLAG elution buffer were 
incubated with the beads for 45 min, shaking at 800 rpm at 4 °C. Samples were cleared by 
centrifugation and the supernatant transferred to a new 1.5 ml tube. For downstream mass 
spectrometry analysis, 35 µl of 4x NuPAGE+DTT, were added to the eluates, followed by a 10 min 
incubation at 70 °C and alkylation with 5.5 mM CAA for 30 min in the dark. Samples were then 
stored at -20 °C before being further processed by Andrea Voigt (Beli lab, IMB Mainz). 
6.2.1.11 5hmC and 5fC DNA Immunoprecipitation (DIP) 
mESCs from two approximately 60 % confluent 15 cm dishes were harvested in 4 °C cold 8 ml 
PBS-0.05 % Tween, each, using a cell scraper, and were transferred to the same 50 ml falcon. 
After centrifugation for 5 min at 300 g at 4 °C, the cell pellet was resuspended in 2720 µl PBS+80 
µl RNase A, incubated for 5 min and transferred to a 15 ml falcon. After the addition of 270 µl 
Proteinase K and 2700 µl Buffer AL, the lysates were incubated overnight, rotating at 56 °C. Next, 
2700 µl ethanol were added, the contents were vortexed and distributed equally to 6 DNeasy spin 
columns, and the subsequent steps were performed as described in the DNeasy Blood & Tissue 
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kit. The DNA was eluted with 2 x 50 µl nuclease-free water and DNA concentration was measured 
on a Nanodrop 2000.  
10 µg of DNA were sheared to ~200 bp using the Covaris S2/E210 focused ultrasonicator using 
130 µl Covaris micro tubes and the following settings: Intensity 5, duty cycle 10 %, cycles per 
burst 200, treatment time 280 s, temperature 7 °C and water level 12. A total of 20 µg of sheared 
DNA were transferred to a DNA LoBind 1.5 ml tube and made up to a total volume of 900 µl using 
nuclease-free water. 2 % of the total volume were taken for the “input” (18 µl) and the remaining 
DNA was denatured for 10 min in a heat block at 95 °C, and cooled on ice for 10 min. For the IP 
reaction, 100 µl of 10x IP buffer and 20 µg of the appropriate antibody or IgG (as control) were 
added and incubated overnight at 4 °C on a rotator at 10 rpm. Before addition to the IP reaction, 
80 µl of Protein G Dynabeads were pre-washed twice with 800 µl PBS-BSA 0.1 % for 5 min on a 
rotator, collected using a magnetic rack, resuspended in 80 µl of 1x IP buffer and added to the IP 
reactions. Samples were incubated with the beads for 2 h at 4 °C, rotating at 10 rpm and washed 
3 times with 1 ml 1x IP buffer for 10 min. Finally, beads were collected using a magnetic rack and 
resuspended in 500 µl Proteinase K digestion buffer. After addition of 7 µl Proteinase K, the 
samples were incubated for 3 h at 56 °C in a heating block, shaking at 950 rpm, and afterwards 
the supernatant was transferred to a new tube. DNA was purified using the QIAquick PCR 
purification kit, using 2535 µl of Buffer PB and adjusting the pH by adding 6 µl sodium acetate 
(3 M) and following the manufacturer’s instructions. The DNA was eluted in 30 µl nuclease-free 
water and used either for qPCR (described in 6.2.1.5; eluted DNA was diluted 25 times and used 
instead of cDNA) or concentrated using a SpeedVac and used for next generation sequencing 
(6.2.1.12). 
6.2.1.12 5fC DNA Immunoprecipitation followed by sequencing 
Library preparation and sequencing was performed by the Genomics Core Facility (IMB Mainz), 
and bioinformatic analysis was performed by Dr. Emil Karaulanov (Bioinformatic Core Facility, 
IMB Mainz) and Dr. Debasish Mukherjee (Niehrs group, IMB Mainz). 5fC DIP-seq was performed 
with Rad21-AID-3xHA cell line F5_F6, using triplicates of the following conditions: “-auxin” 
(control), “+auxin” (RAD21-depleted), “-auxin/+Vitamin C” (Vitamin C-treated), and 
“+auxin/+Vitamin C” (Vitamin C-treated and RAD21-depleted). Libraries of the 12 DIP-samples 
and four inputs, one pool from each condition, were prepared using a modified chromatin 
immunoprecipitation followed by sequencing (ChIP-seq) library prep protocol. Subsequently, the 
samples were sequenced on a NextSeq500, using the paired-end 42 mode, yielding an average 
of 2.4 x 107 reads per sample. Reads were mapped to the mm10 mouse genome using the 
Bowtie2 read alignment tool [229]. Since mapping of the paired-end reads resulted in many 
discordant and singleton reads in the DIP samples, single reads (read 1 from each pair) were 
mapped to the mm10 mouse genome using the Bowtie1 aligner [230]. Peaks were called using 
MACS2 peak finder algorithm [231], which yielded 203,404 common 5fC peaks (present in at 
least two DIP samples). 
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6.2.2 Cell culture 
6.2.2.1 Thawing and Freezing of cells 
Frozen cells were quickly thawed in a water bath and added to 10 ml of the respective cell culture 
medium in a 15 ml falcon. The cell suspension was centrifuged 3 min at 300 g, then cells were 
resuspended in fresh cell culture medium and plated on a cell culture dish.  
For cryopreservation, cells were detached from their culture dish with Trypsin-EDTA, 
resuspended in the respective cell culture medium and pelleted for 3 min at 300 g. Cells were 
resuspended in a small volume of cell culture medium, and supplemented with the same volume 
of 2x freezing medium (20 % DMSO, 50 % FBS, 30 % cell culture medium). 1 ml aliquots of cells 
in freezing medium were transferred to cryo tubes and slowly frozen to -80 °C at a cooling rate of 
1 °C/min in a Cryo-Safe Cooler filled with isopropanol. Cells were transferred to -150 °C for long-
term storage. 
6.2.2.2 General culture of HEK293T 
HEK293T cells were cultured in supplemented DMEM medium (DMEM with 10% FBS, 2 mM L-
Glutamine and 50 U/ml penicillin/streptomycin), at 37 °C, 5 % CO2 and 21 % O2, without changing 
medium between passaging. Cells were passaged every 2 days, once reaching approximately 
80 % confluency, by washing cells with PBS once, detaching cells with 0.05 % Trypsin-EDTA for 
2 min, quenching Trypsin with supplemented DMEM medium and plating 1/6 of the cells on a new 
cell culture flask. 
6.2.2.3 DNA transfection of HEK293T 
For plasmid DNA transfection, HEK293T cells were transfected with X-tremeGENE 9 24 h after 
plating cells in 600 µl supplemented DMEM medium without antibiotics. For a 12-well format, 
480 ng of plasmid DNA were diluted in 20 µl TE buffer, and 1.6 µl X-tremeGENE 9 were mixed 
with 18.4 µl OptiMEM. Both solutions were vortexed and incubated for 2 min. Afterwards, both 
solutions were mixed and incubated for 30 min. Subsequently, the transfection mix was added 
dropwise to the cells and distributed by gentle swirling of the cell culture dish. Cells were usually 
harvested 48 h post DNA transfection. 
6.2.2.4 siRNA transfection of HEK293T 
For siRNA transfection, HEK293T cells were transfected with Lipofectamine 2000. For a 12-well 
format, 1.5 µl 20 µM siRNA were mixed with 13.5 µl OptiMEM, and 3 µl Lipofectamine 2000 were 
mixed with 12 µl OptiMEM. Both solutions were vortexed and incubated for 5 min. Afterwards, the 
two solutions were mixed and incubated for 20 min. Meanwhile, cells were plated on 12-well 
dishes in 600 µl supplemented DMEM medium without antibiotics and subsequently, the 
transfection mix was added dropwise to the cells and distributed by gentle swirling of the cell 
culture dish. The cell culture medium was exchanged the next morning. Cells were usually 
harvested 72 h post siRNA transfection. 
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6.2.2.5 Isotopic labeling of 5mC in HEK293T 
To isotopically label 5mC in cells, HEK293T cells were cultured for at least 14 days (see 6.2.2.2) 
with the following medium: DMEM (high glucose, no glutamine, no methionine, no cysteine) 
supplemented with 0.2 mM L-Methionine-(methyl-13C,d3), 0.2 mM L-Cysteine, 1 mM sodium 
pyruvate, 10 % dialyzed FBS, 2 mM L-Glutamine. 
6.2.2.6 Stable isotope labeling by amino acids in cell culture (SILAC) of HEK293T 
In order to quantify proteins via mass spectrometry, HEK293T cells were cultured for at least 14 
days (see 6.2.2.2) with stable isotopes of L-Arginine and L-Lysine, using “light”, “medium” or 
“heavy” DMEM: 
Light DMEM: DMEM for SILAC, 10 % dialyzed FBS, 2 mM L-Glutamine, 50 U/ml penicillin/ 
streptomycin, 42 µg/ml L-Arginine-0, 73 µg/ml L-Lysine-0 
Medium DMEM: DMEM for SILAC, 10 % dialyzed FBS, 2 mM L-Glutamine, 50 U/ml penicillin/ 
streptomycin, 42 µg/ml L-Arginine-6, 73 µg/ml L-Lysine-4 
Heavy DMEM: DMEM for SILAC, 10 % dialyzed FBS, 2 mM L-Glutamine, 50 U/ml penicillin/ 
streptomycin, 42 µg/ml L-Arginine-10, 73 µg/ml L-Lysine-8 
6.2.2.7 General culture of 293F 
293F suspension cells were cultured in FreeStyle 293 Expression Medium in a volume of 30 ml 
in a 125 ml bottle, or 60-90 ml in a 250 ml bottle, shaking at 37 °C, 8 % CO2 and 21 % O2, without 
changing medium between passaging. Cells were passaged every 2 days, once reaching a 
density of 1-3 x 106 cells/ml, and diluted in fresh medium to a new density of 0.4 x 106 cells/ml. 
6.2.2.8 DNA transfection of 293F 
For plasmid DNA transfection, 293F suspension cells were transfected with PEI MAX. One day 
before transfection, cells were split to a final density of 1 x 106 cells/ml. At the day of transfection, 
9 x 107 cells were collected by a 10 min centrifugation at 300 g, resuspended in 45 ml fresh 
FreeStyle 293 Expression Medium, transferred to a 250 ml bottle, and incubated in the cell culture 
incubator for 3-4 h. Then, 180 µg DNA were diluted to 0.5 µg/µl in fresh FreeStyle 293 Expression 
Medium and added directly to the cells. Cells were vortexed for 5 s and incubated in the cell 
culture incubator for another 5 min. Afterwards, 360 µl 1 µg/µl PEI MAX solution were mixed with 
360 µl FreeStyle 293 Expression Medium by vortexing, and the mixture was also added to the 
cells. After 24 h, the cell culture incubator was switched to 34 °C and cells were harvested for 
TET1 in vitro oxidation assay 48 h post transfection. 
6.2.2.9 General culture of mESCs 
E14tg2a mESCs were cultured on gelatinized cell culture dishes. For this purpose, the surface 
area of a cell culture dish was completely covered in 0.1 % gelatin in ultrapure water (Millipore) 
and incubated for at least 15 min. Gelatin was aspirated immediately before plating cells. mESCs 
were cultured in mESC medium at 37 °C, 5 % CO2 and 21 % O2, with daily medium changes. 
Cells were passaged every 2 days once reaching approximately 60 % confluency, by washing 
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the cells with PBS once, detaching cells with 0.25 % Trypsin-EDTA for 2 min at 37 °C, quenching 
Trypsin-EDTA with mESC medium, spinning down the cells for 3 min at 300 g, resuspending cells 
in an adequate amount of mESC medium and plating 1/8 of the cells on a new cell culture dish.  
mESC medium: DMEM supplemented with 15 % ES-grade FBS, 2 mM L-Glutamine, 50 U/ml 
penicillin/streptomycin, 1x MEM Non-essential amino acids, 1 mM sodium pyruvate, 100 µM β-
mercaptoethanol, 8 % LIF 
6.2.2.10 Mycoplasma Treatment of mESCs 
As the original E14tg2a mESC-line was mycoplasma positive, cells were treated with antibiotics 
to remove mycoplasma contamination before performing experiments. Treatment was started one 
day after thawing cells, by seeding 1.8 x 105 cells on a gelatinized 6 cm dish, in 3 ml regular 
mESC medium containing 25 µg/ml Plasmocin. Cells were passaged every 2 days and each time, 
1.8 x 105 cells were reseeded on a new 6 cm dish, in 3 ml regular mESC medium containing 
25 µg/ml Plasmocin, without changing medium between passaging. After a total of 14 days, cells 
were frozen as described in 6.2.2.1 and success of the treatment was confirmed using the PCR 
Mycoplasma Test Kit I/C. 
6.2.2.11 DNA transfection of mESCs 
For plasmid DNA transfection, mESCs were transfected with Lipofectamine 2000. For a 10 cm 
dish, 1 x 106 mESCs were plated in 9.5 ml mESC medium without antibiotics and incubated in 
the cell culture incubator for 3-4 h. Generally, 6 µg of plasmid DNA were diluted in 250 µl 
OptiMEM and 12 µl of Lipofectamine 2000 were mixed with 238 µl OptiMEM medium. Both 
solutions were vortexed and incubated for 5 min. Afterwards, both solutions were mixed and 
incubated for 30 min. Subsequently, the transfection mix was added dropwise to the cells and 
distributed by gentle swirling of the cell culture dish. The cell culture medium was exchanged with 
10 ml regular mESC medium the next morning. Cells were usually harvested 48 h post DNA 
transfection. 
6.2.2.12 siRNA transfection of mESCs 
For siRNA transfection, mESCs were transfected with Lipofectamine 2000. For a 6 cm dish, 
3.5 x 105 mESCs were plated in 2 ml mESC medium without antibiotics and incubated in the cell 
culture incubator for 2-3 h. 2 µl 20 µM siRNA were mixed with 48 µl OptiMEM and 2 µl of 
Lipofectamine 2000 were mixed with 48 µl OptiMEM medium. Both solutions were vortexed and 
incubated for 5 min. Afterwards, both solutions were mixed and incubated for 20 min. 
Subsequently, the transfection mix was added dropwise to the cells and distributed by gentle 
swirling of the cell culture dish. The cell culture medium was exchanged with 3 ml regular mESC 
medium the next morning. Cells were usually harvested 48 h post siRNA transfection. 
6.2.2.13 Double Thymidine Block of mESCs 
To arrest mESCs at the G1/S boundary, a double thymidine block was performed [232]. For a 
15 cm dish format, 5 x 106 cells were plated in 20 ml regular mESC medium and incubated in the 
cell culture incubator for 8 h. Then, the medium was exchanged with 20 ml mESC medium 
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containing 2.5 mM thymidine, and cells were incubated in the cell culture incubator for 14 h. 
Afterwards, cells were washed twice with 15 ml PBS and 20 ml fresh regular mESC medium were 
added to the cells, followed by a 9 h incubation in the cell culture incubator. For the second 
thymidine block, the medium was exchanged once more with 20 ml mESC medium containing 
2.5 mM thymidine, and cells were incubated in the cell culture incubator for another 14 h. Finally, 
cells were washed twice with 15 ml PBS and 20 ml fresh regular mESC medium were added to 
the cells for release. Cells were harvested at suitable time points after release for downstream 
analyses such as 5fC and 5hmC DIP (6.2.1.11), mass spectrometry of genomic DNA (6.2.1.7), 
flow cytometry (6.2.2.15), or Western blot (6.2.1.3). 
6.2.2.14  Auxin-Inducible Degron tagging of Rad21 in mESCs via CRISPR/Cas9 
Auxin-Inducible Degron tagging of Rad21 in mESCs was performed in two steps, 1) both Rad21 
genes were tagged with the auxin-inducible degron and 2) OsTir1 was inserted into the Tigre 
locus. 
For the first step, 1 x 106 E14tg2a mycoplasma-free mESCs were seeded on 10 cm dishes in 
9.5 ml mESC medium without antibiotics, and transfected after 3 h with 5 µg pMK_mmRad21_ 
mAID_Neo, 5 µg pMK_mmRad21_mAID_Hygro, and 5 µg pX330_Cas9_gRNA Rad21 plasmids, 
using 45µl Lipofectamine 2000 in a volume of 250 µl OptiMEM, but otherwise as described in 
chapter 6.2.2.11. The cell culture medium was exchanged with 10 ml regular mESC medium the 
next morning and in the evening, mESCs were passaged from 1 x 10 cm to 2 x 15 cm dishes. 
48 h post transfection, cells were selected by the addition of 500 µg/ml Geneticin and 500 µg/ml 
Hygromycin B to the cell culture medium, and kept under selection until the day of freezing. 
Single mESC colonies were picked 12 days after transfection. Using the microscope, single 
colonies were detached using a 10 µl pipette, set to its maximum volume, by a combination of 
gentle pushing and pipetting-induced medium currents. Colonies were subsequently transferred 
to 96-well plates containing 50 µl 0.25 % Trypsin-EDTA, incubated for 5 min at room temperature, 
diluted with 2 x 100 µl mESC medium including selection antibiotics, and transferred to a new, 
gelatinized 96-well plate. Medium of cells was changed every day, until the cells reached 
approximately 60 % confluency after 3-4 days. At this time, cells were split and transferred to 24-
well plates by washing with 100 µl PBS, incubating with 50 µl 0.25 % Trypsin-EDTA for 2 min at 
37 °C, quenching and resuspending with 100 µl mESC medium including selection antibiotics. 
Then, 75 µl of the cell suspension were transferred to a gelatinized 24-well plate, containing 
500 µl mESC medium including selection antibiotics. The other half of the cell suspension was 
used for genotyping PCRs, as described in chapter 6.2.1.6.  
Double-positive cells, as determined by genotyping PCRs (see chapter 6.2.1.6), were expanded 
to 6-well plates after approximately 2-3 days and further to 10 cm dishes after another 3-5 days, 
when having reached approximately 60 % confluency, with daily medium changes. The cells of 
½ of a 10 cm dish were frozen in two cryo tubes as described in chapter 6.2.2.1. The other ½ was 
pelleted by centrifugation and snap-frozen in liquid nitrogen and stored at -80 °C until further 
processed for Western blot analysis (see chapter 6.2.1.3). 
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For the second step, the two positive Rad21-AID-3xHA cell lines, A1 and F5, were transfected 
with 10 µg pEN396_Tigre OsTir1 and 5 µg pX330_EN1201_Cas9_gRNA Tigre, using 
Lipofectamine 2000 and the same protocol as for the first round of transfection described above, 
with the exception that 2 µg/ml Puromycin were used for antibiotic selection. To identify positive 
clones, genotyping PCRs were performed and positive clones were expanded and frozen as 
described above.  
To verify an efficient and acute depletion of RAD21, approximately 60 % confluent cells on a 6 cm 
dish were treated with 500 µM of the auxin analog indole-3-acetic acid sodium salt (referred to as 
“auxin” in this thesis) and cells were harvested and processed for Western blot analysis (see 
chapter 6.2.1.3). 
6.2.2.15 Cell cycle analysis via flow cytometry 
mESCs were grown on a 6 cm cell culture dish to 80 % confluency. After detachment with 1 ml 
0.25 % Trypsin-EDTA for 4 min at 37° C and quenching with mESC medium, cells were 
transferred to a 15 ml falcon tube and centrifuged at 300 g for 3 min. Cells were resuspended in 
3 ml PBS+1 % FBS, counted using a cell counter, and centrifuged one more time at 300 g for 
3 min. The supernatant was discarded and cells were fixed by dropwise addition of 1 ml ice-cold 
ethanol per 6.7 x 106 cells, under constant vortexing. Fixed cells were stored at -20 °C for at least 
1 h. For propidium iodide staining, fixed cells were washed twice with ice-cold PBS containing 
100 µg/ml RNAse A, by inverting the falcon tubes and centrifuging at 500 g for 5 min at 4 °C, 
before addition of 200 μl propidium iodide staining solution (1x PBS, 50 µg/ml propidium iodide, 
1 mM EDTA) and incubation for 10 min in the dark. The cell suspension was pipetted through a 
cell-strainer and propidium iodide intensity was analyzed by flow cytometry using an LSRFortessa 
SORP system using FACSDiVa software. Signals from 50 000 cells were recorded and analyzed 
with FlowJo software v10.6.1. 
6.2.3 In vitro TET1 oxidation assay 
For the TET1 oxidation assay, FLAG-tagged TET1CD was overexpressed in 293F (see chapter 
6.2.2.8) or HEK293T cells (see chapter 6.2.2.3). Volumes are referring to the conditions for 293F 
cells, and volumes for HEK293T cells are indicated in brackets if deviating. For cell extracts from 
293F cells, 30 ml cell suspension were used per condition, while one dense 10 cm dish was used 
for HEK293T. Cells were pelleted by centrifugation for 5 min at 300 g and washed with 10 ml 
PBS. Afterwards, the cell pellet was resuspended in 10 ml (2 ml) IVA5 buffer and cell disruption 
was achieved by 5 times needle homogenization using a 20 g needle followed by sonication for 
28 cycles 15 s on/off, high setting, using a Bioruptor. Lysates were transferred to a 50 ml (15 ml) 
falcon, followed by the addition of 20 ml (8 ml) IVA5 buffer. To immunoprecipitate FLAG-tagged 
TET1CD, 70 µl (10 µl) ANTI-FLAG M2 Affinity Gel (FLAG beads) was washed 3 times with 1 ml 
IVA5 buffer for 10 min on a rotating wheel at 4 °C, followed by 3 min centrifugation at 300 g and 
4 °C in a Heraeus centrifuge, and afterwards resuspended in 70 µl (10 µl) IVA5 buffer. 
Subsequently, the FLAG beads were added to the lysates and incubation was performed 
overnight on a rotating wheel at 8 rpm and 4 °C. Subsequently, lysates were washed twice with 
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10 ml IVA3 buffer and once with 10 ml Reaction wash buffer for 10 min on a rotating wheel at 
4 °C, followed by 5 min centrifugation at 870 g and 4 °C in a Heraeus centrifuge. Then, 1 ml 
Reaction wash buffer was added to the FLAG beads and the beads were transferred to a 1.5 ml 
tube. After another centrifugation for 5 min at 870 g and 4 °C, the last traces of buffer were 
removed using a gel loading tip and the in vitro TET1 oxidation assay was started by adding 
100 µl freshly prepared Reaction buffer to the samples. Samples were incubated for 3, 12 or 
24 min, shaking at 450 rpm at 37 °C, and the reaction was stopped by the addition of 16 µl 0.5 M 
EDTA. Beads were collected by centrifugation for 3 min at 870 g and 4 °C, and the supernatant 
was transferred to a new 1.5 ml tube. DNA was precipitated by the addition of 10 µl 7.5 M 
ammonium acetate and 330 µl ethanol, and further processed for mass spectrometry as 
described in chapter 6.2.1.7. 
6.2.3.1 Generation of an isotopically labelled and in vitro methylated substrate for the 
TET1 oxidation assay 
To generate the substrate for the TET1 oxidation assay, a PCR was set up with the following 
components and PCR program: 
 
Component 
Volume 
(µl) 
10x Reaction Buffer HM, 
including 15 mM MgCl2 
5 
MgCl2 (25 mM) 2.5 
dNTPs (with 15N-dCTP) (5 
mM) 
2.5 
Primer IVO biotin 
forward+reverse (10µM) 
1.5 
Nuclease-free H20 32.25 
AccuPrime Taq 1.25 
IVO2 template (100 nM) 1.5 
 
Table 6.15 PCR components 
 
Temperature (°C) Time  
94 7 min  
94 15 s 
30 x 57 15 s 
68 20 s 
68 2 min  
4 2 min  
 
Table 6.16 PCR program 
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DNA was purified using the QIAquick PCR purification kit. 10 µg of DNA were then in vitro 
methylated using the following reagents: 
Component Volume (µl) 
Purified DNA x (10 µg) 
10x Reaction Buffer 2 40 
SAM (32 mM) 8 
M.SssI (20,000 U/µl) 6 
Nuclease-free H2O 346-x µl 
 
Table 6.17 In vitro methylation of purified DNA 
 
Incubation was performed overnight at 37 °C, then 6 µl SAM and 4 µl M.SssI were added to the 
reaction mix and incubated for additional 4 h at 37 °C. The substrate was purified using phenol-
chloroform extraction followed by ammonium-acetate/ethanol precipitation.  
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8 List of Abbreviations  
53BP1 p53-binding protein 1 
5caC 5-carboxylcytosine 
5fC 5-formylcytosine 
5hmC 5-hydroxymethylcytosine 
5mC 5-methylcytosine 
a.a. Amino acid 
AID Auxin-Inducible Degron 
α-KG α-ketoglutarate 
AP Abasic 
ADD ATRX-DNMT3-DNMT3L 
AID Activation-induced deaminase 
AML Acute Myeloid Leukaemia 
APEX1 DNA-(apurinic or apyrimidinic site) lyase 
BER Base-Excision Repair 
bp Base pair 
BSA Bovine serum albumin 
cDNA Complementary DNA 
C/EBPβ CCAAT/enhancer-binding protein beta 
CF IMB Core-Facility IMB 
ChAHP CHD4-ADNP-HP1 complex 
ChIP-Seq Chromatin Immunoprecipitation followed by sequencing 
CHX Cycloheximide 
Co Control 
Co-IP Co-Immunoprecipitation 
CpG Cytosine-Guanine dinucleotide 
CRISPR Clustered Regularly Interspaced Short Palindromic Repeats 
CRL4 Cullin-ring finger ligase-4 
CTCF CCCTC-binding factor 
CUT&RUN Cleavage Under Targets and Release Using Nuclease 
CUT&TAG Cleavage Under Targets and Tagmentation 
DamID DNA adenine methyltransferase Identification 
DAPI 4′,6-diamidino-2-phenylindole 
DAZL Deleted in azoospermia-like 
DIP DNA Immunoprecipitation 
DIP-seq DIP followed by sequencing 
DDB1 Damaged DNA binding protein 1 
ddCp Delta delta Crossing point 
DMEM Dulbecco’s Modiﬁed Eagle's Medium 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic Acid 
DNMT DNA methyltransferase 
dNTP Nucleoside triphosphate 
DSBH Double-stranded β-helix domain 
dTAG Degradation tag 
DTT Dithiothreitol 
EGR1 Early growth response protein 1 
ESRRB Estrogen-related receptor b 
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EZH2 Enhancer of zeste homolog 2 
FACT Facilitates Chromatin Transcription 
FBS Fetal Bovine Serum 
fCAB-seq 5fC chemical modification-Assisted Bisulfite sequencing 
fC-Seal 5-formylcytosine-selective chemical labeling 
FDR False Discovery Rate 
G45A Growth arrest and DNA-damage-inducible protein 45 alpha 
GADD45A Growth arrest and DNA-damage-inducible protein 45 alpha 
GADD45B Growth arrest and DNA-damage-inducible protein 45 beta 
GADD45G Growth arrest and DNA-damage-inducible protein 45 gamma 
GFP Green fluorescent protein 
GlcNAc attachment of O-linked N-acetylglucosamine 
γH2AX Phosphorylated histone H2AX 
gRNA Guide RNA 
GS-linker Glycine-serine-linker 
H3K4me1,2,3 Histone 3 mono-/di-/trimethylated at lysine 4 
H3K9me1,2,3  Histone 3 mono-/di-/trimethylated at lysine 9 
H3K27me3 Histone 3 trimethylated at lysine 27 
H3K36me3 Histone 3 trimethylated at lysine 36 
H4K16 Histone 4 lysine 16 
HA Human influenza hemagglutinin 
HDAC1/2 Histone deacetylase 1/2 
HEK293F/T Human Embryonic Kidney 293F/T cells 
IDH Isocitrate dehydrogenase 
IF Immunofluorescence  
IgG Immunoglobulin G 
IMB Insitute of Molecular Biology 
ING1 Inhibitor of growth protein 1 
IP Immunoprecipitation 
KLF4 Krueppel-like factor 4 
LB Luria Broth 
LIF Leukemia inhibitory factor 
LIG3 DNA ligase 3 
LINE Long Interspersed Nuclear Elements 
MAB-seq M.SssI Methylase-Assisted Bisulfite sequencing 
MAP3K4 Mitogen-activated protein kinase kinase kinase 4 
MAPK Mitogen-activated protein kinase 
MAPKK Mitogen-activated protein kinase kinase 
MAPKKK Mitogen-activated protein kinase kinase kinase 
MBD4 Methyl-CpG-binding domain protein 4 
MeCP2 Methyl-CpG-binding protein 2 
MEF Mouse Embryonic Fibroblast 
mESC Mouse Embryonic stem Cell 
min Minute 
miRNA microRNA 
MLL Mixed Lineage Leukaemia 
mm Mus musculus 
mRNA Messenger RNA 
MTase Methyltransferase 
MuERV-L Murine endogenous retrovirus-like 
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MW Molecular Weight 
N/D Non Detectable 
NEM N-Ethylmaleimide 
NER Nucleotide Excision Repair 
NIPBL Nipped-B-like protein 
ns Non significant 
OGT O-linked N-acetylglucosamine transferase 
OsTIR1 Oryza sativa Transport inhibitor response 1-like protein 
PAR poly [ADP-ribose] 
PARP1 poly [ADP-ribose] polymerase 1 
PBS Phosphate Buffered Saline 
PCR Polymerase Chain Reaction 
PGC Primordial Germ Cell 
Pol β DNA polymerase β 
PPARγ Peroxisome proliferator-activated receptor γ 
PRC1/2 Polycomb Repressive Complex 1/2 
PRDM14 PR domain zinc finger protein 14 
qPCR Quantitative Polymerase Chain Reaction 
resBS-seq Reduced Bisulfite sequencing 
RFTS Replication Foci Targeting Sequence 
RNA Ribonucleic Acid 
rpm Revolutions per minute 
RT-qPCR Reverse Transcription followed by quantitative Polymerase Chain 
Reaction 
SAM S-adenosyl-L-methionine 
SD Standard Deviation 
SDS-PAGE Sodium dodecyl sulfate Polyacrylamide Gel Electrophoresis 
SILAC Stable Isotope Labeling with Amino acids in Cell culture 
siRNA small interfering Ribonucleic Acid 
SRA SET- and RING-Associated 
SMC Structural maintenance of chromosomes  
SUMO Small ubiquitin-related modifier 
SUZ12 Suppressor of zeste 12 protein homolog 
TAD Topologically Associating Domain 
TAF12 Transcription initiation factor TFIID subunit 12 
TARID TCF21 Antisense RNA Inducing Promoter Demethylation 
TBP TATA-box-binding protein 
TBS Tris-Buffered Saline 
TDG Thymine DNA glycosylase 
TDG-S SUMOylated TDG 
TET Ten-Eleven translocation  
TET1CD Catalytic domain of Ten-Eleven translocation 1 
TET1/3FL Full-length isoform of TET1/3 
TET1/3s Short isoform of TET1/3 
Tigre Tightly regulated 
TRIM Tripartite motif-containing protein 
UBL Ubiquitin-like 
UPL Universal probe library 
VitC Vitamin C 
VprBP DDB1- and CUL4-associated factor 1 
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WAPL Wings apart-like protein homolog 
WB Western blot 
WT Wildtype 
WT1 Wilms tumor protein 1 
XRCC1 X‐ray repair cross‐complementing protein 1 
YY1 Yin Yang 1 
ZNF143/750 Zinc finger protein 143/750 
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